

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 June 2006 (15.06.2006)

PCT

(10) International Publication Number
WO 2006/062716 A2

- (51) International Patent Classification: Not classified
- (21) International Application Number: PCT/US2005/041664
- (22) International Filing Date: 18 November 2005 (18.11.2005)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
- | | | |
|------------|-------------------------------|----|
| 60/629,363 | 18 November 2004 (18.11.2004) | US |
| 60/649,479 | 2 February 2005 (02.02.2005) | US |
| 60/672,346 | 18 April 2005 (18.04.2005) | US |
- (71) Applicant (for all designated States except US): **YALE UNIVERSITY [US/US]**; Two Whitney Avenue, New Haven, CT 06511 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **HOH, Josephine** [US/US]; Apartment 506, 152 Temple Street, New Haven, CT 06510 (US).
- (74) Agent: **GRANAHAN, Patricia**; Fish & Neave IP Group, Ropes & Gray LLP, One International Place, Boston, MA 02110-2624 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SI, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TI, TMO), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2006/062716 A2

(54) Title: METHODS AND COMPOSITIONS FOR TREATING OCULAR DISORDERS

(57) Abstract: The present invention relates to identification of a human gene, Complement Factor H (CFH), associated with the occurrence for developing age related macular degeneration (AMD), which is useful for identifying or aiding in identifying individuals at risk for developing AMD, as well as for diagnosing or aiding in the diagnosis of AMD.

METHODS AND COMPOSITIONS FOR TREATING OCULAR DISORDERS

FUNDING

This invention was made with United States government support under grants NIH-K25HG000060 and NIH-R01EY015771, awarded by the National Institutes of Health.

- 5 The United States government has certain rights in the invention.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 60/629,363, filed November 18, 2004; U.S. Provisional Application No. 60/649,479, filed February 2, 2005; and U.S. Provisional Application No. 60/672,346, filed April 18, 2005. The 10 teachings of each of these referenced provisional applications are incorporated by reference herein in their entirety.

BACKGROUND OF THE INVENTION

Age-related macular degeneration (AMD) is the leading cause of age-related blindness in the developed world. Its incidence is increasing as lifespan lengthens and the 15 elderly population expands (D.S. Friedman et al., Arch Ophthalmol 122, 564 (2004)). It is a chronic disease characterized by progressive destruction of the retina's central region (macula), causing central field visual loss (J. Tuo, C. M. Bojanowski, C. C. Chan, Prog Retin Eye Res 23, 229 (2004)). One key characteristic of AMD is the formation of extracellular deposits called drusen that are concentrated in and around the macula behind 20 the retina between the retina pigment epithelium (RPE) and choroid. To date, no therapy for this disease has proven to be broadly effective, especially in more advanced forms. Several risk factors have been linked to AMD, including age, smoking, and family history (AREDS Research Group, Ophthalmology 107, 2224 (2000)). Candidate gene association 25 studies and genome-wide linkage scans have been performed to identify genetic risk factors for AMD. A variety of candidate genes have been proposed based on their association with other retinal diseases or their known function. While some rare variants of some of these genes are associated with disease phenotype, no genetic differences have been observed that can account for a large proportion of the overall prevalence (J. Tuo, C.

M. Bojanowski, C. C. Chan, Prog Retin Eye Res 23, 229 (2004)). Additional information about genetic determinants of AMD is badly needed.

SUMMARY OF THE INVENTION

The present invention relates to identification of variations in a human gene correlated with a predisposition to AMD, which is useful in identifying or aiding in identifying individuals at risk for developing AMD, as well as for diagnosing or aiding in the diagnosis of AMD. It also relates to methods for identifying or aiding in identifying individuals at risk for developing AMD, methods for diagnosing or aiding in the diagnosis of AMD, polynucleotides (e.g., probes, primers) useful in the methods, diagnostic kits containing probes or primers, methods of treating an individual at risk for or suffering from AMD and compositions useful for treating an individual at risk for or suffering from AMD.

In one embodiment, the present invention provides polynucleotides useful for the detection or aiding in the detection of a CFH gene that is correlated with the occurrence of AMD in humans and, in specific embodiments, variations in the CFH gene that are correlated with AMD in humans. In another embodiment, the present invention provides methods and compositions useful for identifying or aiding in identifying individuals at risk for developing AMD. In a further embodiment, the methods and compositions of the invention may be used for the treatment of an individual suffering from AMD or at risk for developing AMD. The disclosure also provides diagnostic kits for detecting a variant CFH gene in a sample from an individual. Such kits are useful in identifying or aiding in identifying individuals at risk for developing AMD, as well as for diagnosing or aiding in the diagnosis of AMD in an individual.

In one embodiment, the invention provides an isolated polynucleotide for the detection of a variant CFH gene; the isolated polynucleotide comprises a nucleic acid molecule that specifically detects a variation in the CFH gene that is correlated with the occurrence of AMD in humans. Isolated polynucleotides are useful for detecting, in a sample from an individual, a variant CFH gene that is correlated with AMD in humans. The polynucleotides of the invention may further be used in allele-specific assays (e.g., allele-specific hybridization, primer extension, or ligation assays known in the art) to detect a variation in the CFH gene that is correlated with the occurrence of AMD. Allele-specific probes and primers are able to specifically hybridize to one or more alleles of a gene and

will not hybridize to other alleles of the same gene. For example, an allele-specific polynucleotide probe of the invention may hybridize to a variant CFH gene but will not hybridize to a wildtype CFH gene. In certain embodiments, the isolated polynucleotide is a probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of AMD in humans. In particular embodiments, an isolated polynucleotide probe of the invention hybridizes, under stringent conditions, to a nucleic acid molecule comprising all or a portion of a CFH gene, or allelic variants thereof, wherein the nucleic acid molecule comprises a variation that is correlated with the occurrence of AMD in humans. In other embodiments, an isolated polynucleotide probe of the invention hybridizes, under stringent conditions, to a nucleic acid molecule comprising at least 10 contiguous nucleotides of a CFH gene, or allelic variants thereof, wherein the nucleic acid molecule comprises a variation that is correlated with the occurrence of AMD in humans. In further embodiments, the isolated polynucleotide is a primer that hybridizes, under stringent conditions, adjacent, upstream, or downstream to a variation in the CFH gene that is correlated with the occurrence of AMD in humans. In certain embodiments, an isolated polynucleotide primer of the invention is at least 10 nucleotides long and hybridizes to one side or another of a variation in the CFH gene that is correlated with the occurrence of AMD in humans. The subject polynucleotides may contain alterations, such as one or more nucleotide substitutions, additions or deletions, provided they hybridize to their target variant CFH gene with the same degree of specificity. As used herein, the term "isolated" when used in relation to a nucleic acid, refers to a nucleic acid sequence that is identified and separated from at least one contaminant nucleic acid with which it is ordinarily associated in its natural source. By contrast, non-isolated nucleic acids are nucleic acids such as DNA and RNA found in the state they exist in nature.

The polynucleotides described herein (e.g., a polynucleotide probe or a polynucleotide primer) may be DNA or RNA. The subject polynucleotide may be single-stranded or double-stranded. Polynucleotide probes and primers of the invention may be from about 5 nucleotides to about 3000 nucleotides. In some embodiments, the polynucleotide probes and primers of the invention are from about 8 nucleotides to about 500 nucleotides. In other embodiments, the polynucleotide probes and primers of the invention are from about 10 nucleotides to about 250 nucleotides. In certain embodiments, the subject polynucleotide probes and primers are about 20 nucleotides (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides). In other embodiments, the

subject polynucleotide probes and primers are from about 50 to about 100 nucleotides (e.g., 45, 50, 55, 60, 65, 75, 85, or 100 nucleotides). The subject polynucleotides may comprise one or more non-natural or modified nucleotides. Non-natural or modified nucleotides include, without limitation, radioactively, fluorescently, or chemically labeled nucleotides.

- 5 In certain embodiments, the polynucleotide primer of the invention hybridizes upstream or downstream from a variation in the CFH gene that is correlated with the occurrence of AMD in humans. In one embodiment, the polynucleotide hybridizes vicinal to a variation in the CFH gene that is correlated with the occurrence of AMD in humans. For example, hybridization may occur in such a manner that fewer than 10 nucleotides
- 10 separate the variation and the end of the hybridized primer proximal to the variation. In another embodiment, hybridization occurs in such a manner that 1-3 nucleotides separate the variation and the end of the hybridized primer proximal to the variation. In certain other embodiments, the polynucleotide primer hybridizes immediately adjacent to the variation. In another embodiment, the polynucleotide primer of the invention hybridizes a
- 15 distance (e.g., at least 10 nucleotides) from a variation in the CFH gene that is correlated with the occurrence of AMD in humans. For example, hybridization may occur in such a manner that the end of the hybridized primer proximal to the variation is 10, 25, 50, 100, 250, 1000, 5000, or up to 10,000 nucleotides from the variation in the CFH gene. The invention described herein also relates to a pair of polynucleotide primers that specifically
- 20 detect a variation in the CFH gene that is correlated with the occurrence of AMD in humans, wherein the first polynucleotide primer hybridizes to one side of the variation and the second polynucleotide primer hybridizes to the other side of the variation. A pair of polynucleotide primers that hybridize to a region of DNA that comprises a variation in the CFH gene that is correlated with the occurrence of AMD in humans may hybridize to the
- 25 region in such a manner that the ends of the hybridized primers proximal to the variation are from about 20 to about 10,000 nucleotides apart. Alternatively, the pair of polynucleotide primers that hybridize to a region of DNA that comprises a variation in the CFH gene that is correlated with the occurrence of AMD in humans may hybridize to the region in such a manner that the ends of the hybridized primers proximal to the variation
- 30 are from about 100 to about 7,500 nucleotides apart, or from about 200 to about 5,000 nucleotides apart.

In another embodiment, the invention described herein provides three or more polymucleotide primers useful for distinguishing between two alleles of the CFH gene (for example, a wildtype allele and an allele that is correlated with the occurrence of AMD in humans). The first primer hybridizes to a nucleotide sequence that is common to both 5 alleles, such as a non-allelic nucleotide sequence that is upstream or downstream of the variation in the CFH gene that is correlated with the occurrence of AMD. A second primer specifically hybridizes to a sequence that is unique to a first allele (e.g., a variation in the CFH gene that is correlated with the occurrence of AMD in humans). A third primer specifically hybridizes to a nucleotide sequence that is unique to the second allele (e.g., a 10 wildtype CFH gene). The set of three primers result in the amplification of a region of DNA that is dependent on which CFH allele is present in the sample. For instance, one region of DNA is amplified if the CFH gene has a variation in the CFH gene that is correlated with the occurrence of AMD, and another region is amplified if a wildtype CFH gene is present in the sample. Alternatively, two primers out of the set may hybridize to a 15 nucleotide sequence that is common to two alleles of the CFH gene, such as non-allelic nucleotide sequences that are upstream and downstream of a variation in the CFH gene that is correlated with the occurrence of AMD in humans, and a third primer specifically hybridizes to one of the two alleles of the CFH gene (such as a wildtype allele or an allele that is correlated with the occurrence of AMD in humans).

20 A variety of variations in the CFH gene that predispose an individual to AMD may be detected by the methods and compositions described herein. In a particular embodiment, the variation encodes an amino acid other than histidine at position 402 of the CFH protein. In a specific embodiment, the variation encodes tyrosine at position 402 of the CFH protein. In another embodiment, the variation encodes an amino acid other than 25 valine at position 62 of the CFH protein. In a specific embodiment, the variation encodes isoleucine at position 62 of the CFH protein. In other embodiments, the methods and compositions described herein may be used to detect variations in the CFH gene that predispose an individual to AMD, such as those listed in Tables 4, 5 and 7. For example, other variant genes, such as those in which the variation is in a coding region (e.g., 30 variations that encode: an amino acid other than serine, such as alanine, at position 58 of the CFH protein; an amino acid other than arginine, such as histidine, at position 127 of the CFH protein; an amino acid other than glutamine, such as lysine, at position 400 of the CFH protein; an amino acid other than valine, such as isoleucine, at position 609 of the

CFH protein; an amino acid other than serine, such as isoleucine, at position 890 of the CFH protein; an amino acid other than glutamic acid, such as aspartic acid, at position 936 of the CFH protein; an amino acid other than valine, such as leucine, at position 1007 of the CFH protein; an amino acid other than asparagine, such as tyrosine, at position 1050 of the CFH protein; an amino acid other than proline, such as glutamine, at position 1166 of the CFH protein; or an amino acid other than arginine, such as cysteine, at position 1210 of the CFH protein. See Tables 4, 5 and 7) can be detected using the methods and compositions described herein. Alternatively, variant genes in which the variation is in a noncoding region, such as those listed in Tables 4, 5 and 7, may be detected using the methods and compositions described herein. As used herein, the term "variant CFH gene" refers to DNA that includes a variation in the CFH gene that is correlated with the occurrence of AMD. As used herein, the terms "wildtype CFH DNA" and "wildtype CFH gene" refer to DNA that does not include a variation in the CFH gene that is correlated with AMD.

The present invention also relates to a method of detecting, in a sample obtained from an individual, a variant CFH gene that is correlated with the occurrence of AMD in humans. Such a method may comprise: (a) combining the sample with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with AMD in humans, but not to a wildtype CFH gene (wildtype CFH DNA is the term used above); and (b) determining whether hybridization occurs. The occurrence of hybridization indicates that a variant CFH gene that is correlated with age related macular degeneration is present in the sample. Samples used in the methods described herein may comprise cells from the eye, ear, nose, teeth, tongue, epidermis, epithelium, blood, tears, saliva, mucus, urinary tract, urine, muscle, cartilage, skin, or any other tissue or bodily fluid from which sufficient DNA or RNA can be obtained. Samples may be collected by a variety of means for collecting cells, such as for example, a buccal swab. The sample is processed, if necessary, to render the DNA or RNA that is present available for assaying in the methods described herein. For example, samples may be processed such that DNA from the sample is available for amplification or for hybridization to another polynucleotide. The processed samples may be crude lysates where available DNA or RNA is not purified from other cellular material, or may be purified to isolate available DNA or RNA. Samples may be processed by any means known in the art that renders DNA or RNA available for assaying in the methods described herein. Methods for

processing samples include, but are not limited to, mechanical, chemical, or molecular means of lysing and/or purifying cells and cell lysates. Processing methods may include, for example, chromatographic methods such as ion exchange (e.g., cation and anion), size exclusion, gel filtration, affinity, and hydrophobic interaction chromatography, or 5 ultrafiltration, electrophoresis, and immunoaffinity purification with antibodies specific for particular epitopes of the polypeptide.

In other embodiments, the invention provides a method of detecting, in a sample obtained from an individual, a variant CFH gene that is correlated with the occurrence of age related macular degeneration in humans, comprising: (a) combining the sample 10 (referred to as a test sample) with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of AMD in humans, thereby producing a combination; (b) maintaining the combination produced in step (a) under stringent hybridization conditions; and (c) comparing hybridization that occurs in the combination with hybridization in a control. The occurrence of hybridization 15 in the combination but not in the control indicates that a variant CFH gene that correlates with AMD is present in the sample. In a further embodiment, the extent of hybridization is determined when comparing hybridization that occurs in the combination with hybridization in a control. The control is the same as the test sample and is treated the same as the test sample except that the polynucleotide probe is one that does not bind to a 20 variation in the CFH gene that is correlated with the occurrence of AMD in humans. Alternatively, the polynucleotide probe is one that binds only to a wildtype CFH gene. The control can be assayed serially or simultaneously with the combination described above. Alternatively, results from a control may be established in a reference assay previously or 25 subsequent to the combination described above. The sample used in the control is typically the same type of sample as the test sample and is treated the same as the test sample except that it is combined with a polynucleotide that does not hybridize to a variant CFH gene that is correlated with the occurrence of AMD in humans.

In another embodiment, the invention provides a method of detecting, in a sample obtained from an individual, a variant CFH gene that is correlated with the occurrence of 30 AMD in humans, comprising: (a) combining a first portion of the sample with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of AMD in humans; (b) combining a second

portion of the sample with a polynucleotide probe that hybridizes, under stringent conditions, to a wildtype CFH gene; and (c) determining whether hybridization occurs. The occurrence of hybridization in the first portion, but not in the second portion, indicates that a variant CFH gene that is correlated with AMD is present in the sample.

5 In another embodiment, the invention provides a method of detecting, in a sample obtained from an individual, a variant CFH gene that is correlated with the occurrence of AMD in humans, comprising: (a) combining the sample with a pair of polynucleotide primers, wherein the first polynucleotide primer hybridizes to one side of DNA encoding amino acid 402 of the CFH protein and the second polynucleotide primer hybridizes to the
10 other side of DNA encoding amino acid 402 of the CFH protein; (b) amplifying DNA in the sample, thereby producing amplified DNA; (c) sequencing amplified DNA; and (d) detecting in the DNA the presence of a variation that encodes an amino acid other than histidine at position 402 of the CFH protein. The presence of the variation indicates that a variant CFH gene that is correlated with the occurrence of AMD in humans is detected in
15 the sample.

In another embodiment, the invention provides a method of detecting, in a sample obtained from an individual, a variant CFH gene that is correlated with the occurrence of AMD in humans, comprising: (a) combining the sample with a pair of polynucleotide primers, wherein the first polynucleotide primer hybridizes to one side of DNA encoding
20 amino acid 62 of the CFH protein and the second polynucleotide primer hybridizes to the other side of DNA encoding amino acid 62 of the CFH protein; (b) amplifying DNA in the sample, thereby producing amplified DNA; (c) sequencing amplified DNA; and (d) detecting in the DNA the presence of a variation that encodes an amino acid other than histidine at position 62 of the CFH protein. The presence of the variation indicates that a variant CFH gene that is correlated with the occurrence of AMD in humans is detected in
25 the sample.

Any method known in the art for amplifying nucleic acids may be used for the methods described herein. For example, DNA in a sample may be amplified using polymerase chain reaction (PCR), RT-PCR, quantitative PCR, real time PCR, Rapid
30 Amplified Polymorphic DNA Analysis, Rapid Amplification of cDNA Ends (RACE), or rolling circle amplification.

In other embodiments, the invention provides methods of identifying or aiding in identifying an individual at risk for developing AMD. In one specific embodiment, such a method comprises assaying a sample obtained from the individual for the presence of a variant CFH gene that is correlated with the occurrence of AMD in humans. The presence 5 of a variant CFH gene indicates that the individual is at risk for developing AMD.

In another embodiment, a method of identifying or aiding in identifying an individual at risk for developing AMD comprises: (a) combining a sample obtained from the individual with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with AMD in humans, but does not hybridize 10 to a wildtype CFH gene; and (b) determining whether hybridization occurs. The occurrence of hybridization indicates that the individual is at risk for developing AMD.

In another embodiment, a method of identifying or aiding in identifying an individual at risk for developing AMD, comprises: (a) obtaining DNA from an individual; 15 (b) sequencing a region of the DNA that comprises the nucleotides that encode amino acid 402 of the CFH protein; and (c) determining whether a variation that encodes an amino acid other than histidine at position 402 of the CFH protein is present in the DNA. The presence of the variation indicates that the individual is at risk for developing AMD.

In another embodiment, a method of identifying or aiding in identifying an individual at risk for developing AMD, comprises: (a) obtaining DNA from an individual; 20 (b) sequencing a region of the DNA that comprises the nucleotides that encode amino acid 62 of the CFH protein; and (c) determining whether a variation that encodes an amino acid other than valine at position 62 of the CFH protein is present in the DNA. The presence of the variation indicates that the individual is at risk for developing AMD.

In another embodiment, the invention provides a method of detecting, in a sample 25 obtained from an individual, a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans. Such a method comprises: (a) combining the sample with an antibody that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans; and (b) determining whether binding occurs. The occurrence of binding indicates that a variant 30 CFH polypeptide that is correlated with the occurrence of age related macular degeneration is present in the sample.

In another embodiment, the invention provides diagnostic kits useful for detecting a variant CFH gene in a sample from an individual. A diagnostic kit may comprise, for example: (a) at least one container means having disposed therein a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated 5 with the occurrence of AMD in humans; and (b) a label and/or instructions for the use of the diagnostic kit in the detection of a variant CFH gene in a sample.

In another embodiment, a diagnostic kit useful for detecting a variant CFH gene in a sample from an individual may comprise, for example: (a) at least one container means having disposed therein a polynucleotide primer that hybridizes, under stringent conditions, 10 adjacent to one side of a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans; and (b) a label and/or instructions for the use of the diagnostic kit in the detection of CFH in a sample. Optionally, the diagnostic kit additionally comprises a second polynucleotide primer that hybridizes, under stringent conditions, to the other side of the variation in the CFH gene that is correlated with the 15 occurrence of age related macular degeneration in humans.

The present invention also relates to compositions for treating a subject suffering from AMD. In a particular embodiment, a composition for treating a subject suffering from AMD comprises an effective amount of an isolated or recombinantly produced CFH polypeptide, or a fragment thereof, and a pharmaceutically acceptable carrier. In a 20 particular embodiment, the CFH polypeptide, or the fragment thereof, inhibits the activation of C3. In another embodiment, the invention provides a method of treating a subject suffering from AMD, comprising administering to the subject an effective amount of an isolated or recombinantly produced CFH polypeptide, or a fragment thereof, and a pharmaceutically acceptable carrier.

25 In another embodiment, the invention provides a composition for treating a subject suffering from AMD, comprising an effective amount of an isolated or recombinantly produced nucleic acid molecule coding for a CFH polypeptide, or a fragment thereof, and a pharmaceutically acceptable carrier. As used herein, the term "effective amount" refers to the amount of an isolated or recombinantly produced CFH nucleic acid or polypeptide, or a 30 composition comprising a CFH nucleic acid or polypeptide, that is in sufficient quantities to treat a subject or to treat the disorder itself. For example, an effective amount is sufficient to delay, slow, or prevent the onset or progression of AMD or related symptoms.

In other embodiments, the invention provides a method of treating a subject suffering from AMD, comprising administering to the subject an effective amount of an isolated or recombinantly produced nucleic acid molecule coding for a CFH polypeptide, or a fragment thereof, and a pharmaceutically acceptable carrier.

- 5 In another embodiment, the invention provides a composition for treating a subject suffering from or at risk for age related macular degeneration, comprising: (a) a nucleic acid molecule comprising an antisense sequence that hybridizes to a variant CFH gene or mRNA that is correlated with the occurrence of age related macular degeneration in humans; and (b) a pharmaceutically acceptable carrier. In certain embodiments, 10 hybridization of the antisense sequence to the variant CFH gene reduces the amount of RNA transcribed from the variant CFH gene. In certain other embodiments, hybridization of the antisense sequence to the variant CFH mRNA reduces the amount of protein translated from the variant CFH mRNA, and/or alters the splicing of the variant CFH mRNA. A nucleic acid molecule comprising an antisense sequence that hybridizes to a 15 variant CFH gene or mRNA may comprise one or more modified nucleotides or nucleosides that enhance in vivo stability, transport across the cell membrane, or hybridization to a variant CFH gene or mRNA. In other embodiments, the invention provides a method for treating a subject suffering from or at risk for age related macular degeneration, comprising administering to the subject an effective amount of a nucleic acid 20 molecule comprising an antisense sequence that hybridizes to a variant CFH gene or mRNA that is correlated with the occurrence of age related macular degeneration in humans, and a pharmaceutically acceptable carrier.

- In another embodiment, the invention provides a composition for treating a subject suffering from or at risk for age related macular degeneration, comprising: (a) a nucleic acid molecule comprising a siRNA or miRNA sequence, or a precursor thereof, that hybridizes to a variant CFH gene or mRNA that is correlated with the occurrence of age related macular degeneration in humans; and (b) a pharmaceutically acceptable carrier. In certain embodiments, hybridization of a nucleic acid molecule comprising a siRNA or miRNA sequence, or a precursor thereof to the variant CFH gene reduces the amount of 25 RNA transcribed from the variant CFH gene. In other embodiments, hybridization of a nucleic acid molecule comprising a siRNA or miRNA sequence, or a precursor thereof to the variant CFH mRNA reduces the amount of protein translated from the variant CFH 30 mRNA.

mRNA, and/or alters the splicing of the variant CFH mRNA. A nucleic acid molecule comprising an antisense sequence that hybridizes to a variant CFH gene or mRNA may comprise one or more modified nucleotides or nucleosides that enhance in vivo stability, transport across the cell membrane, or hybridization to a variant CFH gene or mRNA. In 5 other embodiments, the invention provides a method for treating a subject suffering from or at risk for age related macular degeneration, comprising administering to the subject an effective amount of a nucleic acid molecule comprising a siRNA or miRNA sequence, or a precursor thereof, that hybridizes to a variant CFH gene or mRNA that is correlated with the occurrence of age related macular degeneration in humans and a pharmaceutically acceptable carrier.

In another embodiment, the invention provides a composition for treating a subject suffering from or at risk for age related macular degeneration, comprising: (a) an aptamer that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans; and (b) a pharmaceutically acceptable carrier, wherein 15 binding of the aptamer to the variant CFH polypeptide reduces the activity of the variant CFH polypeptide. In other embodiments, the invention provides a method for treating a subject suffering from or at risk for age related macular degeneration, comprising administering to the subject an effective amount of an aptamer that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in 20 humans and a pharmaceutically acceptable carrier.

In another embodiment, the invention provides a composition for treating a subject suffering from or at risk for age related macular degeneration, comprising: (a) a small molecule that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans; and (b) a pharmaceutically acceptable carrier. 25 In certain embodiments, binding of the small molecule to the variant CFH polypeptide reduces the activity of the variant CFH polypeptide. In another embodiment, the invention provides a method for treating a subject suffering from or at risk for age related macular degeneration, comprising administering to the subject an effective amount of a small molecule that binds to a variant CFH polypeptide that is correlated with the occurrence of 30 age related macular degeneration in humans and a pharmaceutically acceptable carrier.

In another embodiment, the invention provides a composition for treating a subject suffering from or at risk for age related macular degeneration, comprising: (a) an antibody

that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans; and (b) a pharmaceutically acceptable carrier. In certain embodiments, binding of the antibody to the variant CFH polypeptide reduces the activity of the variant CFH polypeptide. In another embodiment, the invention also provides a 5 method for treating a subject suffering from or at risk for age related macular degeneration, comprising administering to the subject an effective amount of an antibody that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans and a pharmaceutically acceptable carrier.

The methods and compositions described herein for treating a subject suffering 10 from AMD may be used for the prophylactic treatment of individuals who have been diagnosed or predicted to be at risk for developing AMD. For instance, the composition is administered in an amount and dose that is sufficient to delay, slow, or prevent the onset of AMD or related symptoms. Alternatively, the methods and compositions described herein may be used for the therapeutic treatment of individuals who suffer from AMD. For 15 example, the composition is administered in an amount and dose that is sufficient to delay or slow the progression of the condition, totally or partially, or in an amount and dose that is sufficient to reverse the condition.

As described herein for CFH, variations in CFH-like genes in humans (e.g., CFHL1, CFHL3, and CFHL4) are also useful for identifying or aiding in identifying 20 individuals at risk for developing AMD. Variations in CFHL1, CFHL3, and CFHL4 may also be useful for diagnosing or aiding in the diagnosis of AMD, identifying or aiding in identifying individuals at risk for developing AMD, methods for diagnosing or aiding in the diagnosis of AMD, polynucleotides (e.g., probes, primers) useful in the methods, diagnostic kits containing probes or primers, methods of treating an individual at risk for or 25 suffering from AMD and compositions useful for treating an individual at risk for or suffering from AMD. Examples of variations in CFHL1, CFHL3, and CFHL4 that may be correlated with the occurrence of AMD are found in Tables 8-10. Such variations, which can be in a coding or noncoding region of a CFHL gene (e.g., CFHL1, CFHL3, and CFHL4) can be useful in the methods and compositions described herein.

In one embodiment, the present invention provides polynucleotides useful for the 30 detection or aiding in the detection of a CFHL gene (e.g., CFHL1, CFHL3, or CFHL4) that is correlated with the occurrence of AMD in humans and, in specific embodiments,

variations in a CFHL gene that are correlated with AMD in humans. The disclosure also provides diagnostic kits for detecting a variant CFHL gene in a sample from an individual. Such kits are useful in identifying or aiding in identifying individuals at risk for developing AMD, as well as for diagnosing or aiding in the diagnosis of AMD in an individual.

5 In another embodiment, the invention provides an isolated polynucleotide for the detection of a variant CFHL gene, such as CFHL1, CFHL3, or CFHL4, in a sample from an individual, comprising a nucleic acid molecule that specifically detects a variation in the CFHL gene that is correlated with the occurrence of age related macular degeneration in humans.

10 In another embodiment, the invention provides a polynucleotide primer that hybridizes, under stringent conditions, adjacent to a variation in a CFHL gene that is correlated with the occurrence of age related macular degeneration in humans. In certain embodiments, the invention provides a pair of polynucleotide primers that specifically detect a variation in a CFHL gene that is correlated with the occurrence of age related 15 macular degeneration in humans, wherein the first polynucleotide primer hybridizes to one side of the variation and the second polynucleotide primer hybridizes to the other side of the variation. The pair of polynucleotide primers may hybridize to a region of a CFHL gene in such a manner that the ends of the hybridized primers proximal to the variation are from about 100 to about 10,000 nucleotides apart.

20 The present invention also relates to a method of detecting, in a sample obtained from an individual, a variant CFHL gene that is correlated with the occurrence of AMD in humans. Such a method may comprise: (a) combining the sample with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFHL gene that is correlated with AMD in humans, but not to a wildtype CFHL gene; and (b) determining 25 whether hybridization occurs. The occurrence of hybridization indicates that a variant CFHL gene that is correlated with age related macular degeneration is present in the sample. As used herein, the term "wildtype CFHL gene" refers to a CFHL gene, such as CFHL1, CFHL3, or CFHL4, that is not correlated with the occurrence of AMD.

In other embodiments, the invention provides a method of detecting, in a sample 30 obtained from an individual, a variant CFHL gene that is correlated with the occurrence of age related macular degeneration in humans, comprising: (a) combining the sample

(referred to as a test sample) with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFHL gene that is correlated with the occurrence of AMD in humans, thereby producing a combination; (b) maintaining the combination produced in step (a) under stringent hybridization conditions; and (c) comparing hybridization that occurs in the combination with hybridization in a control. The occurrence of hybridization in the combination but not in the control indicates that a variant CFHL gene that correlates with AMD is present in the sample. In a further embodiment, the extent of hybridization is determined when comparing hybridization that occurs in the combination with hybridization in a control. The control is the same as the test sample and is treated the same as the test sample except that the polynucleotide probe is one that does not bind to a variation in the CFHL gene that is correlated with the occurrence of AMD in humans. Alternatively, the polynucleotide probe is one that binds only to a wildtype CFHL gene.

In another embodiment, the invention provides a method of detecting, in a sample obtained from an individual, a variant CFHL gene that is correlated with the occurrence of AMD in humans, comprising: (a) combining a first portion of the sample with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFHL gene that is correlated with the occurrence of AMD in humans; (b) combining a second portion of the sample with a polynucleotide probe that hybridizes, under stringent conditions, to a wildtype CFHL gene; and (c) determining whether hybridization occurs. The occurrence of hybridization in the first portion, but not in the second portion, indicates that a variant CFHL gene that is correlated with AMD is present in the sample.

In other embodiments, the invention provides methods of identifying or aiding in identifying an individual at risk for developing AMD. In one specific embodiment, such a method comprises assaying DNA obtained from the individual for the presence of a variant CFHL gene that is correlated with the occurrence of AMD in humans. The presence of a variant CFHL gene indicates that the individual is at risk for developing AMD.

In another embodiment, a method of identifying or aiding in identifying an individual at risk for developing AMD comprises: (a) combining a sample obtained from the individual with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFHL gene that is correlated with AMD in humans, but does not hybridize to a wildtype CFHL gene; and (b) determining whether hybridization occurs. The occurrence of hybridization indicates that the individual is at risk for developing AMD.

In another embodiment, the invention provides diagnostic kits useful for detecting a variant CFHL gene in a sample from an individual. A diagnostic kit may comprise, for example: (a) at least one container means having disposed therein a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFHL gene that is correlated with the occurrence of AMD in humans; and (b) a label and/or instructions for the use of the diagnostic kit in the detection of a variant CFHL gene in a sample.

In another embodiment, a diagnostic kit useful for detecting a variant CFHL gene in a sample from an individual may comprise, for example: (a) at least one container means having disposed therein a polynucleotide primer that hybridizes, under stringent conditions, adjacent to one side of a variation in the CFHL gene that is correlated with the occurrence of age related macular degeneration in humans; and (b) a label and/or instructions for the use of the diagnostic kit in the detection of CFHL in a sample. Optionally, the diagnostic kit additionally comprises a second polynucleotide primer that hybridizes, under stringent conditions, to the other side of the variation in the CFHL gene that is correlated with the occurrence of age related macular degeneration in humans.

The embodiments and practices of the present invention, other embodiments, and their features and characteristics, will be apparent from the description, figures and claims that follow, with all of the claims hereby being incorporated by this reference into this Summary.

20 BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1A-1B are graphs showing statistical data of a genome-wide association study of genes associated with AMD. Figure 1A shows p-values of the genome-wide association scan. $-\log_{10}(p)$ is plotted for each SNP in chromosomal order. The spacing between SNPs on the plot is uniform and does not reflect distances between SNPs on the chromosomes. The dotted horizontal line shows the cutoff for $p=0.05$ after Bonferroni correction. The vertical lines show chromosomal boundaries. Figure 1B shows variations in genotype frequencies between cases and controls.

Figures 2A-2D show data on SNPs that are associated with AMD. Figure 2A shows linkage disequilibrium (LD) across the CFH region, plotted as pairwise D' values. Figure 2B shows a schematic of the region in strong LD with the two associated SNPs in

the data. The vertical bars represent the approximate location of the SNPs available in the data set. The shaded region is the haplotype block found in the HapMap data. Figure 2C shows haplotype blocks in the HapMap CEU data cross the region. Darker shades indicate higher values of D'. Lighter shades indicate high D' with a low LOD score. The dark lines show the boundaries of haplotype blocks. Figure 2D shows a maximum parsimony cladogram derived from haplotypes across the 6-SNP region. The number by each line indicates which of the six SNPs varies along the branch. SNP 4 is rs380390 and SNP 6 is rs1329428, which are the two SNPs initially identified as associated with AMD.

Figures 3A-3C show immunofluorescent localization of CFH protein in human retina. Figure 3A shows human retina sections stained with anti-human CFH antibody. Figure 3B shows human retina sections stained with anti-human CFH antibody pre-incubated with CFH protein as negative control. The nuclei are identified by DAPI staining. The magnified view of the boxed area in Figure 3A is shown in Figure 3C. The fluorescent and DIC channels are collected from each image and presented as the left and right pictures, respectively, in each panel. The fluorescent pictures in Figure 3A and Figure 3B are merged images from CFH labeling and DAPI stained nuclei. The DIC picture in Figure 3C is a merged image of CFH labeling and the DIC channel. The black spots in DIC images correspond to melanin granules in RPE and choroids. The anti-CFH antibody primarily stains the choroids (Figure 3A), especially strong in the wall of vessels human and in area close to RPE (Figure 3C), and the immunoreactivity can be competed away with purified human CFH protein (Figure 3B). The fluorescent signal from RPE arises from the autofluorescence of lipofusion which cannot be competed away by human factor H protein. GC: ganglion cells layer, INL: inner nuclear layer, ONL: outer nuclear layer, RPE: retinal pigment epithelium. Scale bar: 40 μ m in Figures 3A and 3B, 20 μ m in Figure 3C.

Figure 4A-4E show immunohistochemistry for activated complement C5b-9. Tissues from three patients are illustrated. Figures 4A and 4B show post-mortem fundus images from patients 1 and 2, respectively. The site illustrated histologically is indicated with an asterisk. Figure 4C shows tissue from patient 1 who is immunopositive for C5b-9 throughout Bruch's membrane and in intercapillary pillars (thin black arrows). Overlying retinal pigment epithelium is hypertrophic, and associated retina demonstrated marked photoreceptor loss. Complement deposition is also present within the elastica of a

choroidal artery (double headed black arrow), as well as within the walls of a choroidal vein (white arrow). Figure 4D shows C5b-9 deposition in Bruch's membrane, intercapillary pillars (arrows) and drusen (asterisk) in patient 2. The internal aspect of a choroidal vein is also immunopositive (white arrow). Figure 4E shows tissue from patient 5 3, an 86-year old with histologic evidence of early AMD. Activated complement deposition is noted throughout Bruch's membrane, in drusen (asterisks) and in the internal wall of a choroidal vein (white arrow). Scale bar: 20 μ m in Figures 4C and 4D), 15 μ m in Figure 4E.

Figure 5 shows the polypeptide sequence for human Complement Factor H
10 (GenBank Accession CAA68704).

DETAILED DESCRIPTION OF THE INVENTION

To provide an overall understanding of the invention, certain illustrative embodiments will now be described, including compositions and methods for identifying or aiding in identifying individuals at risk for developing AMD, as well as for diagnosing 15 or aiding in the diagnosis of AMD. However, it will be understood by one of ordinary skill in the art that the compositions and methods described herein may be adapted and modified as is appropriate for the application being addressed and that the compositions and methods described herein may be employed in other suitable applications, and that such other additions and modifications will not depart from the scope hereof.

20 1. Overview

The discovery that variations in the CFH gene are associated with AMD is useful for the early diagnosis and treatment of individuals predisposed to AMD. The determination of the genetic constitution of the CFH gene in an individual is useful in treating AMD at earlier stages, or even before an individual displays any symptoms of 25 AMD. Furthermore, diagnostic tests to genotype CFH may allow individuals to alter their behavior to minimize environmental risks to AMD (e.g., smoking). Accordingly, the present invention relates to the identification of a variant CFH gene correlated with a predisposition to AMD, which is useful in identifying or aiding in identifying individuals at risk for developing AMD, as well as for diagnosing or aiding in the diagnosis of AMD. It 30 also relates to methods for identifying or aiding in identifying individuals at risk for

developing AMD, methods for diagnosing or aiding in the diagnosis of AMD, polynucleotides (e.g., probes, primers) useful in the methods, diagnostic kits containing probes or primers, methods of treating an individual at risk for or suffering from AMD and compositions useful for treating an individual at risk for or suffering from AMD.

5 In accordance with the present invention, a common variation in the CFH gene has been shown to be strongly associated with AMD. The present invention relates to methods and compositions for detecting such variations that predispose a human to AMD. A CFH gene can either be the cDNA or the genomic form of the gene, which may include upstream and downstream regulatory sequences. The CFH polypeptide can be encoded by 10 a full length coding sequence or by any portion of the coding sequence so long as the desired activity or functional properties (e.g., enzymatic activity, ligand binding, signal transduction, etc.) of the full-length or fragment are retained. Examples of CFH nucleotide sequences include human nucleotide sequences (SEQ ID NOs: 1 or 2), a mouse nucleotide sequence (SEQ ID NO: 3), and a rat nucleotide sequence (SEQ ID NO: 4). Polynucleotide 15 probes and primers of the invention may hybridize to any contiguous portion of a CFH gene, such as those shown in SEQ ID NOs 1-4. Examples of CFH polypeptide sequences include human polypeptide sequences (SEQ ID NOs: 5 or 6 and Figure 5), a mouse polypeptide sequence (SEQ ID NO: 7), and a rat polypeptide sequence (SEQ ID NO: 8). The CFH gene may further include sequences located adjacent to the coding region on both 20 the 5' and 3' ends for a distance of about 1-2 kb on either end such that the gene corresponds to the length of the full-length mRNA. The sequences which are located 5' of the coding region and which are present on the mRNA are referred to as 5' non-translated sequences. The sequences which are located 3' or downstream of the coding region and which are present on the mRNA are referred to as 3' non-translated sequences.

25 The CFH gene is a member of the Regulator of Complement Activation (RCA) gene cluster and encodes a protein with twenty short consensus repeat (SCR) domains of 60 amino acids each. This protein is secreted into the bloodstream and has an essential role in the regulation of complement activation (Rodriguez de Cordoba et al., *Mol Immunol.* 41:355-67 (2004)). The complement system protects against infection and attacks diseased 30 and dysplastic cells and normally spares healthy cells. Cells involved in immune surveillance and response to disease are recruited to augment the lytic action of activated complement components. When C3 convertase is activated, it leads to the production of

- C3a and C3b and then to the terminal C5b-9 complex. CFH on cells and in circulation regulates complement activity by inhibiting the activation of C3 to C3a and C3b, and by inactivating existing C3b. Variations in the CFH gene have previously been associated with hemolytic-uremic syndrome (HUS) and chronic hypocomplementemic nephropathy.
- 5 Alternate transcriptional splice variants, encoding different isoforms, have been characterized.

2. CFH polynucleotide probes and primers

In certain embodiments, the invention provides isolated and/or recombinant polynucleotides that specifically detect a variation in the CFH gene that is correlated with the occurrence of AMD. Polynucleotide probes of the invention hybridize to a variation (referred to as a variation of interest) in such a CFH gene, and the flanking sequence, in a specific manner and thus typically have a sequence which is fully or partially complementary to the sequence of the variation and the flanking region. Polynucleotide probes of the invention may hybridize to a segment of target DNA such that the variation aligns with a central position of the probe, or the variation may align with a terminal position of the probe. In one embodiment, an isolated polynucleotide probe of the invention hybridizes, under stringent conditions, to a nucleic acid molecule comprising a variant CFH gene, or a portion or allelic variant thereof, that is correlated with the occurrence of AMD in humans. In another embodiment, an isolated polynucleotide probe of the invention hybridizes, under stringent conditions, to a nucleic acid molecule comprising at least 10 contiguous nucleotides of a CFH gene, or an allelic variant thereof, wherein the nucleic acid molecule comprises a variation that is correlated with the occurrence of AMD in humans.

In certain embodiments, a polynucleotide probe of the invention is an allele-specific probe. The design and use of allele-specific probes for analyzing polymorphisms is described by e.g., Saiki et al., Nature 324:163-166 (1986); Dattagupta, EP 235726; and Saiki WO 89/11548. Allele-specific probes can be designed to hybridize to a segment of a target DNA from one individual but do not hybridize to the corresponding segment from another individual due to the presence of different polymorphic forms or variations in the respective segments from the two individuals. Hybridization conditions should be

sufficiently stringent such that there is a significant difference in hybridization intensity between alleles. In some embodiments, a probe hybridizes to only one of the alleles.

A variety of variations in the CFH gene that predispose an individual to AMD may be detected by the methods and polynucleotides described herein. For example, any 5 nucleotide polymorphism of a coding region, exon, exon-intron boundary, signal peptide, 5'-prime untranslated region, promoter region, enhancer sequence, 3'-prime untranslated region or intron that is associated with AMD can be detected. These polymorphisms include, but are not limited to, changes that: alter the amino acid sequence of the proteins encoded by the CFH gene, produce alternative splice products, create truncated products, 10 introduce a premature stop codon, introduce a cryptic exon, alter the degree or expression to a greater or lesser extent, alter tissue specificity of CFH expression, introduce changes in the tertiary structure of the proteins encoded by CFH, introduce changes in the binding affinity or specificity of the proteins expressed by CFH or alter the function of the proteins encoded by CFH. In a specific embodiment, the variation in the CFH gene encodes an 15 amino acid other than histidine (e.g., tyrosine) at position 402 of the CFH protein. In another specific embodiment, the variation in the CFH gene encodes an amino acid other than valine (e.g., isoleucine) at position 62 of the CFH protein. Other examples of variations in the CFH gene that may predispose an individual to AMD are found in Tables 20 4 and 5. For example, other variant genes, such as those in which the variation is in a coding region (e.g., variations that encode: an amino acid other than serine, such as alanine, at position 58 of the CFH protein; an amino acid other than arginine, such as histidine, at position 127 of the CFH protein; an amino acid other than glutamine, such as lysine, at position 400 of the CFH protein; an amino acid other than valine, such as isoleucine, at position 609 of the CFH protein; an amino acid other than serine, such as 25 isoleucine, at position 890 of the CFH protein; an amino acid other than glutamic acid, such as aspartic acid, at position 936 of the CFH protein; an amino acid other than valine, such as leucine, at position 1007 of the CFH protein; an amino acid other than asparagine, such as tyrosine, at position 1050 of the CFH protein; an amino acid other than proline, such as glutamine, at position 1166 of the CFH protein; or an amino acid other than arginine, such as cysteine, at position 1210 of the CFH protein. See Tables 4 and 5) can be 30 detected using the methods and compositions described herein for other variants. Alternatively, variant genes in which the variation is in a noncoding region, such as those listed in Tables 4 and 5, may be detected using the methods and compositions described

herein. The subject polynucleotides are further understood to include polynucleotides that are variants of the polynucleotides described herein, provided that the variant polynucleotides maintain their ability to specifically detect a variation in the CFH gene that is correlated with the occurrence of AMD. Variant polynucleotides may include, for 5 example, sequences that differ by one or more nucleotide substitutions, additions or deletions.

In certain embodiments, the isolated polynucleotide is a probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of AMD in humans. As used herein, the term "hybridization" is used in 10 reference to the pairing of complementary nucleic acids. The term "probe" refers to a polynucleotide that is capable of hybridizing to another nucleic acid of interest. The polynucleotide may be naturally occurring, as in a purified restriction digest, or it may be produced synthetically, recombinantly or by nucleic acid amplification (e.g., PCR amplification).

15 It is well known in the art how to perform hybridization experiments with nucleic acid molecules. The skilled artisan is familiar with the hybridization conditions required in the present invention and understands readily that appropriate stringency conditions which promote DNA hybridization can be varied. Such hybridization conditions are referred to in standard text books, such as Molecular Cloning: A Laboratory Manual, Cold Spring 20 Harbor Laboratory (2001); and Current Protocols in Molecular Biology, eds. Ausubel et al., John Wiley & Sons (1992). Particularly useful in methods of the present invention are polynucleotides which are capable of hybridizing to a variant CFH gene, or a region of a variant CFH gene, under stringent conditions. Under stringent conditions, a polynucleotide that hybridizes to a variant CFH gene does not hybridize to a wildtype CFH gene.

25 Nucleic acid hybridization is affected by such conditions as salt concentration, temperature, organic solvents, base composition, length of the complementary strands, and the number of nucleotide base mismatches between the hybridizing nucleic acids, as will readily be appreciated by those skilled in the art. Stringent temperature conditions will generally include temperatures in excess of 30°C, or may be in excess of 37°C or 45°C. 30 Stringency increases with temperature. For example, temperatures greater than 45°C are highly stringent conditions. Stringent salt conditions will ordinarily be less than 1000 mM, or may be less than 500 mM or 200 mM. For example, one could perform the

hybridization at 6.0x sodium chloride/sodium citrate (SSC) at about 45 °C, followed by a wash of 2.0x SSC at 50 °C. For example, the salt concentration in the wash step can be selected from a low stringency of about 2.0x SSC at 50 °C to a high stringency of about 0.2x SSC at 50 °C. In addition, the temperature in the wash step can be increased from low 5 stringency conditions at room temperature, about 22 °C, to high stringency conditions at about 65 °C. Both temperature and salt may be varied, or temperature or salt concentration may be held constant while the other variable is changed. Particularly useful in methods of the present invention are polynucleotides which are capable of hybridizing to a variant CFH gene, or a region of a variant CFH gene, under stringent conditions. It is understood, 10 however, that the appropriate stringency conditions may be varied in the present invention to promote DNA hybridization. In certain embodiments, polynucleotides of the present invention hybridize to a variant CFH gene, or a region of a variant CFH gene, under highly stringent conditions. Under stringent conditions, a polynucleotide that hybridizes to a variation in the CFH gene does not hybridize to a wildtype CFH gene. In one embodiment, 15 the invention provides nucleic acids which hybridize under low stringency conditions of 6.0x SSC at room temperature followed by a wash at 2.0x SSC at room temperature. The combination of parameters, however, is much more important than the measure of any single parameter. See, e.g., Wetmur and Davidson, 1968. Probe sequences may also hybridize specifically to duplex DNA under certain conditions to form triplex or higher 20 order DNA complexes. The preparation of such probes and suitable hybridization conditions are well known in the art. One method for obtaining DNA encoding the biosynthetic constructs disclosed herein is by assembly of synthetic oligonucleotides produced in a conventional, automated, oligonucleotide synthesizer.

A polynucleotide probe or primer of the present invention may be labeled so that it 25 is detectable in a variety of detection systems, including, but not limited, to enzyme (e.g., ELISA, as well as enzyme-based histochemical assays), fluorescent, radioactive, chemical, and luminescent systems. A polynucleotide probe or primer of the present invention may further include a quencher moiety that, when placed in proximity to a label (e.g., a fluorescent label), causes there to be little or no signal from the label. Detection of the 30 label may be performed by direct or indirect means (e.g., via a biotin/avidin or a biotin/streptavidin linkage). It is not intended that the present invention be limited to any particular detection system or label.

In another embodiment, the isolated polynucleotide of the invention is a primer that hybridizes, under stringent conditions, adjacent, upstream, or downstream to a variation in the CFH gene that is correlated with the occurrence of AMD in humans. The isolated polynucleotide may hybridize, under stringent conditions, to a nucleic acid molecule comprising all or a portion of a variant CFH gene that is correlated with the occurrence of AMD in humans. Alternatively, the isolated polynucleotide primer may hybridize, under stringent conditions, to a nucleic acid molecule comprising at least 50 contiguous nucleotides of a variant CFH gene that is correlated with the occurrence of AMD in humans. For example, a polynucleotide primer of the invention can hybridize adjacent, upstream, or downstream to the region of the CFH gene that encodes amino acid 402 of the CFH protein. Alternatively, a polynucleotide primer of the invention can hybridize adjacent, upstream, or downstream to the region of the CFH gene that encodes amino acid 62 of the CFH protein.

As used herein, the term "primer" refers to a polynucleotide that is capable of acting as a point of initiation of nucleic acid synthesis when placed under conditions in which synthesis of a primer extension product that is complementary to a nucleic acid strand occurs (for example, in the presence of nucleotides, an inducing agent such as DNA polymerase, and suitable temperature, pH, and electrolyte concentration). Alternatively, the primer may be capable of ligating to a proximal nucleic acid when placed under conditions in which ligation of two unlinked nucleic acids occurs (for example, in the presence of a proximal nucleic acid, an inducing agent such as DNA ligase, and suitable temperature, pH, and electrolyte concentration). A polynucleotide primer of the invention may be naturally occurring, as in a purified restriction digest, or may be produced synthetically. The primer is preferably single stranded for maximum efficiency in amplification, but may alternatively be double stranded. If double stranded, the primer is first treated to separate its strands before being used. Preferably, the primer is an oligodeoxyribonucleotide. The exact lengths of the primers will depend on many factors, including temperature, source of primer and the use of the method. In certain embodiments, the polynucleotide primer of the invention is at least 10 nucleotides long and hybridizes to one side or another of a variation in the CFH gene that is correlated with the occurrence of AMD in humans. The subject polynucleotides may contain alterations, such as one or more nucleotide substitutions, additions or deletions, provided they hybridize to their target variant CFH gene with the same degree of specificity.

In one embodiment, the invention provides a pair of primers that specifically detect a variation in the CFH gene that is correlated with the occurrence of AMD. In such a case, the first primer hybridizes upstream from the variation and a second primer hybridizes downstream from the variation. It is understood that one of the primers hybridizes to one 5 strand of a region of DNA that comprises a variation in the CFH gene that is correlated with the occurrence of AMD, and the second primer hybridizes to the complementary strand of a region of DNA that comprises a variation in the CFH gene that is correlated with the occurrence of AMD. As used herein, the term "region of DNA" refers to a sub-chromosomal length of DNA.

10 In another embodiment, the invention provides an allele-specific primer that hybridizes to a site on target DNA that overlaps a variation in the CFH gene that is correlated with the occurrence of AMD in humans. An allele-specific primer of the invention only primes amplification of an allelic form to which the primer exhibits perfect complementarity. This primer may be used, for example, in conjunction with a second 15 primer which hybridizes at a distal site. Amplification can thus proceed from the two primers, resulting in a detectable product that indicates the presence of a variant CFH gene that is correlated with the occurrence of AMD in humans.

3. Detection assays

20 In certain embodiments, the invention relates to polynucleotides useful for detecting a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration. Preferably, these polynucleotides are capable of hybridizing under stringent hybridization conditions to a region of DNA that comprises a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration.

25 The polynucleotides of the invention may be used in any assay that permits detection of a variation in the CFH gene that is correlated with the occurrence of AMD. Such methods may encompass, for example, DNA sequencing, hybridization, ligation, or primer extension methods. Furthermore, any combination of these methods may be utilized in the invention.

30 In one embodiment, the presence of a variation in the CFH gene that is correlated with the occurrence of AMD is detected and/or determined by DNA sequencing. DNA sequence determination may be performed by standard methods such as dideoxy chain

termination technology and gel-electrophoresis, or by other methods such as by pyrosequencing (Biotage AB, Uppsala, Sweden). For example, DNA sequencing by dideoxy chain termination may be performed using unlabeled primers and labeled (e.g., fluorescent or radioactive) terminators. Alternatively, sequencing may be performed using 5 labeled primers and unlabeled terminators. The nucleic acid sequence of the DNA in the sample can be compared to the nucleic acid sequence of wildtype DNA to identify whether a variation in the CFH gene that is correlated with the occurrence of AMD is present.

In another embodiment, the presence of a variation in the CFH gene that is correlated with the occurrence of AMD is detected and/or determined by hybridization. In 10 one embodiment, a polynucleotide probe hybridizes to a variation in the CFH gene, and flanking nucleotides, that is correlated with AMD, but not to a wildtype CFH gene. The polynucleotide probe may comprise nucleotides that are fluorescently, radioactively, or chemically labeled to facilitate detection of hybridization. Hybridization may be performed and detected by standard methods known in the art, such as by Northern blotting, Southern blotting, fluorescent in situ hybridization (FISH), or by hybridization to 15 polynucleotides immobilized on a solid support, such as a DNA array or microarray. As used herein, the term "DNA array," and "microarray" refers to an ordered arrangement of hybridizable array elements. The array elements are arranged so that there are preferably at least one or more different array elements immobilized on a substrate surface. The 20 hybridization signal from each of the array elements is individually distinguishable. In a preferred embodiment, the array elements comprise polynucleotides, although the present invention could also be used with cDNA or other types of nucleic acid array elements.

In a specific embodiment, the polynucleotide probe is used to hybridize genomic DNA by FISH. FISH can be used, for example, in metaphase cells, to detect a deletion in 25 genomic DNA. Genomic DNA is denatured to separate the complimentary strands within the DNA double helix structure. The polynucleotide probe of the invention is then added to the denatured genomic DNA. If a variation in the CFH gene that is correlated with the occurrence of AMD is present, the probe will hybridize to the genomic DNA. The probe signal (e.g., fluorescence) can then be detected through a fluorescent microscope for the 30 presence of absence of signal. The absence of signal, therefore, indicates the absence of a variation in the CFH gene that is correlated with the occurrence of AMD. In another specific embodiment, a labeled polynucleotide probe is applied to immobilized

polynucleotides on a DNA array. Hybridization may be detected, for example, by measuring the intensity of the labeled probe remaining on the DNA array after washing. The polynucleotides of the invention may also be used in commercial assays, such as the Taqman assay (Applied Biosystems, Foster City, CA).

5 In another embodiment, the presence of a variation in the CFH gene that is correlated with the occurrence of AMD is detected and/or determined by primer extension with DNA polymerase. In one embodiment, a polynucleotide primer of the invention hybridizes immediately adjacent to the variation. A single base sequencing reaction using labeled dideoxynucleotide terminators may be used to detect the variation. The presence of
10 a variation will result in the incorporation of the labeled terminator, whereas the absence of a variation will not result in the incorporation of the terminator. In another embodiment, a polynucleotide primer of the invention hybridizes to a variation in the CFH gene that is correlated with the occurrence of AMD. The primer, or a portion thereof, will not hybridize to a wildtype CFH gene. The presence of a variation will result in primer
15 extension, whereas the absence of a variation will not result in primer extension. The primers and/or nucleotides may further include fluorescent, radioactive, or chemical probes. A primer labeled by primer extension may be detected by measuring the intensity of the extension product, such as by gel electrophoresis, mass spectrometry, or any other method for detecting fluorescent, radioactive, or chemical labels.

20 In another embodiment, the presence of a variation in the CFH gene that is correlated with the occurrence of AMD is detected and/or determined by ligation. In one embodiment, a polynucleotide primer of the invention hybridizes to a variation in the CFH gene that is correlated with the occurrence of AMD. The primer, or a portion thereof will not hybridize to a wildtype CFH gene. A second polynucleotide that hybridizes to a region
25 of the CFH gene immediately adjacent to the first primer is also provided. One, or both, of the polynucleotide primers may be fluorescently, radioactively, or chemically labeled. Ligation of the two polynucleotide primers will occur in the presence of DNA ligase if a variation in the CFH gene that is correlated with the occurrence of AMD is present.
30 Ligation may be detected by gel electrophoresis, mass spectrometry, or by measuring the intensity of fluorescent, radioactive, or chemical labels.

In another embodiment, the presence of a variation in the CFH gene that is correlated with the occurrence of AMD is detected and/or determined by single-base extension (SBE). For example, a fluorescently-labeled primer that is coupled with fluorescence resonance energy transfer (FRET) between the label of the added base and the 5 label of the primer may be used. Typically, the method, such as that described by Chen et al., (PNAS 94:10756-61 (1997), incorporated herein by reference) uses a locus-specific polynucleotide primer labeled on the 5' terminus with 5-carboxyfluorescein (FAM). This labeled primer is designed so that the 3' end is immediately adjacent to the polymorphic site of interest. The labeled primer is hybridized to the locus, and single base extension of 10 the labeled primer is performed with fluorescently labeled dideoxyribonucleotides (ddNTPs) in dye-terminator sequencing fashion, except that no deoxyribonucleotides are present. An increase in fluorescence of the added ddNTP in response to excitation at the wavelength of the labeled primer is used to infer the identity of the added nucleotide.

Methods of detecting a variation in the CFH gene that is correlated with the 15 occurrence of AMD may include amplification of a region of DNA that comprises the variation. Any method of amplification may be used. In one specific embodiment, a region of DNA comprising the variation is amplified by using polymerase chain reaction (PCR). PCR was initially described by Mullis (See e.g., U.S. Pat. Nos. 4,683,195 4,683,202, and 4,965,188, herein incorporated by reference), which describes a method for 20 increasing the concentration of a region of DNA, in a mixture of genomic DNA, without cloning or purification. Other PCR methods may also be used to nucleic acid amplification, including but not limited to RT-PCR, quantitative PCR, real time PCR, Rapid Amplified Polymorphic DNA Analysis, Rapid Amplification of cDNA Ends (RACE), or rolling circle amplification. For example, the polynucleotide primers of the 25 invention are combined with a DNA mixture (or any polynucleotide sequence that can be amplified with the polynucleotide primers of the invention), wherein the DNA comprises the CFH gene. The mixture also includes the necessary amplification reagents (e.g., deoxyribonucleotide triphosphates, buffer, etc.) necessary for the thermal cycling reaction. According to standard PCR methods, the mixture undergoes a series of denaturation, 30 primer annealing, and polymerase extension steps to amplify the region of DNA that comprises the variation in the CFH gene. The length of the amplified region of DNA is determined by the relative positions of the primers with respect to each other, and

therefore, this length is a controllable parameter. For example, hybridization of the primers may occur such that the ends of the primers proximal to the variation are separated by 1 to 10,000 base pairs (e.g., 10 base pairs (bp) 50 bp, 200 bp, 500 bp, 1,000 bp, 2,500 bp, 5,000 bp, or 10,000 bp).

5 Standard instrumentation known to those skilled in the art are used for the amplification and detection of amplified DNA. For example, a wide variety of instrumentation has been developed for carrying out nucleic acid amplifications, particularly PCR, e.g. Johnson et al, U.S. Pat. No. 5,038,852 (computer-controlled thermal cycler); Wittwer et al, Nucleic Acids Research, 17: 4353-4357 (1989)(capillary tube PCR);
10 Hallsby, U.S. Pat. No. 5,187,084 (air-based temperature control); Garner et al, Biotechniques, 14: 112-115 (1993)(high-throughput PCR in 864-well plates); Wilding et al, International application No. PCT/US93/04039 (PCR in micro-machined structures); Schnipelsky et al, European patent application No. 90301061.9 (publ. No. 0381501 A2)(disposable, single use PCR device), and the like. In certain embodiments, the
15 invention described herein utilizes real-time PCR or other methods known in the art such as the Taqman assay.

In certain embodiments, a variant CFH gene that is correlated with the occurrence of AMD in humans may be detected using single-strand conformation polymorphism analysis, which identifies base differences by alteration in electrophoretic migration of
20 single stranded PCR products, as described in Orita et al., Proc. Nat. Acad. Sci. 86, 2766-2770 (1989). Amplified PCR products can be generated as described above, and heated or otherwise denatured, to form single stranded amplification products. Single-stranded nucleic acids may refold or form secondary structures which are partially dependent on the base sequence. The different electrophoretic mobilities of single-stranded amplification products can be related to base-sequence differences between alleles of target sequences.
25

In one embodiment, the amplified DNA is analyzed in conjunction with one of the detection methods described herein, such as by DNA sequencing. The amplified DNA may alternatively be analyzed by hybridization with a labeled probe, hybridization to a DNA array or microarray, by incorporation of biotinylated primers followed by avidin-30 enzyme conjugate detection, or by incorporation of ³²P-labeled deoxynucleotide triphosphates, such as dCTP or dATP, into the amplified segment. In a specific

embodiment, the amplified DNA is analyzed by determining the length of the amplified DNA by electrophoresis or chromatography. For example, the amplified DNA is analyzed by gel electrophoresis. Methods of gel electrophoresis are well known in the art. See for example, *Current Protocols in Molecular Biology*, eds. Ausubel et al., John Wiley & Sons: 1992. The amplified DNA can be visualized, for example, by fluorescent or radioactive means, or with other dyes or markers that intercalate DNA. The DNA may also be transferred to a solid support such as a nitrocellulose membrane and subjected to Southern Blotting following gel electrophoresis. In one embodiment, the DNA is exposed to ethidium bromide and visualized under ultra-violet light.

10 4. Therapeutic Nucleic Acids Encoding CFH Polypeptides

In certain embodiments, the invention provides isolated and/or recombinant nucleic acids encoding a CFH polypeptide, including functional variants, disclosed herein. For example, SEQ ID NOs: 1 or 2 are nucleic acid sequences that encode CFH and SEQ ID NOs: 5 or 6 and Figure 5 encode CFH polypeptides. The subject nucleic acids may be 15 single-stranded or double stranded. Such nucleic acids may be DNA or RNA molecules. These nucleic acids may be used, for example, in methods for making CFH polypeptides or as direct therapeutic agents (e.g., in a gene therapy approach).

The subject nucleic acids encoding CFH polypeptides are further understood to include nucleic acids that are variants of SEQ ID NOs: 1 or 2. Variant nucleotide 20 sequences include sequences that differ by one or more nucleotide substitutions, additions or deletions, such as allelic variants; and will, therefore, include coding sequences that differ from the nucleotide sequence of the coding sequence designated in SEQ ID NOs: 1 or 2. Coding sequences that differ from the nucleotide sequence of the coding sequence designated in SEQ ID NOs: 1 or 2 may be tested for their ability to inhibit the activation of 25 C3 to C3a and C3b, and by inactivating existing C3.

In certain embodiments, the invention provides isolated or recombinant nucleic acid sequences that are at least 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 1 or 2. One of ordinary skill in the art will appreciate that nucleic acid sequences complementary to SEQ ID NO: 1 or 2, and variants of SEQ ID NO: 1 or 2 are 30 also within the scope of this invention. In further embodiments, the nucleic acid sequences

of the invention can be isolated, recombinant, and/or fused with a heterologous nucleotide sequence, or in a DNA library.

In other embodiments, nucleic acids of the invention also include nucleic acids that hybridize under stringent conditions to the nucleotide sequence designated in SEQ ID NO: 5 1 or 2, complement sequence of SEQ ID NO: 1 or 2, or fragments thereof. As discussed above, one of ordinary skill in the art will understand readily that appropriate stringency conditions which promote DNA hybridization can be varied. For example, one could perform the hybridization at 6.0 x sodium chloride/sodium citrate (SSC) at about 45 °C, followed by a wash of 2.0 x SSC at 50 °C. For example, the salt concentration in the wash 10 step can be selected from a low stringency of about 2.0 x SSC at 50 °C to a high stringency of about 0.2 x SSC at 50 °C. In addition, the temperature in the wash step can be increased from low stringency conditions at room temperature, about 22 °C, to high stringency conditions at about 65 °C. Both temperature and salt may be varied, or temperature or salt concentration may be held constant while the other variable is changed. In one 15 embodiment, the invention provides nucleic acids which hybridize under low stringency conditions of 6 x SSC at room temperature followed by a wash at 2 x SSC at room temperature.

Isolated nucleic acids which differ from the nucleic acids as set forth in SEQ ID NO: 1 or 2 due to degeneracy in the genetic code are also within the scope of the invention. 20 For example, a number of amino acids are designated by more than one triplet. Codons that specify the same amino acid, or synonyms (for example, CAU and CAC are synonyms for histidine) may result in "silent" variations which do not affect the amino acid sequence of the protein. However, it is expected that DNA sequence polymorphisms that do lead to changes in the amino acid sequences of the subject proteins will exist among mammalian 25 cells. One skilled in the art will appreciate that these variations in one or more nucleotides (up to about 3-5% of the nucleotides) of the nucleic acids encoding a particular protein may exist among individuals of a given species due to natural allelic variation. Any and all such nucleotide variations and resulting amino acid polymorphisms are within the scope of this invention.

30 The nucleic acids and polypeptides of the invention may be produced using standard recombinant methods. For example, the recombinant nucleic acids of the invention may be operably linked to one or more regulatory nucleotide sequences in an

expression construct. Regulatory nucleotide sequences will generally be appropriate to the host cell used for expression. Numerous types of appropriate expression vectors and suitable regulatory sequences are known in the art for a variety of host cells. Typically, said one or more regulatory nucleotide sequences may include, but are not limited to,

5 promoter sequences, leader or signal sequences, ribosomal binding sites, transcriptional start and termination sequences, translational start and termination sequences, and enhancer or activator sequences. Constitutive or inducible promoters as known in the art are contemplated by the invention. The promoters may be either naturally occurring promoters, or hybrid promoters that combine elements of more than one promoter. An

10 expression construct may be present in a cell on an episome, such as a plasmid, or the expression construct may be inserted in a chromosome. The expression vector may also contain a selectable marker gene to allow the selection of transformed host cells.

Selectable marker genes are well known in the art and will vary with the host cell used.

In certain embodiments of the invention, the subject nucleic acid is provided in an expression vector comprising a nucleotide sequence encoding a CFH polypeptide and operably linked to at least one regulatory sequence. Regulatory sequences are art-recognized and are selected to direct expression of the CFH polypeptide. Accordingly, the term regulatory sequence includes promoters, enhancers, termination sequences, preferred ribosome binding site sequences, preferred mRNA leader sequences, preferred protein processing sequences, preferred signal sequences for protein secretion, and other expression control elements. Examples of regulatory sequences are described in Goeddel; *Gene Expression Technology: Methods in Enzymology*, Academic Press, San Diego, CA (1990). For instance, any of a wide variety of expression control sequences that control the expression of a DNA sequence when operatively linked to it may be used in these vectors to express DNA sequences encoding a CFH polypeptide. Such useful expression control sequences, include, for example, the early and late promoters of SV40, tet promoter, adenovirus or cytomegalovirus immediate early promoter, RSV promoters, the lac system, the trp system, the TAC or TRC system, T7 promoter whose expression is directed by T7 RNA polymerase, the major operator and promoter regions of phage lambda, the control regions for fd coat protein, the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the promoters of acid phosphatase, e.g., Pho5, the promoters of the yeast α -mating factors, the polyhedron promoter of the baculovirus system and other sequences known to control the expression of genes of prokaryotic or eukaryotic cells or their viruses,

and various combinations thereof. It should be understood that the design of the expression vector may depend on such factors as the choice of the host cell to be transformed and/or the type of protein desired to be expressed. Moreover, the vector's copy number, the ability to control that copy number and the expression of any other 5 protein encoded by the vector, such as antibiotic markers, should also be considered.

A recombinant nucleic acid of the invention can be produced by ligating the cloned gene, or a portion thereof, into a vector suitable for expression in either prokaryotic cells, eukaryotic cells (yeast, avian, insect or mammalian), or both. Expression vehicles for production of recombinant CFH polypeptides include plasmids and other vectors. For 10 instance, suitable vectors include plasmids of the types: pBR322-derived plasmids, pEMBL-derived plasmids, pEX-derived plasmids, pBTac-derived plasmids and pUC-derived plasmids for expression in prokaryotic cells, such as *E. coli*.

Some mammalian expression vectors contain both prokaryotic sequences to facilitate the propagation of the vector in bacteria, and one or more eukaryotic transcription 15 units that are expressed in eukaryotic cells. The pcDNAI/amp, pcDNAI/neo, pRc/CMV, pSV2gpt, pSV2neo, pSV2-dhfr, pTk2, pRSVneo, pMSG, pSVT7, pko-neo and pHyg derived vectors are examples of mammalian expression vectors suitable for transfection of eukaryotic cells. Some of these vectors are modified with sequences from bacterial plasmids, such as pBR322, to facilitate replication and drug resistance selection in both 20 prokaryotic and eukaryotic cells. Alternatively, derivatives of viruses such as the bovine papilloma virus (BPV-1), or Epstein-Barr virus (pHEBo, pREP-derived and p205) can be used for transient expression of proteins in eukaryotic cells. Examples of other viral (including retroviral) expression systems can be found below in the description of gene therapy delivery systems. The various methods employed in the preparation of the 25 plasmids and in transformation of host organisms are well known in the art. For other suitable expression systems for both prokaryotic and eukaryotic cells, as well as general recombinant procedures, see Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory (2001). In some instances, it may be desirable to express the recombinant polypeptide by the use of a baculovirus expression system. Examples of such 30 baculovirus expression systems include pVL-derived vectors (such as pVL1392, pVL1393 and pVL941), pAcUW-derived vectors (such as pAcUW1), and pBlueBac-derived vectors (such as the β -gal containing pBlueBac III).

In one embodiment, a vector will be designed for production of a subject CFH polypeptide in CHO cells, such as a Pcmv-Script vector (Stratagene, La Jolla, Calif.), pcDNA4 vectors (Invitrogen, Carlsbad, Calif.) and pCI-neo vectors (Promega, Madison, Wisc.). In other embodiments, the vector is designed for production of a subject CFH polypeptide in prokaryotic host cells (e.g., *E. coli* and *B. subtilis*), eukaryotic host cells such as, for example, yeast cells, insect cells, myeloma cells, fibroblast 3T3 cells, monkey kidney or COS cells, mink-lung epithelial cells, human foreskin fibroblast cells, human glioblastoma cells, and teratocarcinoma cells. Alternatively, the genes may be expressed in a cell-free system such as the rabbit reticulocyte lysate system.

As will be apparent, the subject gene constructs can be used to express the subject CFH polypeptide in cells propagated in culture, e.g., to produce proteins, including fusion proteins or variant proteins, for purification.

This invention also pertains to a host cell transfected with a recombinant gene including a coding sequence (e.g., SEQ ID NO: 1 or 2) for one or more of the subject CFH polypeptides. The host cell may be any prokaryotic or eukaryotic cell. For example, a CFH polypeptide of the invention may be expressed in bacterial cells such as *E. coli*, insect cells (e.g., using a baculovirus expression system), yeast, or mammalian cells. Other suitable host cells are known to those skilled in the art.

Accordingly, the present invention further pertains to methods of producing the subject CFH polypeptides. For example, a host cell transfected with an expression vector encoding a CFH polypeptide can be cultured under appropriate conditions to allow expression of the CFH polypeptide to occur. CFH polypeptides may be secreted and isolated from a mixture of cells and medium containing the CFH polypeptides.

Alternatively, the polypeptide may be retained cytoplasmically or in a membrane fraction and the cells harvested, lysed and the protein isolated. A cell culture includes host cells, media and other byproducts. Suitable media for cell culture are well known in the art. The polypeptide can be isolated from cell culture medium, host cells, or both using techniques known in the art for purifying proteins, including ion-exchange chromatography, gel filtration chromatography, ultrafiltration, electrophoresis, and immunoaffinity purification with antibodies specific for particular epitopes of the polypeptide. In a particular embodiment, the CFH polypeptide is a fusion protein containing a domain which facilitates the purification of the CFH polypeptide.

In another embodiment, a fusion gene coding for a purification leader sequence, such as a poly-(His)/enterokinase cleavage site sequence at the N-terminus of the desired portion of the recombinant CFH polypeptide, can allow purification of the expressed fusion protein by affinity chromatography using a Ni²⁺ metal resin. The purification leader 5 sequence can then be subsequently removed by treatment with enterokinase to provide the purified polypeptide (e.g., see Hochuli et al., (1987) *J. Chromatography* 411:177; and Janknecht et al., *PNAS USA* 88:8972).

Techniques for making fusion genes are well known. Essentially, the joining of various DNA fragments coding for different polypeptide sequences is performed in 10 accordance with conventional techniques, employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR 15 amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed to generate a chimeric gene sequence (see, for example, *Current Protocols in Molecular Biology*, eds. Ausubel et al., John Wiley & Sons: 1992).

5. Other therapeutic modalities

20 *Antisense polynucleotides*

In certain embodiments, the invention provides polynucleotides that comprise an antisense sequence that acts through an antisense mechanism for inhibiting expression of a variant CFH gene. Antisense technologies have been widely utilized to regulate gene expression (Buskirk et al., *Chem Biol* 11, 1157-63 (2004); and Weiss et al., *Cell Mol Life 25 Sci* 55, 334-58 (1999)). As used herein, "antisense" technology refers to administration or in situ generation of molecules or their derivatives which specifically hybridize (e.g., bind) under cellular conditions, with the target nucleic acid of interest (mRNA and/or genomic 30 DNA) encoding one or more of the target proteins so as to inhibit expression of that protein, e.g., by inhibiting transcription and/or translation, such as by steric hindrance, altering splicing, or inducing cleavage or other enzymatic inactivation of the transcript. The binding may be by conventional base pair complementarity, or, for example, in the

case of binding to DNA duplexes, through specific interactions in the major groove of the double helix. In general, "antisense" technology refers to the range of techniques generally employed in the art, and includes any therapy that relies on specific binding to nucleic acid sequences.

5 A polynucleotide that comprises an antisense sequence of the present invention can be delivered, for example, as a component of an expression plasmid which, when transcribed in the cell, produces a nucleic acid sequence that is complementary to at least a unique portion of the target nucleic acid. Alternatively, the polynucleotide that comprises an antisense sequence can be generated outside of the target cell, and which, when
10 introduced into the target cell causes inhibition of expression by hybridizing with the target nucleic acid. Polynucleotides of the invention may be modified so that they are resistant to endogenous nucleases, e.g. exonucleases and/or endonucleases, and are therefore stable *in vivo*. Examples of nucleic acid molecules for use in polynucleotides of the invention are phosphoramidate, phosphothioate and methylphosphonate analogs of DNA (see also U.S.
15 Pat. Nos. 5,176,996; 5,264,564; and 5,256,775). General approaches to constructing polynucleotides useful in antisense technology have been reviewed, for example, by van der krol et al. (1988) *Biotechniques* 6:958-976; and Stein et al. (1988) *Cancer Res* 48:2659-2668.

Antisense approaches involve the design of polynucleotides (either DNA or RNA)
20 that are complementary to a target nucleic acid encoding a variant CFH gene. The antisense polynucleotide may bind to an mRNA transcript and prevent translation of a protein of interest. Absolute complementarity, although preferred, is not required. In the case of double-stranded antisense polynucleotides, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend
25 on both the degree of complementarity and the length of the antisense sequence. Generally, the longer the hybridizing nucleic acid, the more base mismatches with a target nucleic acid it may contain and still form a stable duplex (or triplex, as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

30 Antisense polynucleotides that are complementary to the 5' end of an mRNA target, e.g., the 5' untranslated sequence up to and including the AUG initiation codon, should work most efficiently at inhibiting translation of the mRNA. However, sequences

complementary to the 3' untranslated sequences of mRNAs have recently been shown to be effective at inhibiting translation of mRNAs as well (Wagner, R. 1994. *Nature* 372:333). Therefore, antisense polynucleotides complementary to either the 5' or 3' untranslated, non-coding regions of a variant CFH gene could be used in an antisense approach to inhibit translation of a variant CFH mRNA. Antisense polynucleotides complementary to the 5' untranslated region of an mRNA should include the complement of the AUG start codon. Antisense polynucleotides complementary to mRNA coding regions are less efficient inhibitors of translation but could also be used in accordance with the invention. Whether designed to hybridize to the 5', 3', or coding region of mRNA, antisense polynucleotides should be at least six nucleotides in length, and are preferably less than about 100 and more preferably less than about 50, 25, 17 or 10 nucleotides in length.

Regardless of the choice of target sequence, it is preferred that in vitro studies are first performed to quantitate the ability of the antisense polynucleotide to inhibit expression of a variant CFH gene. It is preferred that these studies utilize controls that distinguish between antisense gene inhibition and nonspecific biological effects of antisense polynucleotide. It is also preferred that these studies compare levels of the target RNA or protein with that of an internal control RNA or protein. Additionally, it is envisioned that results obtained using the antisense polynucleotide are compared with those obtained using a control antisense polynucleotide. It is preferred that the control antisense polynucleotide is of approximately the same length as the test antisense polynucleotide and that the nucleotide sequence of the control antisense polynucleotide differs from the antisense sequence of interest no more than is necessary to prevent specific hybridization to the target sequence.

Polynucleotides of the invention, including antisense polynucleotides, can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. Polynucleotides of the invention can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc. Polynucleotides of the invention may include other appended groups such as peptides (e.g., for targeting host cell receptors), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al., 1989, *Proc Natl Acad Sci. USA*

86:6553-6556; Lemaitre et al., 1987, *Proc Natl Acad Sci. USA* 84:648-652; PCT Publication No. W088/09810, published Dec. 15, 1988) or the blood- brain barrier (see, e.g., PCT Publication No. W089/10134, published Apr. 25, 1988), hybridization-triggered cleavage agents. (See, e.g., Krol et al., 1988, *BioTechniques* 6:958-976) or intercalating agents. (See, e.g., Zon, *Pharm. Res.* 5:539-549 (1988)). To this end, a polynucleotide of the invention may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

Polynucleotides of the invention, including antisense polynucleotides, may comprise at least one modified base moiety which is selected from the group including but not limited to 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxyethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5- carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6- isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 15 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil; beta-D-mannosylqueosine, 5-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methyl ester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-20 3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

Polynucleotides of the invention may also comprise at least one modified sugar moiety selected from the group including but not limited to arabinose, 2-fluoroarabinose, xylulose, and hexose.

25 A polynucleotide of the invention can also contain a neutral peptide-like backbone. Such molecules are termed peptide nucleic acid (PNA)-oligomers and are described, e.g., in Perry-O'Keefe et al. (1996) *Proc. Natl. Acad. Sci. USA* 93:14670 and in Egli et al. (1993) *Nature* 365:566. One advantage of PNA oligomers is their capability to bind to complementary DNA essentially independently from the ionic strength of the medium due 30 to the neutral backbone of the DNA. In yet another embodiment, a polynucleotide of the invention comprises at least one modified phosphate backbone selected from the group consisting of a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a

phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

In a further embodiment, polynucleotides of the invention, including antisense polynucleotides are -anomeric oligonucleotides. An -anomeric oligonucleotide forms 5 specific double-stranded hybrids with complementary RNA in which, contrary to the usual -units, the strands run parallel to each other (Gautier et al., 1987, *Nucl. Acids Res.* 15:6625-6641). The oligonucleotide is a 2'-O-methylribonucleotide (Inoue et al., 1987, *Nucl. Acids Res.* 15:6131-6148), or a chimeric RNA-DNA analogue (Inoue et al., 1987, *FEBS Lett.* 215:327-330).

10 Polynucleotides of the invention, including antisense polynucleotides, may be synthesized by standard methods known in the art, e.g., by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein et al. *Nucl. Acids Res.* 16:3209 (1988)), methylphosphonate oligonucleotides can be 15 prepared by use of controlled pore glass polymer supports (Sarin et al., *Proc. Natl. Acad. Sci. USA* 85:7448-7451 (1988)), etc.

While antisense sequences complementary to the coding region of an mRNA sequence can be used, those complementary to the transcribed untranslated region and to the region comprising the initiating methionine are most preferred.

20 Antisense polynucleotides can be delivered to cells that express target genes *in vivo*. A number of methods have been developed for delivering nucleic acids into cells; e.g., they can be injected directly into the tissue site, or modified nucleic acids, designed to target the desired cells (e.g., antisense polynucleotides linked to peptides or antibodies that specifically bind receptors or antigens expressed on the target cell surface) can be 25 administered systematically.

However, it may be difficult to achieve intracellular concentrations of the antisense polynucleotides sufficient to attenuate the activity of a variant CFH gene or mRNA in certain instances. Therefore, another approach utilizes a recombinant DNA construct in 30 which the antisense polynucleotide is placed under the control of a strong pol III or pol II promoter. The use of such a construct to transfet target cells in the patient will result in the transcription of sufficient amounts of antisense polynucleotides that will form

complementary base pairs with the variant CFH gene or mRNA and thereby attenuate the activity of CFH protein. For example, a vector can be introduced in vivo such that it is taken up by a cell and directs the transcription of an antisense polynucleotide that targets a variant CFH gene or mRNA. Such a vector can remain episomal or become

5 chromosomally integrated, as long as it can be transcribed to produce the desired antisense polynucleotide. Such vectors can be constructed by recombinant DNA technology methods standard in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in mammalian cells. A promoter may be operably linked to the sequence encoding the antisense polynucleotide. Expression of the sequence encoding

10 the antisense polynucleotide can be by any promoter known in the art to act in mammalian, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include but are not limited to: the SV40 early promoter region (Bernoist and Chambon, *Nature* 290:304-310 (1981)), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., *Cell* 22:787-797 (1980)), the herpes thymidine kinase

15 promoter (Wagner et al., *Proc. Natl. Acad. Sci. USA* 78:1441-1445 (1981)), the regulatory sequences of the metallothionein gene (Brinster et al, *Nature* 296:3942 (1982)), etc. Any type of plasmid, cosmid, YAC or viral vector can be used to prepare the recombinant DNA construct that can be introduced directly into the tissue site. Alternatively, viral vectors can be used which selectively infect the desired tissue, in which case administration may be

20 accomplished by another route (e.g., systematically).

RNAi constructs - siRNAs and miRNAs

RNA interference (RNAi) is a phenomenon describing double-stranded (ds)RNA-dependent gene specific posttranscriptional silencing. Initial attempts to harness this phenomenon for experimental manipulation of mammalian cells were foiled by a robust and nonspecific antiviral defense mechanism activated in response to long dsRNA molecules. Gil et al. *Apoptosis* 2000, 5:107-114. The field was significantly advanced upon the demonstration that synthetic duplexes of 21 nucleotide RNAs could mediate gene specific RNAi in mammalian cells, without invoking generic antiviral defense mechanisms. Elbashir et al. *Nature* 2001, 411:494-498; Caplen et al. *Proc Natl Acad Sci* 2001, 98:9742-9747. As a result, small-interfering RNAs (siRNAs) and micro RNAs (miRNAs) have become powerful tools to dissect gene function. The chemical synthesis of small RNAs is one avenue that has produced promising results. Numerous groups have

also sought the development of DNA-based vectors capable of generating such siRNA within cells. Several groups have recently attained this goal and published similar strategies that, in general, involve transcription of short hairpin (sh)RNAs that are efficiently processed to form siRNAs within cells. Paddison et al. PNAS 2002, 99:1443-1448; Paddison et al. Genes & Dev 2002, 16:948-958; Sui et al. PNAS 2002, 8:5515-5520; and Brummelkamp et al. Science 2002, 296:550-553. These reports describe methods to generate siRNAs capable of specifically targeting numerous endogenously and exogenously expressed genes.

Accordingly, the present invention provides a polynucleotide comprising an RNAi sequence that acts through an RNAi or miRNA mechanism to attenuate expression of a variant CFH gene. For instance, a polynucleotide of the invention may comprise a miRNA or siRNA sequence that attenuates or inhibits expression of a variant CFH gene. In one embodiment, the miRNA or siRNA sequence is between about 19 nucleotides and about 75 nucleotides in length, or preferably, between about 25 base pairs and about 35 base pairs in length. In certain embodiments, the polynucleotide is a hairpin loop or stem-loop that may be processed by RNase enzymes (e.g., Drosha and Dicer).

An RNAi construct contains a nucleotide sequence that hybridizes under physiologic conditions of the cell to the nucleotide sequence of at least a portion of the mRNA transcript for a variant CFH gene. The double-stranded RNA need only be sufficiently similar to natural RNA that it has the ability to mediate RNAi. The number of tolerated nucleotide mismatches between the target sequence and the RNAi construct sequence is no more than 1 in 5 basepairs, or 1 in 10 basepairs, or 1 in 20 basepairs, or 1 in 50 basepairs. It is primarily important that the RNAi construct is able to specifically target a variant CFH gene. Mismatches in the center of the siRNA duplex are most critical and may essentially abolish cleavage of the target RNA. In contrast, nucleotides at the 3' end of the siRNA strand that is complementary to the target RNA do not significantly contribute to specificity of the target recognition.

Sequence identity may be optimized by sequence comparison and alignment algorithms known in the art (see Gribskov and Devereux, Sequence Analysis Primer, Stockton Press, 1991, and references cited therein) and calculating the percent difference between the nucleotide sequences by, for example, the Smith-Waterman algorithm as implemented in the BESTFIT software program using default parameters (e.g., University

of Wisconsin Genetic Computing Group). Greater than 90% sequence identity, or even 100% sequence identity, between the inhibitory RNA and the portion of the target gene is preferred. Alternatively, the duplex region of the RNA may be defined functionally as a nucleotide sequence that is capable of hybridizing with a portion of the target gene transcript (e.g., 400 mM NaCl, 40mM PIPES pH 6.4, 1 mM EDTA, 50 °C or 70 °C hybridization for 12-16 hours; followed by washing).

Production of polynucleotides comprising RNAi sequences can be carried out by any of the methods for producing polynucleotides described herein. For example, polynucleotides comprising RNAi sequences can be produced by chemical synthetic methods or by recombinant nucleic acid techniques. Endogenous RNA polymerase of the treated cell may mediate transcription *in vivo*, or cloned RNA polymerase can be used for transcription *in vitro*. Polynucleotides of the invention, including wildtype or antisense polynucleotides, or those that modulate target gene activity by RNAi mechanisms, may include modifications to either the phosphate-sugar backbone or the nucleoside, e.g., to reduce susceptibility to cellular nucleases, improve bioavailability, improve formulation characteristics, and/or change other pharmacokinetic properties. For example, the phosphodiester linkages of natural RNA may be modified to include at least one of a nitrogen or sulfur heteroatom. Modifications in RNA structure may be tailored to allow specific genetic inhibition while avoiding a general response to dsRNA. Likewise, bases may be modified to block the activity of adenosine deaminase. Polynucleotides of the invention may be produced enzymatically or by partial/total organic synthesis, any modified ribonucleotide can be introduced by *in vitro* enzymatic or organic synthesis.

Methods of chemically modifying RNA molecules can be adapted for modifying RNAi constructs (see, for example, Heidenreich et al. (1997) Nucleic Acids Res, 25:776-780; Wilson et al. (1994) J Mol Recog 7:89-98; Chen et al. (1995) Nucleic Acids Res 23:2661-2668; Hirschbein et al. (1997) Antisense Nucleic Acid Drug Dev 7:55-61). Merely to illustrate, the backbone of an RNAi construct can be modified with phosphorothioates, phosphoramidate, phosphodithioates, chimeric methylphosphonate-phosphodiesters, peptide nucleic acids, 5-propynyl-pyrimidine containing oligomers or sugar modifications (e.g., 2'-substituted ribonucleosides, α -configuration).

The double-stranded structure may be formed by a single self-complementary RNA strand or two complementary RNA strands. RNA duplex formation may be initiated either

inside or outside the cell. The RNA may be introduced in an amount which allows delivery of at least one copy per cell. Higher doses (e.g., at least 5, 10, 100, 500 or 1000 copies per cell) of double-stranded material may yield more effective inhibition, while lower doses may also be useful for specific applications. Inhibition is sequence-specific in
5 that nucleotide sequences corresponding to the duplex region of the RNA are targeted for genetic inhibition.

In certain embodiments, the subject RNAi constructs are "siRNAs." These nucleic acids are between about 19-35 nucleotides in length, and even more preferably 21-23 nucleotides in length, e.g., corresponding in length to the fragments generated by nuclease
10 "dicing" of longer double-stranded RNAs. The siRNAs are understood to recruit nuclease complexes and guide the complexes to the target mRNA by pairing to the specific sequences. As a result, the target mRNA is degraded by the nucleases in the protein complex or translation is inhibited. In a particular embodiment, the 21-23 nucleotides siRNA molecules comprise a 3' hydroxyl group.

15 In other embodiments, the subject RNAi constructs are "miRNAs." microRNAs (miRNAs) are small non-coding RNAs that direct post transcriptional regulation of gene expression through interaction with homologous mRNAs. miRNAs control the expression of genes by binding to complementary sites in target mRNAs from protein coding genes. miRNAs are similar to siRNAs. miRNAs are processed by nucleolytic cleavage from
20 larger double-stranded precursor molecules. These precursor molecules are often hairpin structures of about 70 nucleotides in length, with 25 or more nucleotides that are base-paired in the hairpin. The RNase III-like enzymes Drosha and Dicer (which may also be used in siRNA processing) cleave the miRNA precursor to produce an miRNA. The processed miRNA is single-stranded and incorporates into a protein complex, termed RISC
25 or miRNP. This RNA-protein complex targets a complementary mRNA. miRNAs inhibit translation or direct cleavage of target mRNAs. (Brennecke et al., Genome Biology 4:228 (2003); Kim et al., Mol. Cells 19:1-15 (2005)).

In certain embodiments, miRNA and siRNA constructs can be generated by
30 processing of longer double-stranded RNAs, for example, in the presence of the enzymes Dicer or Drosha. Dicer and Drosha are RNase III-like nucleases that specifically cleave dsRNA. Dicer has a distinctive structure which includes a helicase domain and dual RNase III motifs. Dicer also contains a region of homology to the

RDE1/QDE2/ARGONAUTE family, which have been genetically linked to RNAi in lower eukaryotes. Indeed, activation of, or overexpression of Dicer may be sufficient in many cases to permit RNA interference in otherwise non-receptive cells, such as cultured eukaryotic cells, or mammalian (non-oocytic) cells in culture or in whole organisms.

5 Methods and compositions employing Dicer, as well as other RNAi enzymes, are described in U.S. Pat. App. Publication No. 2004/0086884.

In one embodiment, the *Drosophila* *in vitro* system is used. In this embodiment, a polynucleotide comprising an RNAi sequence or an RNAi precursor is combined with a soluble extract derived from *Drosophila* embryo, thereby producing a combination. The 10 combination is maintained under conditions in which the dsRNA is processed to RNA molecules of about 21 to about 23 nucleotides.

The miRNA and siRNA molecules can be purified using a number of techniques known to those of skill in the art. For example, gel electrophoresis can be used to purify such molecules. Alternatively, non-denaturing methods, such as non-denaturing column 15 chromatography, can be used to purify the siRNA and miRNA molecules. In addition, chromatography (e.g., size exclusion chromatography), glycerol gradient centrifugation, affinity purification with antibody can be used to purify siRNAs and miRNAs.

In certain embodiments, at least one strand of the siRNA sequence of an effector domain has a 3' overhang from about 1 to about 6 nucleotides in length, or from 2 to 4 20 nucleotides in length. In other embodiments, the 3' overhangs are 1-3 nucleotides in length. In certain embodiments, one strand has a 3' overhang and the other strand is either blunt-ended or also has an overhang. The length of the overhangs may be the same or different for each strand. In order to further enhance the stability of the siRNA sequence, the 3' overhangs can be stabilized against degradation. In one embodiment, the RNA is 25 stabilized by including purine nucleotides, such as adenosine or guanosine nucleotides. Alternatively, substitution of pyrimidine nucleotides by modified analogues, e.g., substitution of uridine nucleotide 3' overhangs by 2'-deoxythymidine is tolerated and does not affect the efficiency of RNAi. The absence of a 2' hydroxyl significantly enhances the nuclease resistance of the overhang in tissue culture medium and may be beneficial *in vivo*.

30 In certain embodiments, a polynucleotide of the invention that comprises an RNAi sequence or an RNAi precursor is in the form of a hairpin structure (named as hairpin RNA). The hairpin RNAs can be synthesized exogenously or can be formed by

transcribing from RNA polymerase III promoters *in vivo*. Examples of making and using such hairpin RNAs for gene silencing in mammalian cells are described in, for example, Paddison et al., *Genes Dev*, 2002, 16:948-58; McCaffrey et al., *Nature*, 2002, 418:38-9; McManus et al., *RNA* 2002, 8:842-50; Yu et al., *Proc Natl Acad Sci USA*, 2002, 99:6047-52). Preferably, such hairpin RNAs are engineered in cells or in an animal to ensure continuous and stable suppression of a desired gene. It is known in the art that miRNAs and siRNAs can be produced by processing a hairpin RNA in the cell.

In yet other embodiments, a plasmid is used to deliver the double-stranded RNA, e.g., as a transcriptional product. After the coding sequence is transcribed, the 10 complementary RNA transcripts base-pair to form the double-stranded RNA.

Aptamers and small molecules

The present invention also provides therapeutic aptamers that specifically bind to variant CFH polypeptides that are associated with AMD, thereby modulating activity of the variant CFH polypeptide. An "aptamer" may be a nucleic acid molecule, such as RNA or DNA that is capable of binding to a specific molecule with high affinity and specificity (Ellington et al., *Nature* 346, 818-22 (1990); and Tuerk et al., *Science* 249, 505-10 (1990)). An aptamer will most typically have been obtained by *in vitro* selection for binding of a target molecule. For example, an aptamer that specifically binds a variant CFH polypeptide can be obtained by *in vitro* selection for binding to a variant CFH polypeptide from a pool of polynucleotides. However, *in vivo* selection of an aptamer is also possible. Aptamers have specific binding regions which are capable of forming complexes with an intended target molecule in an environment wherein other substances in the same environment are not complexed to the nucleic acid. The specificity of the binding is defined in terms of the comparative dissociation constants (K_d) of the aptamer for its ligand (e.g., a variant CFH polypeptide) as compared to the dissociation constant of the aptamer for other materials in the environment or unrelated molecules in general. A ligand (e.g., a variant CFH polypeptide) is one which binds to the aptamer with greater affinity than to unrelated material. Typically, the K_d for the aptamer with respect to its ligand will be at least about 10-fold less than the K_d for the aptamer with unrelated material or 20 accompanying material in the environment. Even more preferably, the K_d will be at least about 50-fold less, more preferably at least about 100-fold less, and most preferably at least about 200-fold less. An aptamer will typically be between about 10 and about 300 25 30

nucleotides in length. More commonly, an aptamer will be between about 30 and about 100 nucleotides in length.

Methods for selecting aptamers specific for a target of interest are known in the art. For example, organic molecules, nucleotides, amino acids, polypeptides, target features on 5 cell surfaces, ions, metals, salts, saccharides, have all been shown to be suitable for isolating aptamers that can specifically bind to the respective ligand. For instance, organic dyes such as Hoechst 33258 have been successfully used as target ligands for in vitro aptamer selections (Werstuck and Green, *Science* 282:296-298 (1998)). Other small 10 organic molecules like dopamine, theophylline, sulforhodamine B, and cellobiose have also been used as ligands in the isolation of aptamers. Aptamers have also been isolated for antibiotics such as kanamycin A, lividomycin, tobramycin, neomycin B, viomycin, chloramphenicol and streptomycin. For a review of aptamers that recognize small 15 molecules, see Famulok, *Science* 9:324-9 (1999).

An aptamer of the invention can be comprised entirely of RNA. In other 15 embodiments of the invention, however, the aptamer can instead be comprised entirely of DNA, or partially of DNA, or partially of other nucleotide analogs. To specifically inhibit translation in vivo, RNA aptamers are preferred. Such RNA aptamers are preferably introduced into a cell as DNA that is transcribed into the RNA aptamer. Alternatively, an RNA aptamer itself can be introduced into a cell.

20 Aptamers are typically developed to bind particular ligands by employing known in vivo or in vitro (most typically, in vitro) selection techniques known as SELEX (Ellington et al., *Nature* 346, 818-22 (1990); and Tuerk et al., *Science* 249, 505-10 (1990)). Methods of making aptamers are also described in, for example, U.S. Pat. No. 5,582,981, PCT Publication No. WO 00/20040, U.S. Pat. No. 5,270,163, Lorsch and Szostak, 25 Biochemistry, 33:973 (1994), Mannironi et al., Biochemistry 36:9726 (1997), Blind, Proc. Nat'l. Acad. Sci. USA 96:3606-3610 (1999), Huijzena and Szostak, Biochemistry, 34:656-665 (1995), PCT Publication Nos. WO 99/54506, WO 99/27133, WO 97/42317 and U.S. Pat. No. 5,756,291.

30 Generally, in their most basic form, in vitro selection techniques for identifying aptamers involve first preparing a large pool of DNA molecules of the desired length that contain at least some region that is randomized or mutagenized. For instance, a common oligonucleotide pool for aptamer selection might contain a region of 20-100 randomized

nucleotides flanked on both ends by an about 15-25 nucleotide long region of defined sequence useful for the binding of PCR primers. The oligonucleotide pool is amplified using standard PCR techniques, although any means that will allow faithful, efficient amplification of selected nucleic acid sequences can be employed. The DNA pool is then 5 in vitro transcribed to produce RNA transcripts. The RNA transcripts may then be subjected to affinity chromatography, although any protocol which will allow selection of nucleic acids based on their ability to bind specifically to another molecule (e.g., a protein or any target molecule) may be used. In the case of affinity chromatography, the transcripts are most typically passed through a column or contacted with magnetic beads or 10 the like on which the target ligand has been immobilized. RNA molecules in the pool which bind to the ligand are retained on the column or bead, while nonbinding sequences are washed away. The RNA molecules which bind the ligand are then reverse transcribed and amplified again by PCR (usually after elution). The selected pool sequences are then put through another round of the same type of selection. Typically, the pool sequences are 15 put through a total of about three to ten iterative rounds of the selection procedure. The cDNA is then amplified, cloned, and sequenced using standard procedures to identify the sequence of the RNA molecules which are capable of acting as aptamers for the target ligand. Once an aptamer sequence has been successfully identified, the aptamer may be further optimized by performing additional rounds of selection starting from a pool of 20 oligonucleotides comprising the mutagenized aptamer sequence. For use in the present invention, the aptamer is preferably selected for ligand binding in the presence of salt concentrations and temperatures which mimic normal physiological conditions.

The unique nature of the in vitro selection process allows for the isolation of a suitable aptamer that binds a desired ligand despite a complete dearth of prior knowledge 25 as to what type of structure might bind the desired ligand.

The association constant for the aptamer and associated ligand is preferably such that the ligand functions to bind to the aptamer and have the desired effect at the concentration of ligand obtained upon administration of the ligand. For in vivo use, for example, the association constant should be such that binding occurs well below the 30 concentration of ligand that can be achieved in the serum or other tissue. Preferably, the required ligand concentration for in vivo use is also below that which could have undesired effects on the organism.

The present invention also provides small molecules and antibodies that specifically bind to a variant CFH polypeptide that is associated with AMD, thereby inhibiting the activity of a variant CFH polypeptide. Examples of small molecules include, without limitation, drugs, metabolites, intermediates, cofactors, transition state analogs, ions, 5 metals, toxins and natural and synthetic polymers (e.g., proteins, peptides, nucleic acids, polysaccharides, glycoproteins, hormones, receptors and cell surfaces such as cell walls and cell membranes).

Antibodies

Another aspect of the invention pertains to antibodies. In one embodiment, an antibody that is specifically reactive with a variant CFH polypeptide may be used to detect the presence of a variant CFH polypeptide or to inhibit activity of a variant CFH polypeptide. For example, by using immunogens derived from a variant CFH peptide, anti-protein/anti-peptide antisera or monoclonal antibodies can be made by standard 10 protocols (see, for example, *Antibodies: A Laboratory Manual* ed. by Harlow and Lane (Cold Spring Harbor Press: 1988)). A mammal, such as a mouse, a hamster or rabbit can be immunized with an immunogenic form of the variant CFH peptide, an antigenic fragment which is capable of eliciting an antibody response, or a fusion protein. In a particular embodiment, the inoculated mouse does not express endogenous CFH, thus 15 facilitating the isolation of antibodies that would otherwise be eliminated as anti-self antibodies. Techniques for conferring immunogenicity on a protein or peptide include conjugation to carriers or other techniques well known in the art. An immunogenic portion of a variant CFH peptide can be administered in the presence of adjuvant. The progress of immunization can be monitored by detection of antibody titers in plasma or serum. 20 Standard ELISA or other immunoassays can be used with the immunogen as antigen to 25 assess the levels of antibodies.

Following immunization of an animal with an antigenic preparation of a variant CFH polypeptide, antisera can be obtained and, if desired, polyclonal antibodies can be isolated from the serum. To produce monoclonal antibodies, antibody-producing cells 30 (lymphocytes) can be harvested from an immunized animal and fused by standard somatic cell fusion procedures with immortalizing cells such as myeloma cells to yield hybridoma cells. Such techniques are well known in the art, and include, for example, the hybridoma

technique (originally developed by Kohler and Milstein, (1975) *Nature*, 256: 495-497), the human B cell hybridoma technique (Kozbar et al., (1983) *Immunology Today*, 4: 72), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al., (1985) *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc. pp. 77-96).

- 5 Hybridoma cells can be screened immunochemically for production of antibodies specifically reactive with a variant CFH polypeptide and monoclonal antibodies isolated from a culture comprising such hybridoma cells.

The term "antibody" as used herein is intended to include fragments thereof which are also specifically reactive with a variant CFH polypeptide. Antibodies can be
10 fragmented using conventional techniques and the fragments screened for utility in the same manner as described above for whole antibodies. For example, F(ab)₂ fragments can be generated by treating antibody with pepsin. The resulting F(ab)₂ fragment can be treated to reduce disulfide bridges to produce Fab fragments. The antibody of the present invention is further intended to include bispecific, single-chain, and chimeric and
15 humanized molecules having affinity for a variant CFH polypeptide conferred by at least one CDR region of the antibody. In preferred embodiments, the antibody further comprises a label attached thereto and able to be detected (e.g., the label can be a radioisotope, fluorescent compound, enzyme or enzyme co-factor).

In certain embodiments, an antibody of the invention is a monoclonal antibody, and
20 in certain embodiments, the invention makes available methods for generating novel antibodies that bind specifically to variant CFH polypeptides. For example, a method for generating a monoclonal antibody that binds specifically to a variant CFH polypeptide may comprise administering to a mouse an amount of an immunogenic composition comprising the CFH polypeptide effective to stimulate a detectable immune response, obtaining
25 antibody-producing cells (e.g., cells from the spleen) from the mouse and fusing the antibody-producing cells with myeloma cells to obtain antibody-producing hybridomas, and testing the antibody-producing hybridomas to identify a hybridoma that produces a monoclonal antibody that binds specifically to the variant CFH polypeptide. Once obtained, a hybridoma can be propagated in a cell culture, optionally in culture conditions
30 where the hybridoma-derived cells produce the monoclonal antibody that binds specifically to the CFH polypeptide. The monoclonal antibody may be purified from the cell culture.

The term "specifically reactive with" as used in reference to an antibody is intended to mean, as is generally understood in the art, that the antibody is sufficiently selective between the antigen of interest (e.g., a variant CFH polypeptide) and other antigens that are not of interest that the antibody is useful for, at minimum, detecting the presence of the antigen of interest in a particular type of biological sample. In certain methods employing the antibody, such as therapeutic applications, a higher degree of specificity in binding may be desirable. Monoclonal antibodies generally have a greater tendency (as compared to polyclonal antibodies) to discriminate effectively between the desired antigens and cross-reacting polypeptides. One characteristic that influences the specificity of an antibody:antigen interaction is the affinity of the antibody for the antigen. Although the desired specificity may be reached with a range of different affinities, generally preferred antibodies will have an affinity (a dissociation constant) of about 10^{-6} , 10^{-7} , 10^{-8} , 10^{-9} or less.

In addition, the techniques used to screen antibodies in order to identify a desirable antibody may influence the properties of the antibody obtained. For example, if an antibody is to be used for binding an antigen in solution, it may be desirable to test solution binding. A variety of different techniques are available for testing interaction between antibodies and antigens to identify particularly desirable antibodies. Such techniques include ELISAs, surface plasmon resonance binding assays (e.g., the Biacore binding assay, Bia-core AB, Uppsala, Sweden), sandwich assays (e.g., the paramagnetic bead system of IGEN International, Inc., Gaithersburg, Maryland), western blots, immunoprecipitation assays, and immunohistochemistry.

6. Screening Assays

In certain aspects, the present invention relates to the use of CFH polypeptides to identify compounds (agents) which are agonist or antagonists of CFH polypeptides. Compounds identified through this screening can be tested in cells of the eye, (e.g., epithelial and endothelial cells) as well as other tissues (e.g., muscle and/or neurons) to assess their ability to modulate CFH activity in vivo or in vitro. In certain aspects, compounds identified through this screening modulate the formation of drusen deposits. Optionally, these compounds can further be tested in animal models to assess their ability to modulate CFH activity in vivo.

There are numerous approaches to screening for therapeutic agents that target CFH polypeptides. In certain embodiments, high-throughput screening of compounds can be carried out to identify agents that affect activity of CFH polypeptides. A variety of assay formats will suffice and, in light of the present disclosure, those not expressly described herein will nevertheless be comprehended by one of ordinary skill in the art. As described herein, the test compounds (agents) of the invention may be created by any combinatorial chemical method. Alternatively, the subject compounds may be naturally occurring biomolecules synthesized *in vivo* or *in vitro*. Compounds (agents) to be tested for their ability to act as modulators of CFH activity can be produced, for example, by bacteria, yeast, plants or other organisms (e.g., natural products), produced chemically (e.g., small molecules, including peptidomimetics), or produced recombinantly. Test compounds contemplated by the present invention include non-peptidyl organic molecules, peptides, polypeptides, peptidomimetics, sugars, hormones, and nucleic acid molecules.

The test compounds of the invention can be provided as single, discrete entities, or provided in libraries of greater complexity, such as made by combinatorial chemistry. These libraries can comprise, for example, alcohols, alkyl halides, amines, amides, esters, aldehydes, ethers and other classes of organic compounds. Presentation of test compounds to the test system can be in either an isolated form or as mixtures of compounds, especially in initial screening steps. Optionally, the compounds may be optionally derivatized with other compounds and have derivatizing groups that facilitate isolation of the compounds. Non-limiting examples of derivatizing groups include biotin, fluorescein, digoxigenin, green fluorescent protein, isotopes, polyhistidine, magnetic beads, glutathione S transferase (GST), photoactivatable crosslinkers or any combinations thereof.

In many drug screening programs which test libraries of compounds and natural extracts, high throughput assays are desirable in order to maximize the number of compounds surveyed in a given period of time. Assays which are performed in cell-free systems, such as may be derived with purified or semi-purified proteins, are often preferred as "primary" screens in that they can be generated to permit rapid development and relatively easy detection of an alteration in a molecular target which is mediated by a test compound. Moreover, the effects of cellular toxicity or bioavailability of the test compound can be generally ignored in the *in vitro* system, the assay instead being focused primarily on the effect of the drug on the molecular target.

In certain embodiments, the subject compounds are identified by their ability to interact with a CFH polypeptide of the invention. The interaction between the compound and the CFH polypeptide may be covalent or non-covalent. For example, such interaction can be identified at the protein level using in vitro biochemical methods, including photo-crosslinking, radiolabeled ligand binding, and affinity chromatography (Jakoby WB et al., 5 1974, Methods in Enzymology 46:1). In certain cases, the compounds may be screened in a mechanism based assay, such as an assay to detect compounds which bind to a CFH polypeptide. This may include a solid phase or fluid phase binding event. Alternatively, the gene encoding a CFH polypeptide can be transfected with a reporter system (e.g., β -10 galactosidase, luciferase, or green fluorescent protein) into a cell and screened against the library preferably by a high throughput screening or with individual members of the library. Other mechanism based binding assays may be used, for example, binding assays which detect changes in free energy. Binding assays can be performed with the target fixed to a well, bead or chip or captured by an immobilized antibody or resolved by 15 capillary electrophoresis. The bound compounds may be detected usually using colorimetric or fluorescence or surface plasmon resonance.

7. Pharmaceutical Compositions

The methods and compositions described herein for treating a subject suffering from AMD may be used for the prophylactic treatment of individuals who have been 20 diagnosed or predicted to be at risk for developing AMD. In this case, the composition is administered in an amount and dose that is sufficient to delay, slow, or prevent the onset of AMD or related symptoms. Alternatively, the methods and compositions described herein may be used for the therapeutic treatment of individuals who suffer from AMD. In this 25 case, the composition is administered in an amount and dose that is sufficient to delay or slow the progression of the condition, totally or partially, or in an amount and dose that is sufficient to reverse the condition to the point of eliminating the disorder. It is understood that an effective amount of a composition for treating a subject who has been diagnosed or predicted to be at risk for developing AMD is a dose or amount that is in sufficient quantities to treat a subject or to treat the disorder itself.

30 In certain embodiments, compounds of the present invention (e.g., an isolated or recombinantly produced nucleic acid molecule coding for a CFH polypeptide or an isolated or recombinantly produced CFH polypeptide) are formulated with a pharmaceutically

acceptable carrier. For example, a CFH polypeptide or a nucleic acid molecule coding for a CFH polypeptide can be administered alone or as a component of a pharmaceutical formulation (therapeutic composition). The subject compounds may be formulated for administration in any convenient way for use in human medicine.

5 In certain embodiments, the therapeutic methods of the invention include administering the composition topically, systemically, or locally. For example, therapeutic compositions of the invention may be formulated for administration by, for example, injection (e.g., intravenously, subcutaneously, or intramuscularly), inhalation or insufflation (either through the mouth or the nose) or oral, buccal, sublingual, transdermal, 10 nasal, or parenteral administration. The compositions described herein may be formulated as part of an implant or device. When administered, the therapeutic composition for use in this invention is in a pyrogen-free, physiologically acceptable form. Further, the composition may be encapsulated or injected in a viscous form for delivery to the site where the target cells are present, such as to the cells of the eye. Techniques and 15 formulations generally may be found in Remington's Pharmaceutical Sciences, Meade Publishing Co., Easton, PA. In addition to CFH polypeptides or nucleic acid molecules coding for CFH polypeptides, therapeutically useful agents may optionally be included in any of the compositions as described above. Furthermore, therapeutically useful agents may, alternatively or additionally, be administered simultaneously or sequentially with 20 CFH polypeptides or nucleic acid molecules coding for CFH polypeptides according to the methods of the invention.

In certain embodiments, compositions of the invention can be administered orally, e.g., in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as 25 an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of an agent as an active ingredient. An agent may also be administered as a bolus, electuary or paste.

30 In solid dosage forms for oral administration (capsules, tablets, pills, dragees, powders, granules, and the like), one or more therapeutic compounds of the present invention may be mixed with one or more pharmaceutically acceptable carriers, such as

sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose, and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-
5 agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, cetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such a talc, calcium stearate, magnesium stearate, solid polyethylene glycols,
10 sodium lauryl sulfate, and mixtures thereof; and (10) coloring agents. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.

15 Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming, and preservative agents.
20

25 Suspensions, in addition to the active compounds, may contain suspending agents such as ethoxylated isostearyl alcohols, polyoxyethylene sorbitol, and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.

Certain compositions disclosed herein may be administered topically, either to skin
30 or to mucosal membranes. The topical formulations may further include one or more of the wide variety of agents known to be effective as skin or stratum corneum penetration enhancers. Examples of these are 2-pyrrolidone, N-methyl-2-pyrrolidone,

dimethylacetamide, dimethylformamide, propylene glycol, methyl or isopropyl alcohol, dimethyl sulfoxide, and azone. Additional agents may further be included to make the formulation cosmetically acceptable. Examples of these are fats, waxes, oils, dyes, fragrances, preservatives, stabilizers, and surface active agents. Keratolytic agents such as 5 those known in the art may also be included. Examples are salicylic acid and sulfur.

Dosage forms for the topical or transdermal administration include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants which may be required. The 10 ointments, pastes, creams and gels may contain, in addition to a subject compound of the invention (e.g., an isolated or recombinantly produced nucleic acid molecule coding for a CFH polypeptide or an isolated or recombinantly produced CFH polypeptide), excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or 15 mixtures thereof.

Powders and sprays can contain, in addition to a subject compound, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates, and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane 20 and propane.

It is understood that the dosage regimen will be determined for an individual, taking into consideration, for example, various factors which modify the action of the subject compounds of the invention (e.g., an isolated or recombinantly produced nucleic acid molecule coding for a CFH polypeptide or an isolated or recombinantly produced CFH 25 polypeptide), the severity or stage of AMD, route of administration, and characteristics unique to the individual, such as age, weight, and size. A person of ordinary skill in the art is able to determine the required dosage to treat the subject. In one embodiment, the dosage can range from about 1.0 ng/kg to about 100 mg/kg body weight of the subject. Based upon the composition, the dose can be delivered continuously, or at periodic 30 intervals. For example, on one or more separate occasions. Desired time intervals of multiple doses of a particular composition can be determined without undue experimentation by one skilled in the art. For example, the compound may be delivered

hourly, daily, weekly, monthly, yearly (e.g. in a time release form) or as a one time delivery.

In certain embodiments, pharmaceutical compositions suitable for parenteral administration may comprise a CFH polypeptide or a nucleic acid molecule coding for a

5 CFH polypeptide in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or

10 thickening agents. Examples of suitable aqueous and nonaqueous carriers which may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of

15 dispersions, and by the use of surfactants.

The compositions of the invention may also contain adjuvants, such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and

20 antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption, such as aluminum monostearate and gelatin.

25 In certain embodiments, the present invention also provides gene therapy for the in vivo production of CFH polypeptides. Such therapy would achieve its therapeutic effect by introduction of CFH polynucleotide sequences into cells or tissues that are deficient for normal CFH function. Delivery of CFH polynucleotide sequences can be achieved using a recombinant expression vector such as a chimeric virus or a colloidal dispersion system.

30 Targeted liposomes may also be used for the therapeutic delivery of CFH polynucleotide sequences.

Various viral vectors which can be utilized for gene therapy as taught herein include adenovirus, herpes virus, vaccinia, or an RNA virus such as a retrovirus. A retroviral vector may be a derivative of a murine or avian retrovirus. Examples of retroviral vectors in which a single foreign gene can be inserted include, but are not limited to: Moloney murine leukemia virus (MoMuLV), Harvey murine sarcoma virus (HaMuSV), murine mammary tumor virus (MuMTV), and Rous Sarcoma Virus (RSV). A number of additional retroviral vectors can incorporate multiple genes. All of these vectors can transfer or incorporate a gene for a selectable marker so that transduced cells can be identified and generated. Retroviral vectors can be made target-specific by attaching, for example, a sugar, a glycolipid, or a protein. Preferred targeting is accomplished by using an antibody. Those of skill in the art will recognize that specific polynucleotide sequences can be inserted into the retroviral genome or attached to a viral envelope to allow target specific delivery of the retroviral vector containing the CFH polynucleotide. In one preferred embodiment, the vector is targeted to cells or tissues of the eye.

Alternatively, tissue culture cells can be directly transfected with plasmids encoding the retroviral structural genes gag, pol and env, by conventional calcium phosphate transfection. These cells are then transfected with the vector plasmid containing the genes of interest. The resulting cells release the retroviral vector into the culture medium.

Another targeted delivery system for CFH polynucleotides is a colloidal dispersion system. Colloidal dispersion systems include macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. The preferred colloidal system of this invention is a liposome. Liposomes are artificial membrane vesicles which are useful as delivery vehicles in vitro and in vivo. RNA, DNA and intact virions can be encapsulated within the aqueous interior and be delivered to cells in a biologically active form (see e.g., Fraley, et al., Trends Biochem. Sci., 6:77, 1981). Methods for efficient gene transfer using a liposome vehicle, are known in the art, see e.g., Mannino, et al., Biotechniques, 6:682, 1988. The composition of the liposome is usually a combination of phospholipids, usually in combination with steroids, especially cholesterol. Other phospholipids or other lipids may also be used. The physical characteristics of liposomes depend on pH, ionic strength, and the presence of divalent cations.

Examples of lipids useful in liposome production include phosphatidyl compounds, such as phosphatidylglycerol, phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, sphingolipids, cerebrosides, and gangliosides. Illustrative phospholipids include egg phosphatidylcholine, dipalmitoylphosphatidylcholine, and 5 distearoylphosphatidylcholine. The targeting of liposomes is also possible based on, for example, organ-specificity, cell-specificity, and organelle-specificity and is known in the art.

Moreover, the pharmaceutical preparation can consist essentially of the gene delivery system in an acceptable diluent, or can comprise a slow release matrix in which 10 the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery system can be produced intact from recombinant cells, e.g. retroviral packages, the pharmaceutical preparation can comprise one or more cells which produce the gene delivery system. In the case of the latter, methods of introducing the viral packaging cells may be provided by, for example, rechargeable or biodegradable devices. Various slow 15 release polymeric devices have been developed and tested in vivo in recent years for the controlled delivery of drugs, including proteinaceous biopharmaceuticals, and can be adapted for release of viral particles through the manipulation of the polymer composition and form. A variety of biocompatible polymers (including hydrogels), including both biodegradable and non-degradable polymers, can be used to form an implant for the sustained release of the viral particles by cells implanted at a particular target site. Such 20 embodiments of the present invention can be used for the delivery of an exogenously purified virus, which has been incorporated in the polymeric device, or for the delivery of viral particles produced by a cell encapsulated in the polymeric device.

A person of ordinary skill in the art is able to determine the required amount to treat 25 the subject. It is understood that the dosage regimen will be determined for an individual, taking into consideration, for example, various factors which modify the action of the subject compounds of the invention, the severity or stage of AMD, route of administration, and characteristics unique to the individual, such as age, weight, and size. A person of ordinary skill in the art is able to determine the required dosage to treat the subject. In one 30 embodiment, the dosage can range from about 1.0 ng/kg to about 100 mg/kg body weight of the subject. The dose can be delivered continuously, or at periodic intervals. For example, on one or more separate occasions. Desired time intervals of multiple doses of a

particular composition can be determined without undue experimentation by one skilled in the art. For example, the compound may be delivered hourly, daily, weekly, monthly, yearly (e.g. in a time release form) or as a one time delivery. As used herein, the term "subject" means any individual animal capable of becoming afflicted with AMD. The 5 subjects include, but are not limited to, human beings, primates, horses, birds, cows, pigs, dogs, cats, mice, rats, guinea pigs, ferrets, and rabbits. In the preferred embodiment, the subject is a human being.

Samples used in the methods described herein may comprise cells from the eye, ear, nose, teeth, tongue, epidermis, epithelium, blood, tears, saliva, mucus, urinary tract, 10 urine, muscle, cartilage, skin, or any other tissue or bodily fluid from which sufficient DNA or RNA can be obtained.

The sample should be sufficiently processed to render the DNA or RNA that is present available for assaying in the methods described herein. For example, samples may be processed such that DNA from the sample is available for amplification or for 15 hybridization to another polynucleotide. The processed samples may be crude lysates where available DNA or RNA is not purified from other cellular material. Alternatively, samples may be processed to isolate the available DNA or RNA from one or more contaminants that are present in its natural source. Samples may be processed by any means known in the art that renders DNA or RNA available for assaying in the methods 20 described herein. Methods for processing samples may include, without limitation, mechanical, chemical, or molecular means of lysing and/or purifying cells and cell lysates. Processing methods may include, for example, ion-exchange chromatography, size exclusion chromatography, affinity chromatography, hydrophobic interaction chromatography, gel filtration chromatography, ultrafiltration, electrophoresis, and 25 immunoaffinity purification with antibodies specific for particular epitopes of the polypeptide

8. Kits

Also provided herein are kits, e.g., kits for therapeutic purposes or kits for detecting a variant CFH gene in a sample from an individual. In one embodiment, a kit comprises at 30 least one container means having disposed therein a premeasured dose of a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of AMD in humans. In another embodiment, a kit

comprises at least one container means having disposed therein a premeasured dose of a polynucleotide primer that hybridizes, under stringent conditions, adjacent to one side of a variation in the CFH gene that is correlated with the occurrence of AMD in humans. In a further embodiment, a second polynucleotide primer that hybridizes, under stringent 5 conditions, to the other side of a variation in the CFH gene that is correlated with the occurrence of AMD in humans is provided in a premeasured dose. Kits further comprise a label and/or instructions for the use of the therapeutic or diagnostic kit in the detection of CFH in a sample. Kits may also include packaging material such as, but not limited to, ice, dry ice, styrofoam, foam, plastic, cellophane, shrink wrap, bubble wrap, paper, cardboard, 10 starch peanuts, twist ties, metal clips, metal cans, drierite, glass, and rubber (see products available from www.papermart.com. for examples of packaging material).

The practice of the present methods will employ, unless otherwise indicated, conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA, and immunology, which are within the skill of 15 the art. Such techniques are explained fully in the literature. See, for example, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory (2001); DNA Cloning, Volumes I and II (D. N. Glover ed., 1985); Oligonucleotide Synthesis (M. J. Gait ed., 1984); Mullis et al. U.S. Patent No: 4,683,195; Nucleic Acid Hybridization (B. D. Hames & S. J. Higgins eds. 1984); Transcription And Translation (B. D. Hames & S. J. Higgins 20 eds. 1984); Culture Of Animal Cells (R. I. Freshney, Alan R. Liss, Inc., 1987); Immobilized Cells And Enzymes (IRL Press, 1986); B. Perbal, A Practical Guide To Molecular Cloning (1984); the treatise, Methods In Enzymology (Academic Press, Inc., N.Y.); Gene Transfer Vectors For Mammalian Cells (J. H. Miller and M. P. Calos eds., 1987, Cold Spring Harbor Laboratory); Methods In Enzymology, Vols. 154 and 155 (Wu 25 et al. eds.), Immunochemical Methods In Cell And Molecular Biology (Mayer and Walker, eds., Academic Press, London, 1987); Handbook Of Experimental Immunology, Volumes I-IV (D. M. Weir and C. C. Blackwell, eds., 1986); Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986).

EXAMPLES

30 The following examples are for illustrative purposes and are not intended to be limiting in any way.

EXAMPLE 1: Whole genome SNP association for genes correlated with AMD.

Described herein is a whole-genome case-control association study for genes involved in AMD. Two crucial factors were used in designing this experiment; clearly defined phenotypes were chosen for cases and controls. The definition of a case was based
 5 on both a quantitative photographic assessment of the presence of at least some large drusen combined with photographic evidence of sight-threatening AMD (geographic atrophy or neovascular AMD). The definition of a control was based on the study participant having either no drusen or only a few small drusen. Data was analyzed using a statistically conservative approach to correct for the large number of SNPs tested, thereby
 10 guaranteeing that the actual probability of a false positive is no greater than the reported p-values.

A subset of individuals who participated in the Age-Related Eye Disease Study (AREDS) (AREDS Research Group, Arch Ophthalmol 119, 1417, (2001)) were used in the association study. From the AREDS sample, 96 case subjects were identified who, at their
 15 most recent study visit, had either uniocular choroidal neovascularization (50 cases) or geographic atrophy either central or non-central to the macula (46 cases). The fellow eye of these case subjects was required to have at least one large drusen ($>125 \mu\text{m}$ in diameter), and total drusen area equivalent to a circle of at least $1061 \mu\text{m}$ in diameter. The group of study participants who had both large drusen and sight-threatening AMD was selected
 20 because there can be many precursors to the development of either choroidal neovascularization or geographic atrophy. Controls were 50 individuals from the AREDS sample who had few or no drusen ($<63 \mu\text{m}$ in diameter in each eye) for the duration of their participation in AREDS. All individuals identified themselves as "White, not of Hispanic origin." To the extent possible, the proportions of gender and smoking status
 25 were kept the same in cases and controls. Controls were purposely chosen to be older than the cases to increase the probability that they will remain without AMD (Table 1).

Table 1. Summary of sample phenotypes.

	Cases (n=96)	Controls (n=50)
Males (%)	44	54
Never smoked (%)	36	52
Formerly smoked (%)	58	48

Currently smoke (%)	5	0
Mean age (\pm s.d.) (years)	79 \pm 5.2	82 \pm 2.2
Age range (years)	65-89	78-87
One eye with neovascular AMD, other eye with at least one large drusen (%)	52	0
One eye with geographic atrophy AMD, other eye with at least one large drusen (%)	48	0
Both eyes with few or no drusen (%)	0	100

EXAMPLE 2: Genotyping and SNP identification of individuals in study population

Each individual was genotyped using the Affymetrix GeneChip Mapping 100K Set 5 of microarrays (H. Matsuzaki et al., Nat Methods 1, 109 (2004)). This mapping assay consists of two chips (XbaI and HindIII) with approximately 50,000 SNPs each that are used for each individual. About 250 ng of genomic DNA was digested with two restriction enzymes XbaI and HindIII and processed according to the Affymetrix protocol (H. Matsuzaki et al., Nat Methods 1, 109 (2004)). The images were analyzed using GDAS 10 software (Affymetrix). For the data obtained from each chip, two internal quality control measures were used: the call rate always exceeded 95% and heterozygosity on the X chromosome correctly identified the gender of the individual. Thirty-one identical SNPs were placed on both chips and checked that they yielded the same genotype for the same individual to ensure that no samples were confused.

15 Three experiments were performed to test the reproducibility of this system. First, 4 samples were processed twice with the Xba chips. Next, 2 replicates of a reference DNA positive control provided by Affymetrix were run on Xba chips alongside the samples. Finally, results for 3 individuals were compared with genotyping using the Affymetrix 10K SNP platform to test the accuracy of this assay (H. Matsuzaki et al., Genome Res 14, 414 20 (2004)).

An assessment of the percentage of the individuals producing a genotype call for 25 each SNP was made in order to examine the genotyping quality for each individual SNP. A SNP with a call rate of 100% means every individual is successfully assigned a genotype for this SNP and there is no missing data. Call rates were required to be at least 85% to remove SNPs for which genotyping was consistently problematic. SNPs which are

monomorphic in the data were also removed, since these SNPs are uninformative. SNPs in which genotype frequencies deviated from the Hardy-Weinberg equilibrium expectation (HWD $\chi^2 > 25$, $P = 0.05$, 1df, after Bonferroni correction) were removed as being likely to contain genotyping errors rather than real disequilibrium. SNPs for which no homozygotes were observed in the entire sample were also likely due to errors and removed. Altogether, of the 116,204 SNPs genotyped, 105,980 SNPs with a call rate of at least 85%, both alleles observed, at least one homozygote observed, and a HWD $\chi^2 \leq 2.5$ were found and considered. Of these, the 103,611 SNPs that lie on the 22 autosomal chromosomes were analyzed. A summary of genotyping quality can be found in Table 2.

Table 2. Genotyping quality control and informativeness.

Per-chip data quality	
Median call rate per chip	99.1%
Minimum call rate per chip	95.6%
Chips for which gender matches	292 (100%)
Per-individual data quality	
Median call rate per individual	99.1%
Minimum call rate per individual	96.7%
Average number of matches for common SNPs between two chips	30.7/31
Minimum number of matches for common SNPs between two chips*	28/31
Reproducibility	
Xba Repeat concordance (4 replicates)	99.886%
Xba Positive control concordance (3 replicates)	99.870%
10K concordance (3 replicates)	99.767%
Call rate (per-SNP)	
Total number of SNPs	116204
SNPs with 100% call rate	81456
SNPs with call rate between 85% and 100%	33262
SNPs with call rate less than 85%	1486
Locus Polymorphism	
Number of SNPs with no polymorphism observed	8538
Number of SNPs with minor allele frequency < 0.01	3604
Number of SNPs with only heterozygotes observed	19
Number of polymorphic SNPs with no heterozygotes observed	71
Hardy-Weinberg Equilibrium	
Number of SNPs significantly out of equilibrium	231

*For the most part, when SNPs do not match it is due to one of the SNPs not being called. In only 3 out of 4485 comparisons is a mismatch observed, which is equivalent to 99.93% concordance.

EXAMPLE 3: Statistical analysis of SNP association with disease status

Allelic association with disease status was tested for each SNP. A 2x2 contingency table of allele frequencies was constructed. The Pearson χ^2 value and a P-value were calculated, based on the central χ^2 distribution under the null hypothesis of no association
5 with 1 degree of freedom. This nominal P-value was corrected for multiple testing by applying the Bonferroni correction, in which only SNPs with a p-value less than $0.05/103,611 = 4.8 \times 10^{-7}$ were considered. This produced a Bonferroni-corrected P-value. This correction is known to be conservative and thus may "overcorrect" the raw p-values
10 (L. M. McIntyre, E. R. Martin, K. L. Simonsen, N. L. Kaplan, Genet Epidemiol 19, 18 (2000)). While this technique may overlook real associations, it adjusts for the large number of multiple comparisons and yields p-values that do not underestimate the false positive rate.

Two methods of genomic control were used to look for population stratification, GC and GCF (B. Devlin, S. A. Bacanu, K. Roeder, Nat Genet 36, 1129 (2004)). In the first
15 method, the median χ^2 value was taken for allelic association with a number of SNPs assumed to be unassociated with the disease (null SNPs). The test statistic $\chi^2_{(1)}$ values were divided by this median, and tested for significance using the χ^2 distribution. Alternatively,
for the GCF method, the mean rather the median of the null χ^2 statistics was used;
significance of the quotient was tested using the F(1,L) distribution, where L is the number
20 of null SNPs used (B. Devlin, S. A. Bacanu, K. Roeder, Nat Genet 36, 1129 (2004)). Two different sets of unassociated SNPs were used: all the SNPs successfully genotyped except
the two significant (see below) ones, and the set of 31 SNPs that are in common between
the two chips used in the assay (see Example 2 above).

The candidate region was defined by looking for adjacent SNPs in which all four
25 gametes were observed (R. R. Hudson, N. L. Kaplan, Genetics 111, 147 (1985)) and
bounding the region there. To look at linkage disequilibrium between SNPs in the
candidate region, haplotype frequencies in the region were inferred using PHASE version
2.1 (M. Stephens, P. Donnelly, Am J Hum Genet 73, 1162 (2003); M. Stephens, N. J.
Smith, P. Donnelly, Am J Hum Genet 68, 978 (2001)). Based on the inferred haplotype
30 frequencies across the entire region, pairwise linkage disequilibrium was calculated by first
computing the two-locus haplotype frequencies implied by the overall haplotype

frequencies. The measure of linkage disequilibrium, D', was then calculated using standard equations (D. L. Hartl, A. G. Clark, *Principles of Population Genetics* (Sinauer Associates, Sunderland, MA, ed. Third, 1997)) and plotted using the program GOLD (G. R. Abecasis, W. O. Cookson, *Bioinformatics* 16, 182 (2000)).

5 To define the smaller haplotype blocks within the 4-gamete region, the HapMap data website was used (<http://www.hapmap.org>). Genotypes for SNPs in the region between SNPs rs10494744 and rs10484502 were downloaded. Genotypes for the CEU population (CEPH Utah population of northern and western European ancestry) were downloaded and visualized using Haploview version 3.0. Haplotype blocks were then
10 defined using the method and parameters of Gabriel et al (S. B. Gabriel et al., *Science* 296, 2225 (2002)).

Haplotypes across the narrower region defined by the HapMap block were also inferred using PHASE version 2.1. Haplotypes with an estimated frequency of at least 1% were considered for further analysis. Phylogenetic trees were built using the maximum
15 parsimony of PHYLP 3.62 ("dnaps" program). The odds ratio in a nested cladistic framework was calculated for the haplotypes (P. Armitage, G. Berry, *Statistical Methods in Medical Research* (Blackwell Scientific Publications, Oxford, ed. Second, 1987); A. R. Templeton, E. Boerwinkle, C. F. Sing, *Genetics* 117, 343 (1987)).

Odds ratios, confidence intervals, and population attributable risk were calculated
20 as described in P. Armitage, G. Berry, *Statistical Methods in Medical Research* (Blackwell Scientific Publications, Oxford, ed. Second, 1987). The population frequency of the alleles of interest (see Example 4 below) is relatively high, 23% for and 41% for homozygous rs380390 and rs1329428, respectively. Therefore, the odds ratios necessarily calculated from the case control design study used here will over-estimate (without changing the
25 significance levels) the equivalent relative risk estimate needed to calculate lifetime risk. A prospective cohort study design will provide valid estimates of lifetime risk in persons who have and have not inherited the alleles.

EXAMPLE 4: Polymorphisms in the Complement Factor H gene are associated with AMD

Of the autosomal SNPs, only two, rs380390 and rs10272438, are significantly associated with disease status (Bonferroni corrected p=0.0043 and p=0.0080, respectively; 5 Figure 1A). One criticism of case-control association studies such as this one is that population stratification can result in false positive results. If the cases and controls are drawn from populations of different ancestry, with different allele frequencies, it is possible to detect these population differences instead of loci associated with the disease. All individuals in this study self-identify their ethnicity as non-Hispanic white and all of 10 the case and control individuals are drawn from the same AREDS population. There was some differential recruiting of cases from office practices and recruiting of controls from radio and newspaper advertising (AREDS Research Group, Ophthalmology 107, 2224 (2000)). Finding two SNPs out of >100,000 implied no genetic stratification, but genomic control methods were used to control for this possibility (B. Devlin, S. A. Bacanu, K. 15 Roeder, Nat Genet 36, 1129 (2004)). It was consistently found that the significance of the tests was not inflated and that, therefore, these two SNPs are significantly associated with disease.

SNP rs380390 was successfully genotyped in all individuals. In 21 individuals, no genotype was determined for SNP rs10272438, and it appears to be excessively out of 20 Hardy-Weinberg equilibrium ($HWE\chi^2=36$), indicating possible genotyping errors. Missing genotypes were determined by resequencing. After including these additional genotypes, the association was no longer significant after Bonferroni correction. Furthermore, the SNP with the third lowest p-value, rs1329428 (Bonferroni corrected p=0.14), is located 1.8 kb away from rs380390 on the same chromosome. The genotype frequencies at these two 25 neighboring loci clearly vary between the case and control populations (Figure 1B). Homozygotes for the C allele of rs380390 and the C allele at rs1329248 clearly have an increased risk of developing AMD (Table 1). The risk conferred by these genotypes accounts for approximately 45% (rs380390) to 61% (rs1329248) of the cases observed in the population (Table 3). Therefore, we decided to focus on these two SNPs as marking 30 our most promising locus.

Table 3. Risk ratios and population attributable risks for various genotypes and haplotypes.

	rs380390 (C/G)	rs1329428 (C/T)
Risk allele	C	C
Alelic Association χ^2 nominal p-value	4.1e-08	1.4e-06
Odds ratio (dominant) (95% CI)	4.6 (2.0-11)	4.7 (1.0-22)
PAR (95% CI)	70% (42%-84%)	80% (0%-96%)
Frequency in HapMap CEU	0.70	0.82
Odds ratio (recessive) (95% CI)	7.4 (2.9-19)	6.2 (2.9-13)
PAR (95% CI)	46% (31%-57%)	61% (43%-73%)
Frequency in HapMap CEU	0.23	0.41

Dominant and recessive refer to the risk factor consisting of having at least one copy (dominant) or two copies (recessive) of the risk allele. PAR is the population attributable risk. The dominant odds ratio and PAR compare likelihood of AMD in individuals with one copy of the risk allele versus individuals with no copy of the risk allele. The recessive odds ratio and PAR compare likelihood of AMD in individuals with two copies of the risk allele versus individuals with no more than one copy of the risk allele. The population frequencies for the risk genotypes are taken from the CEU HapMap population (CEPH collection of Utah residents of northern and western European ancestry).

- 15 rs380390 and rs1329248 lie in an intron of the gene for complement factor H (CFH). As both of these SNPs are noncoding and neither appears to alter a conserved sequence, these two SNPs may be in linkage disequilibrium with a corresponding functional mutation. To circumscribe the region in which the functional mutation may lie, the linkage disequilibrium throughout this region was analyzed (Figure 2A). The two
 20 associated SNPs lie in a region of high linkage disequilibrium that is around 500 kb long. As this region is longer than other typically observed blocks of high linkage disequilibrium (S. B Gabriel et al., Science 296, 2225 (2002)) and there are long stretches in this region where there are no SNPs in our dataset (Figure 2B), other data sources with denser SNP coverage were used to narrow down the region.
- 25 Data from the International HapMap project was used to analyze patterns of linkage disequilibrium in a population of residents of Utah with ancestry from northern and western Europe (the CEPH sample) (The International HapMap Consortium, Nature 426, 789 (2003)). In the 500 kb region of interest, there are 152 SNPs in the HapMap data set. Using a standard definition of linkage disequilibrium blocks (S. B Gabriel et al., Science

296, 2225 (2002)), it was found that the two associated SNPs lie in a block that is 41 kb long and entirely contained within the CFH gene (Figure 2C).

- There are six SNPs from the present study's data set in this 41 kb region. These SNPs form four predominant haplotypes with a frequency greater than 1% (Table 4).
- 5 Combined, these four haplotypes represent 99% of the chromosomes in this study. Reconstructing inferred haplotypes and building a phylogenetic tree allowed assessment of the evolutionary relationship between haplotypes (Figure 2D). Using inferred haplotypes for each individual, the odds ratio of disease in a nested cladistic framework under both dominant and recessive models were computed (A. R. Templeton, E. Boerwinkle, C. F. Sing, *Genetics* 117, 343 (1987)). The highest risk is conferred by haplotype N1, which is the only haplotype containing the risk allele at SNP rs380390.
- 10

Table 4. Haplotypes in the haplotype block that harbors the putative disease variant.

Name	rs2019727	rs10489456	rs3753396	rs380390	rs2284664	rs1329428	Frequency
N1	A	C	T	C	C	G	0.59
N1	A	C	T	G	C	G	0.0068
N3	A	C	T	G	T	A	0.12
N4	A	T	C	G	C	G	0.15
N5	T	C	T	G	C	A	0.12
N6	T	C	T	G	C	G	0.0071

Haplotype frequencies are estimated using the program PHASE (M. Stephens, P. Donnelly, *Am J Hum Genet* 73, 1162 (2003); M. Stephens, N. J. Smith, P. Donnelly, *Am J Hum Genet* 68, 978 (2001)). The SNPs used to construct the haplotypes are the SNPs from the mapping microarrays found in the 41 kb haplotype block defined by the HapMap data. Frequencies are the estimated frequency of each haplotype in the combined case and control population. The two SNPs that show association in the initial analysis are indicated in boldface.

- 15 Having at least one copy of this haplotype increases the risk for AMD 4.6-fold (95% CI 2.0-11). Having two copies of this haplotype increases the risk for AMD 7.4-fold (95% CI 3.0-19). Therefore, functionally relevant mutation should be found in the context of haplotype N1. This mutation will occur somewhere in the CFH gene, as the 41kb haplotype block is entirely within CFH.
- 20

EXAMPLE 5: Resequencing confirms that variations in CFH are correlated with AMD

- To identify the functional mutation underlying susceptibility to AMD, 96 individuals (66 cases and 30 controls) were chosen for exonic resequencing, including the exon/intron junctions. Most of these individuals were selected either because SNP 5 rs380390 was homozygous (representing opposite risk groups) or SNP rs10272438 was not successfully genotyped (the same plates were used to re-sequence this SNP for genotyping). Three additional individuals were randomly selected to get a total of 96 for a full plate. Primer design, PCR amplification, bi-directional sequencing of PCR products, and mutation analyses were performed by Genaissance (New Haven, CT).
- 10 All CFH exons were sequenced, including those outside of the 41kb block, as well as the region of SNP rs380390 as a control. Priority was given to sequencing homozygotes at SNP rs380390 to make it easier to determine haplotypes. SNP rs380390 was successfully resequenced in 93 individuals; the genotype derived from resequencing matched the original genotype in all cases. A total of 50 polymorphisms were identified; 15 17 of these have a minor allele frequency of at least 5% (Table 5). Of these 17, three represent non-synonymous mutations. If these SNPs are ranked based on the allelic association χ^2 measure, SNP rs1061170 is the most associated among the non-synonymous SNPs. This SNP represents a mutation between tyrosine and histidine. This SNP is located in exon 9 of CFH, only 2 kb upstream of the 41 kb haplotype block. Adding this 20 SNP to the haplotype analysis reveals that 97% of the chromosomes with the highest-risk haplotype (N1) also have the risk allele (His).

Table 5. New polymorphisms identified through resequencing.

Region	Position	Change	Type	MAF	AA Change	rs Number
promoter	120992	A/G	noncoding	0.005263		
promoter	120865	A/G	noncoding	0.010526		
promoter	120546	C/T	noncoding	0.242105		rs3753394
promoter	120410	T/C	noncoding	0.005263		
promoter	120294	A/G	noncoding	0.005263		
intron 1	99391	C/T	noncoding	0.117021		rs511397
exon 2	99242	T/G	nonsynonomous	0.005319	Ser 58 Ala	
exon 2	99230	G/A	nonsynonomous	0.117021	Val 62 Ile	rs800292
intron 2	99114	G/A	noncoding	0.005319		
intron 3	98283	T/C	noncoding	0.005263		

intron 3	98188	T/G	noncoding	0.005263		
exon 4	96315	G/A	nonsynonomous	0.005263	Arg 127 His	
exon 7	87139	A/C	synonomous	0.415789		rs1061147
intron 7	83059	T/C	noncoding	0.005263		
intron 7	82966	G/T	noncoding	0.410526		rs482934
intron 7	82957	A/G	noncoding	0.005263		
exon 9	82232	C/A	nonsynonomous	0.005208	Gln 400 Lys	
exon 9	82226	C/T	nonsynonomous	0.414894	His 402 Tyr	rs1061170
intron 9	58652	T/C	noncoding	0.005319		
exon 10	58516	G/A	synonomous	0.22043		rs2274700
intron 10	58319	A/G	noncoding	0.005319		rs203678
intron 10	58260	C/G	noncoding	0.005319		
intron 10	56838	G/T	noncoding	0.367021		rs203674
exon 12	47084	G/A	nonsynonomous	0.005263	Val 609 Ile	
intron 12	46992	T/G	noncoding	0.005208		
exon 13	45721	A/G	synonomous	0.143617		rs3753396
exon 15	43875	A/G	synonomous	0.005376		
intron 15	40549	A/G	noncoding	0.213054		rs7514261
intron 15	40445	C/T	noncoding	0.021277		
intron 15	40412	G/C	noncoding	0.365591		rs380390
intron 15	40335	G/C	noncoding	0.005319		rs380060
intron 15	40179	C/T	noncoding	0.215054		rs7540032
intron 15	35577	T/G	noncoding	0.005208		rs435628
intron 15	35537	C/A	noncoding	0.357895		rs375046
intron 16	35263	C/T	noncoding	0.005263		rs428060
exon 17	34821	C/T	synonomous	0.026316		
exon 17	34786	G/T	nonsynonomous	0.005263	Ser 890 Ile	rs515299
intron 17	31825	A/C	noncoding	0.005319		
exon 18	31689	G/T	nonsynonomous	0.154255	Glu 936 Asp	rs1065489
intron 18	30673	T/G	noncoding	0.005556		rs385892
intron 18	30547	T/C	noncoding	0.111702		rs16840522
intron 18	30546	A/G	noncoding	0.005319		rs385543
exon 19	30396	G/T	nonsynonomous	0.005319	Val 1007 Leu	rs534399
intron 19	28886	T/C	noncoding	0.154255		rs513699
exon 20	28877	C/T	synonomous	0.154255		rs513729
exon 20	28867	A/T	nonsynonomous	0.015957	Asn 1050 Tyr	
intron 20	28592	A/G	noncoding	0.012987		

intron 20	26589	G/C	noncoding	0.005618		
exon 22	25219	C/A	nonsynonymous	0.005556	Pro 1166 Gln	
exon 22	25088	C/T	nonsynonymous	0.005618	Arg 1210 Cys	

Location of each polymorphism refers to the position on GenBank accession AL049744.8 (SEQ ID NO: 9), or the complementary DNA strand of GenBank accession AL049744.8. MAF is minor allele frequency.

- Other data support the finding that mutations in CFH are correlated with AMD. The gene for CFH is located on chromosome 1q31, a region that had been previously identified by six independent linkage scans to be involved in AMD (J. Majewski et al., Am J Hum Genet 73, 540 (2003); J. M. Seddon, S. L. Santangelo, K. Book, S. Chong, J. Cote, Am J Hum Genet 73, 780 (2003); D. E. Weeks et al., Am J Hum Genet 75, 174 (2004); G. R. Abecasis et al., Am J Hum Genet 74, 482 (2004); S. K. Iyengar et al., Am J Hum Genet 74, 20 (2004); and D. W. Schultz et al., Hum Mol Genet 12, 3315 (2003)). In one of these linkage studies, using a single large pedigree the authors concluded that mutations in a different gene in this region (HEMICENTIN-1), was responsible for AMD (D. W. Schultz et al., Hum Mol Genet 12, 3315 (2003)). This conclusion was based on the observation that of all the polymorphisms tested, only the HEMICENTIN-1 mutation perfectly cosegregated with disease status. Mutations in HEMICENTIN-1, however, have not been found to be generally associated with AMD in three separate, independent population-based association studies (G. R. Abecasis et al., Am J Hum Genet 74, 482 (2004); M. Hayashi et al., Ophthalmic Genet 25, 111 (2004); and G. J. McKay et al., Mol Vis 10, 682 (2004)). Mutations in CFH, as disclosed herein, are therefore more likely to be the cause of linkage signals observed at chromosome 1q31.
- Example 6: Immunolocalization of C5b-9 complex in the eyes of patients suffering from AMD

Various components of the complement cascade, including the terminal C5b-9 complex, have been identified as components of drusen in the eyes of patients with AMD (L. V. Johnson, W. P. Leitner, M. K. Staples, D. H. Anderson, Exp Eye Res 73, 887 (2001); R. F. Mullins, S. R. Russell, D. H. Anderson, G. S. Hageman, FASEB J 14, 835 (2000)). The eyes of four patients with AMD were examined to look for the presence of C5b-9 (Figure 4). Post-mortem retinas from four donors were examined. Three were obtained through the Foundation Fighting Blindness (FFB) eye donor program. All of these had a clinical diagnosis of dry AMD. One pair of eyes embedded in paraffin was

obtained from an 86 year old Caucasian female through the autopsy service of the Yale School of Medicine. No clinical history was available. Histologically, these retinas have multiple large or coalescing drusen with minimal RPE and photoreceptor loss consistent with a diagnosis of early AMD. Approval for research on human post mortem donor eyes
5 was obtained from the Yale School of Medicine.

Upon enucleation, eyes were fixed in 4% paraformaldehyde, 0.5% glutaraldehyde in 0.1 M phosphate buffer for several days. The fixed eyes were transferred to 2% paraformaldehyde for storage. Six 0.5 cm circular punches were taken from each of the AMD donor eyes. Three of these were selected from the central retina at the junction of
10 atrophic and more normal retina, and the remaining three from peripheral retina. Retinal plugs were embedded in paraffin and sections cut at 5 μ m.

Following deparaffinization and rehydration, antigen retrieval was performed by boiling sections in a microwave oven for 10 minutes in 10 mM sodium citrate (pH 6.0). Sections were allowed to cool for 20 minutes, prior to a 5-minute endogenous peroxidase
15 block in 5% H₂O₂. Immunohistochemistry was performed using a mouse monoclonal antibody against human activated complement C5b-9 (Quidel Corporation, San Diego, CA, catalogue #A239). Primary antibody was applied at a concentration of 1:250 in 1X PBS. Biotinylated goat anti-mouse (cat # BA9200) secondary antibody (Vector, Burlingame, CA) was used at a concentration of 1:200. Nickel enhanced diaminobenzidine (DAB; cat
20 # SK4100; Vector) was used to visualize bound antibody. Negative controls were obtained by omission of the primary antibody. Images were obtained with a Zeiss Axioplan microscope equipped with differential interference contrast lenses and a Zeiss AxioCam digital camera.

Immunofluorescence Microscopy for CFH

25 Donor eyes were embedded in optimal cutting temperature compound (OCT; Miles Laboratory, Elkhart, IN), snap frozen, and stored at -70°C. Frozen retina sections were cut at 8 to 10 μ m and placed on slides (Superfrost/Plus; Fisher Scientific, Fair Lawn, NJ). All human eyes were obtained with the informed consent of the donors, and the research with
30 human eyes was performed in accordance with the tenets of the Declaration of Helsinki and the Institutional Review Board (IRB).

For immunofluorescence labeling, frozen sections of human retina were fixed in 4% paraformaldehyde in phosphate buffer saline (PBS) for 10 minutes. The tissue sections were blocked for 30 minutes with 5% normal donkey serum (Jackson Immunoresearch, West Grove, PA), diluted in IC buffer (PBS, containing 0.2% Tween-20, 0.1% sodium azide), and incubated for 1 hour at room temperature with a goat anti-human Factor H antibody (Quidel, Santa Clara, CA) diluted 1:200 in staining buffer (IC buffer plus 1% normal donkey serum). Sections were washed repeatedly in IC buffer and incubated for 1 hour with the nuclear dye 4',6'-diamino-2 phenylindole (DAPI; 1 µg/mL) and Alexa-488 Donkey anti-goat antibodies (Molecular Probes, Eugene, OR) diluted 1:250 in staining buffer. After repeated washing with IC buffer, sections were covered in mounting medium (Gel Mount; Biomedica, Foster City, CA) and coverslipped. For the control, the same concentration of anti-human factor H antibody was preincubated for 1 hour with purified human factor H protein (Calbiochem, La Jolla, CA) at the ratio of 3 µg for 1 µl of antibodies. The pretreated antibodies were then used to stain tissue sections as just described. Specimens were analyzed on a laser scanning confocal microscope (model SP2; Leica Microsystems, Exton, PA) equipped with Nomarski optics. Immunolabeled and negative control sections were imaged under identical scanning conditions. Images were processed with Photoshop (Adobe Systems, San Jose, CA).

In all patients, deposition of activated complement C5b-9 was noted in Bruch's membrane. Immunostaining frequently extended to include the intercapillary pillars, and was strongly present within drusen. Staining was rarely noted in the stroma vascularis. However, when it was present, it was invariably located in the inner (toward the retina) walls of choroidal veins, and in severe cases, arteries. No immunostaining for C5b-9 was noted in the retina or elsewhere in sections. The negative control failed to exhibit any staining. These and other biochemical analyses of the composition of drusen may indicate that AMD results from an aberrant inflammatory process in which inappropriate complement activation plays a role (G. S. Hageman et al., *Prog Retin Eye Res* 20, 705 (2001)). This is supported by a mouse model of AMD in which complement components are found in the drusen (J. Ambati et al., *Nat Med* 9, 1390 (2003)).

Moreover, both age and smoking, two significant risk factors for AMD, influence plasma levels of complement factor H (J. Esparza-Gordillo et al., *Immunogenetics* 56, 77 (2004)). CFH sequences have also been observed in an EST library derived from human

RPE and choroid (G. Wistow et al., *Mol Vis* 8, 205 (2002)). Immunofluorescence experiments confirm that CFH is present in this region of the eye (Figure 3). The fluorescent images and their corresponding DIC images obtained from two different areas of human retina sections show strong staining in choroid vessels and area close to RPE (likely to be underneath the Bruch's membrane) (Figure 3). This finding is consistent with the observation that the RPE and choroid produce mRNA for several complement components found in drusen (R. F. Mullins, S. R. Russell, D. H. Anderson, G. S. Hageman, *FASEB J* 14, 835 (2000)). Drusen of similar composition to that found in AMD are found in the eyes of patients with membranoproliferative glomerulonephritis type II (MPGNII), a kidney disease (R. F. Mullins, N. Aptsiauri, G. S. Hageman, *Eye* 15, 390 (2001)); factor H deficiency can cause MPGNII (S. R. D. Cordoba, J. Esparza-Gordillo, E. G. d. Jorge, M. Lopez-Trascasa, P. Sanchez-Corral, *Mol Immunol* 41, 355 (2004)). Our immunostaining experiments (Figures 3 and 4) suggest a pathogenesis of AMD in which loss, impairment, or deficiency of factor H results in complement deposition in choroidal capillaries (more severe) and choroidal vessels (less severe) with subsequent leakage of plasma proteins in to Bruch's membrane. Finally, nutritional supplementation with zinc at 80 mg/day decreases the risk of AMD; biochemical studies have shown that factor H function is sensitive to zinc concentration (AREDS Research Group, *Arch Ophthalmol* 119, 1417, (2001); A. M. Blom, L. Kask, B. Ramesh, A. Hillarp, *Arch Biochem Biophys* 418, 108 (2003)).

The present invention provides among other things polynucleotides useful for identifying or aiding in identifying individuals at risk for developing AMD, as well as for diagnosing or aiding in the diagnosis of AMD. While specific embodiments of the subject invention have been discussed, the above specification is illustrative and not restrictive. Many variations of the invention will become apparent to those skilled in the art upon review of this specification. The full scope of the invention should be determined by reference to the claims, along with their full scope of equivalents, and the specification, along with such variations.

All publications and patents mentioned herein are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.

Also incorporated by reference in their entirety are any polynucleotide and polypeptide sequences which reference an accession number correlating to an entry in a public database, such as those maintained by The Institute for Genomic Research (TIGR) (www.tigr.org) and/or the National Center for Biotechnology Information (NCBI) (www.ncbi.nlm.nih.gov).

5

Table 6. Primer sequences used in resequencing.

Region	Forward primer sequence	Reverse primer sequence
promoter	AGAATCGGTCTCTGTGTCGG	AGCAGCTGGTGAATCCTCTGG
promoter	TCAAATGAGAGTGAGCCAGTTGC	CTGTTCACAAACGTCCAGTTCTCC
exon 1	GTGGGAGTGCAGTGAGAATTGG	AACTCAACAATGTCAAAAGCC
exon 2	GATAAACCTGTGACTGTCTAGGC	GGCAATAGTGAATATAATTCAAGGC
exon 3	ACCTCAOCCTCCCAAAGTGC	TGCATACTGTTTCCCACCTCTCC
exon 4	AAGGAGGAGGAGAAGGAGGAAGG	CAGGCTGCATTCGTTTGG
exon 5	CCACTCCCATAGAAAAGAACAGG	ACTTCTTGCACCAGTCTCTCC
exon 6	GATAAACATTTATTAAAGCGG	GAACCTTGAACACAGAAAATGC
exon 7	GGATGACTTGGAGAAGAAGG	TATGAGTTTCGGCAACTTCG
exon 8	TCATCTTCATTAACAAAGACC	AGATCTATTTGGTCACTTGC
exon 9	CTTGTAGTAACTTAGTTGC	TTATACACAGTTGAAAAACC
exon 10	GGCAACTCTGAGCTTATTTCC	AGAGTAGGAAAAGCCTGAATGG
exon 11	CATAGATTATTTGTACGG	CAAAACTCCCTCTTTCCC
exon 12	ATCTGATGCCCTCTGTATGACC	ATTCACTACATCAATACATGTCC
exon 13	CACCATCTTGATTGTTAGG	GAATCTCCATAGTAATAAGG
exon 14	CAATGTGTTGATGGAGAGTGG	ATTGAATTATAAGCAATATGC
exon 15	CATTTCAAGGACAGAACACAGG	GTCGTGTGTGTGTGTGTGC
intron 15	AAGGCAGGAAAGTGTCTTATGC	GTCAAATTACTGAAAATCACC
exon 16	AACTGTTACACAGCTGAAAAG	GTGGTGAATTGATTAATGTGC
exon 17	GGTGGAGGAATATATCTTTGC	ATAGAATAGATTCAATCATGC
exon 18	CGATAGACAGACAGACACCAAGAAGG	CAGCTATAATTCCCCACACAGTCC
exon 19	GTGTAATCTCAATTGCTACGGCTACC	CAAGTACTGGGACTTCAGATGC
exon 20	TAGTTTCATGTCCTTCCTC	GAATTAAAGCACCACATCAGTC
exon 21	CCAGGACTCATTCTTTCAACC	CTTTCTGACAGAAATATTGG
exon 22	TGATGTTCTACATAGTTGG	GGAGTAAAACAATACATAAAAAATG

Table 7. Variations in CFH identified through resequencing that may be correlated with the occurrence of AMD. Each variation is shown in the context of its surrounding DNA sequence. Location of each variation refers to the position on GenBank accession AL049744.8, or the complementary DNA strand of GenBank Accession AL049744.8.

Region	Position	Common/Common Rare/Rare	Rare/Rare	Change	Sequence Context
promoter	1209921	94	1	0	A/G
promoter	120865	94	0	1	-2,276,618 A/G
promoter	120546	57	30	8	-4,771,987 G/A
promoter	120610	94	1	0	C/T
promoter	120294	94	1	0	T/C
intron 1	95391	72	22	9	0,451,283 T/G
exon 2	98242	93	1	0	C/T
exon 2	99235	72	22	0	0,451,283 T/G
intron 2	95114	93	1	0	G/A
intron 2	98485	75	20	0	0,285,378 T/G
intron 3	98285	94	1	0	G/A
intron 3	98188	94	1	0	G/A
exon 4	96315	94	1	0	G/A
intron 4	96211	94	1	0	T/D
exon 7	87139	46	19	30	-7,584,979 T/G
intron 7	8,3071	94	1	0	A/G
intron 7	83059	94	1	0	A/G
intron 7	82966	48	16	31	-10,039,955 G/T
intron 7	82957	94	1	0	A/G
exon 9	82232	95	1	0	C/A
exon 9	82226	46	18	30	-8,605,781 C/T
intron 9	58632	93	1	0	T/C
exon 10	58516	59	37	7	3,967,769 G/A
intron 10	58319	93	1	0	C/T
intron 10	58260	93	1	0	A/G
intron 10	56838	54	11	29	-13,637,269 G/T
exon 12	47084	94	1	0	G/A
intron 12	46992	95	1	0	T/G
exon 13	4,5721	71	19	4	-1,945,792 A/G

exon 15	43875	92	1	0	0	A/G Glu 783 Gln
intron 15	40549	69	26	7	-0.9218916	G/A
intron 15	40445	90	4	0	0	C/T
intron 15	40812	54	10	29	-13.6695984	G/C
intron 15	40835	93	1	0	0	G/C
intron 15	40179	60	26	7	-0.9218916	C/T
intron 15	35377	95	1	0	0	T/G
intron 15	35937	55	12	28	+12.229781	C/A
intron 16	35253	94	1	0	0	C/T
exon 17	34821	90	5	0	0	C/T His 878 His 881 Gln/Gln
exon 17	34786	94	1	0	0	C/T Ser 890 Ile
intron 17	31825	93	1	0	0	A/C
exon 18	31889	70	19	5	-1.4115993	G/T Glu 936 Asp
intron 18	30673	89	1	0	0	T/G
intron 18	30647	78	11	5	-2.5065654	T/C
intron 18	30546	93	1	0	0	A/G
exon 19	30196	93	1	0	0	G/T Val 1007 Leu
intron 19	28886	65	20	0	0.915038	T/C
exon 20	28877	65	29	0	0.933938	C/T Thr 1046 Thr
exon 20	28867	91	3	0	0	A/T Asn 1050 Tyr
intron 20	28592	35	2	0	0	A/G
intron 20	26389	88	1	0	0	G/C
exon 22	25219	89	1	0	0	C/A Pro 1166 Gln/Gln
exon 22	25088	88	1	0	0	C/T Arg 1219 Cys

Table 8. Variations in CFH11 that may be correlated with the occurrence of AMD. Each variation is shown in the context of its surrounding DNA sequence. Location of each variation refers to the position on GenBank Accession AL049741.7, or the complementary DNA strand of GenBank Accession AL049741.7.

Table 9. Variations in CFHIL3 that may be correlated with the occurrence of AMD. Each variation is shown in the context of its surrounding DNA sequence. Location of each variation refers to the position on GenBank Accession AL049741.8, or the complementary DNA strand of GenBank Accession AL049741.8.

Table 10. Variations in CPHI.4 that may be correlated with the occurrence of AMD. Each variation is shown in the context of its surrounding DNA sequence in Chromosome 7:32512024-33512123.

Region	Position	Common/Common			Rare/Rare	log HW P-value	Change	Sequence Context
		Common	Common	Rare				
promoter	7013	93	1	0	0	0	C/T	GTTAACTCAACGATGTCACA
promoter	7369	91	4	0	0	0	C/G	AATAGTTCGAAAGCCTTCATTCC
promoter	7577	91	5	0	0	0	C/A	CCTAACTTGTATACTAAGTG
promoter	7585	95	1	0	0	0	C/G	TGATATTTACTAACGCTTAAGG
exon 2	22144	94	2	0	0	0	T/C Asp 76 Asp	GGGGATACATTCACACAAAGA
exon 3	32236	94	1	0	0	0	T/C Ile 112 Ile	CAGATGGAATTCTCAGGTCATTC
intron 5	37640	88	4	2	2.226371993	T/G	GCTAAAGTCAGTATGTCACAAATTG	
intron 5	37701	69	18	6	-1.933271388	G/A	TATTTTACCTAAACIACATAG	
exon 6	37884	74	19	2	-0.3082375585	A/G Giv 306 Giv	ACCATTTGAAATTATGAAATTTC	

Claims

We claim:

1. An isolated polynucleotide for the detection of a variant CFH gene, in a sample from an individual, comprising a nucleic acid molecule that specifically detects a variation 5 in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans.
2. The polynucleotide of claim 1, wherein the polynucleotide is a probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans.
- 10 3. The probe of claim 2, wherein the variation encodes an amino acid other than histidine at position 402 of the CFH protein.
4. The probe of claim 3, wherein the variation encodes tyrosine at position 402 of the CFH protein.
- 15 5. The probe of claim 2, wherein the probe is a DNA probe.
6. The probe of claim 5, wherein the probe is from about 8 nucleotides to about 500 nucleotides.
7. The probe of claim 5, wherein the probe is from about 10 nucleotides to about 250 nucleotides.
- 20 8. The probe of claim 5, wherein the probe comprises one or more non-natural or modified nucleotides.
9. The probe of claim 8, wherein the one or more non-natural or modified nucleotides are radioactive, fluorescently, or chemically labeled nucleotides.
- 25 10. A polynucleotide primer that hybridizes, under stringent conditions, adjacent to a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans.
11. The polynucleotide primer of claim 10, which hybridizes immediately adjacent to a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans.
- 30 12. A pair of polynucleotide primers that specifically detect a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans,

wherein the first polynucleotide primer hybridizes to one side of the variation and the second polynucleotide primer hybridizes to the other side of the variation.

13. A pair of polynucleotide primers that hybridize to a region of DNA that comprises a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans, wherein the polynucleotide primers hybridize to the region in such a manner that the ends of the hybridized primers proximal to the variation are from about 20 to about 10,000 nucleotides apart.

14. The pair of polynucleotide primers of claim 12, wherein the variation encodes an amino acid other than histidine at position 402 of the CFH protein.

10 15. The pair of polynucleotide primers of claim 14, wherein the variation encodes tyrosine at position 402 of the CFH protein.

16. The pair of polynucleotide primers of claim 12, wherein the primers are DNA primers.

15 17. The pair of polynucleotide primers of claim 16, wherein the primers are each from about 8 nucleotides to about 500 nucleotides.

18. The pair of polynucleotide primers of claim 16, wherein the primers are each from about 10 nucleotides to about 250 nucleotides.

19. The pair of polynucleotide primers of claim 16, wherein the primers comprise one or more non-natural or modified nucleotides.

20 20. The pair of polynucleotide primers of claim 19, wherein the one or more non-natural or modified nucleotides are radioactive or fluorescently labeled nucleotides.

21. A method of detecting, in a sample obtained from an individual, a variant CFH gene that is correlated with the occurrence of age related macular degeneration in humans, comprising:

25 (a) combining the sample with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans, but not to a wildtype CFH gene; and

30 (b) determining whether hybridization occurs,
wherein the occurrence of hybridization indicates that a variant CFH gene

that is correlated with the occurrence of age related macular degeneration is present in the sample.

22. A method of detecting, in a sample obtained from an individual, a variant CFH gene that is correlated with the occurrence of age related macular degeneration in humans, 5 comprising:

- (a) combining the sample with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans, thereby producing a combination;
- 10 (b) maintaining the combination produced in step (a) under stringent hybridization conditions; and
- (c) comparing hybridization that occurs in the combination with hybridization in a control, wherein the control is a polynucleotide probe that does not bind to a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans or binds only to a wildtype CFH gene, and the sample is the same type of sample as in (a) and is treated the same as the sample in (a), and
15 wherein the occurrence of hybridization in the combination but not in the control indicates that a variant CFH gene that correlates with age related macular degeneration is present in the sample.
- 20

23. The method of claim 22, wherein the extent of hybridization is determined in step (c).

24. A method of detecting, in a sample obtained from an individual, a variant CFH gene that is correlated with the occurrence of age related macular degeneration in humans, 25 comprising:

- (a) combining a first portion of the sample with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans;
- 30 (b) combining a second portion of the sample with a polynucleotide probe that hybridizes, under stringent conditions, to a wildtype CFH gene; and

(c) determining whether hybridization occurs,
wherein the occurrence of hybridization in the first portion but not in the
second portion indicates that a variant CFH gene that is correlated with the
occurrence of age related macular degeneration is present in the sample.

5 25. The method of claim 21, wherein the variation encodes an amino acid other
than histidine at position 402 of the CFH protein.

26. The method of claim 25, wherein the variation encodes tyrosine at position 402
of the CFH protein.

10 27. The method of claim 21, wherein the sample comprises cells obtained from the
eye, ear, nose, teeth, tongue, epidermis, epithelium, blood, tears, saliva, mucus, urinary
tract, urine, muscle, cartilage, skin, or any other tissue or bodily fluid.

28. The method of claim 21, wherein the polynucleotide probe is a DNA probe.

29. The method of claim 21, wherein the polynucleotide probe is from about 8
nucleotides to about 500 nucleotides.

15 30. A method of detecting, in a sample obtained from an individual, a variant CFH
gene that is correlated with the occurrence of age related macular degeneration in humans,
comprising:

20 (a) combining the sample with a pair of polynucleotide primers, wherein the
first polynucleotide primer hybridizes to one side of DNA encoding amino
acid 402 of the CFH protein and the second polynucleotide primer
hybridizes to the other side of DNA encoding amino acid 402 of the CFH
protein;

25 (b) amplifying DNA in the sample, thereby producing amplified DNA;

(c) sequencing amplified DNA; and

(d) detecting in the DNA the presence of a variation that encodes an amino
acid other than histidine at position 402 of the CFH protein,
wherein the presence of the variation indicates that a variant CFH gene that
is correlated with the occurrence of age related macular degeneration in
humans is detected in the sample.

31. A method of identifying or aiding in identifying an individual at risk for developing age related macular degeneration, comprising assaying a sample obtained from the individual for the presence of a variant CFH gene that is correlated with the occurrence of age related macular degeneration in humans, wherein the presence of a variant CFH gene indicates that the individual is at risk for developing age related macular degeneration.

5 32. A method of identifying or aiding in identifying an individual at risk for developing age related macular degeneration, comprising:

10 (a) combining a sample obtained from the individual with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans, but does not hybridize to a wildtype CFH gene; and

15 (b) determining whether hybridization occurs, wherein the occurrence of hybridization indicates that the individual is at risk for developing age related macular degeneration.

33. A method of identifying or aiding in identifying an individual at risk for developing age related macular degeneration, comprising:

20 (a) obtaining DNA from an individual;

 (b) sequencing a region of the DNA that comprises the nucleotides that encode amino acid 402 of the CFH protein; and

 (c) determining whether a variation that encodes an amino acid other than histidine at position 402 of the CFH protein is present in the DNA, wherein the presence of the variation indicates that the individual is at risk for developing age related macular degeneration.

25 34. A diagnostic kit for detecting a variant CFH gene in a sample from an individual, comprising:

30 (a) at least one container means having disposed therein a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans; and

(b) a label and/or instructions for the use of the diagnostic kit in the detection of a variant CFH gene in a sample.

35. A diagnostic kit for detecting a variant CFH gene in a sample from an individual, comprising:

- 5 (a) at least one container means having disposed therein a polynucleotide primer that hybridizes, under stringent conditions, adjacent to one side of a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans; and
- 10 (b) a label and/or instructions for the use of the diagnostic kit in the detection of CFH in a sample.

36. The diagnostic kit of claim 35, additionally comprising a second polynucleotide primer that hybridizes, under stringent conditions, to the other side of the variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans.

15 37. A composition for treating a subject suffering from age related macular degeneration, comprising:

- (a) an effective amount of an isolated or recombinantly produced wildtype CFH polypeptide, or a fragment thereof; and
- (b) a pharmaceutically acceptable carrier.

20 38. The composition of claim 37, wherein the CFH polypeptide or the fragment thereof inhibits the activation of C3.

39. A method of treating a subject suffering from age related macular degeneration, comprising administering to the subject an effective amount of the composition of claim 37.

25 40. A composition for treating a subject suffering from age related macular degeneration, comprising:

- (a) an effective amount of an isolated or recombinantly produced nucleic acid molecule coding for a CFH polypeptide, or a fragment thereof; and
- (b) a pharmaceutically acceptable carrier.

41. A method of treating a subject suffering from age related macular degeneration, comprising administering to the subject an effective amount of the composition of claim 40.

42. A method of detecting, in a sample obtained from an individual, a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans, comprising:

(a) combining the sample with an antibody that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans; and

10 (b) determining whether binding occurs,

wherein the occurrence of binding indicates that a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration is present in the sample.

43. A composition for treating a subject suffering from or at risk for age related macular degeneration, comprising:

15 (a) a nucleic acid molecule comprising an antisense sequence that hybridizes to a variant CFH gene or mRNA that is correlated with the occurrence of age related macular degeneration in humans; and

(b) a pharmaceutically acceptable carrier.

44. The composition of claim 43, wherein hybridization of the antisense sequence to the variant CFH gene reduces the amount of RNA transcribed from the variant CFH gene.

45. The composition of claim 43, wherein hybridization of the antisense sequence to the variant CFH mRNA reduces the amount of protein translated from the variant CFH mRNA, and/or alters the splicing of the variant CFH mRNA.

25 46. The composition of claim 43, wherein said nucleic acid molecule includes one or more modified nucleotides or nucleosides that enhance in vivo stability, transport across the cell membrane, or hybridization to a variant CFH gene or mRNA.

47. A method for treating a subject suffering from or at risk for age related macular degeneration, comprising administering to the subject an effective amount of the 30 composition of claim 43.

48. A composition for treating a subject suffering from or at risk for age related macular degeneration, comprising:

- 5 (a) a nucleic acid molecule comprising a siRNA or miRNA sequence, or a precursor thereof, that hybridizes to a variant CFH gene or mRNA that is correlated with the occurrence of age related macular degeneration in humans; and
- (b) a pharmaceutically acceptable carrier.

49. The composition of claim 48, wherein hybridization of the siRNA or miRNA sequence to the variant CFH gene reduces the amount of RNA transcribed from the variant 10 CFH gene.

50. The composition of claim 48, wherein hybridization of the siRNA or miRNA sequence to the variant CFH mRNA reduces the amount of protein translated from the variant CFH mRNA, and/or alters the splicing of the variant CFH mRNA.

51. The composition of claim 48, wherein said nucleic acid molecule includes one 15 or more modified nucleotides or nucleosides that enhance in vivo stability, transport across the cell membrane, or hybridization to a variant CFH gene or mRNA.

52. A method for treating a subject suffering from or at risk for age related macular degeneration, comprising administering to the subject an effective amount of the composition of claim 48.

20 53. A composition for treating a subject suffering from or at risk for age related macular degeneration, comprising:

- (a) an aptamer that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans; and
- (b) a pharmaceutically acceptable carrier,
- 25 wherein binding of the aptamer to the variant CFH polypeptide reduces the activity of the variant CFH polypeptide.

54. A method for treating a subject suffering from or at risk for age related macular degeneration, comprising administering to the subject an effective amount of the composition of claim 53.

55. A composition for treating a subject suffering from or at risk for age related macular degeneration, comprising:

wherein binding of the small molecule to the variant CFH polypeptide reduces the activity of the variant CFH polypeptide.

56. A method for treating a subject suffering from or at risk for age related macular degeneration, comprising administering to the subject an effective amount of the composition of claim 55.

57. A composition for treating a subject suffering from or at risk for age related macular degeneration, comprising:

- 15 (a) an antibody that binds to a variant CFH polypeptide that is correlated
with the occurrence of age related macular degeneration in humans; and

(b) a pharmaceutically acceptable carrier;

wherein binding of the antibody to the variant CFH polypeptide reduces the activity of the variant CFH polypeptide.

58. A method for treating a subject suffering from or at risk for age related macular degeneration, comprising administering to the subject an effective amount of the composition of claim 57.




FIG. 1A




FIG. 1B




FIG. 2A




FIG. 2B




FIG. 2C




FIG. 2D




FIG. 3A





FIG. 3B



FIG. 3C

FIG. 4

**Polypeptide Sequence for Homo sapiens Complement Factor H
(GenBank Accession CAA68704)**

1	mrllakikcl	mlwaisicvaed	kerpgyrs1g
61	nvimwcrkge	wvalnplrkic	vytcraegyql
121	lgeinnyrecd	tdgwtndipri	ggavvrfvns
181	gykiesgdeen	hcdddgfwsk	erfcqykcnng
241	yeysergdav	ctesgnrwlpp	tygcncfyp
301	atrgntakct	stgwipaprc	kyssyycdeh
361	fetpsgsywd	hhctqdgcws	sidvachbpgy
421	alpkacttvt	cmengwspth	ekakyqcklg
481	yvtadgatssg	sircgkdgws	tlidyechdgy
541	esntgsttgs	ivoqyngwsd	nhgrkfvgqk
601	frivgnswq	cyrhfglspdl	sescyryalk
661	prflmkgnk	iqcvdgewrt	ndftwfklnd
721	esftmighrs	iteihgvwtq	drkkcdykvqg
781	crskewiht	vcingzwdp	vkektkceeyas
841	enyliqgees	itckdgrwqs	hseveyycn
901	ceggfrisee	nettccymgkw	ygdsverfnsc
961	eatglldgpa	akclgekwsh	fdhnsniixyr
1021	yykmndgasuv	tcinsrwtrgx	dgekksvvlca
1081	yemfgdeevm	c1ngnwtepp	yahgtklsyt
1141	lyqleonkri	tcrnqwsed	gceavtytcat
1201	ckrgyyrlssr	shtrlttcsd	ervryqcrsp
			assveyqcon
			srtrgesvefu
			x

FIG. 5

SEQUENCE LISTING

<110> Yale University
Moh, Josephine

<120> METHODS AND COMPOSITIONS FOR TREATING OCULAR DISORDERS

<130> YU-PWO-038

<150> US 60/629,363
<151> 2004-11-18

<150> US 60/649,479
<151> 2005-02-02

<150> US 60/672,346
<151> 2005-04-18

<160> 59

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 4004
<212> DNA
<213> Homo sapiens

<400> 1
cctttgcag caagttcttt cctgcactaa tcacaattct tggaaaggaa gaactggacg 60
ttgtgaacag agttagctgg taaaatgtct cttaaaaatg ccaaaaaatg agacttctag 120
caaagattat ttgcctttag ttatggctt ttgtgttagc agaagattgc aatgaacttc 180
ctccaaagaag aaatacagaa attctgacag gttccctggtc tgacccaaaca tatccagaag 240
gcaccceaggc tatctataaa tggcccgtt gatatacgatc tcttggaaat gtaataatgg 300
tatgcaggaa gggagaatgg gttgtctta atccattaa gaaatgtcag aaaaggcccc 360
gtggacatcc tggagataact cttttggta cttttaccct tacaggagga aatgtgtttg 420
aatatggtgt aaaaatgttg tatacatgtt atgggggtta tcaatitgtctt ggtgagatta 480
attaccgtga atgtgacaca gatggatggc ccaatgtatc tcttatatgt gaagttgtga 540
agtgttacc agtgcacgcg ccagagaatg gaaaaattgt cagtagtgcg atggAACCG 600
atcgggaaata ccattttggc caagcgttac gttttgtatg taactcaggc tacaagatgg 660
aaggagatga agaaatgtat tgttcagacg atgggttttg gagtaaagag aaacccaaagt 720
gtgtggaaat ttcatgcaaa tccccagatg ttataatgg atctccata ttcagaaga 780
ttattttataa ggagaatgaa cgatttcaat ataaatgtaa catgggttat gaatacagtg 840
aaagaggaga tgcgttatgc actgaatotg gatggcgtcc gttgccttca tgcgttggaa 900
aatcatgtga taatccattat atccccaaatg gtgtacttc accttttaagg ataaacacaca 960
gaactggaga tgaatcactt taccgtgtt gaaatggttt ttatctgcg accggggaa 1020
atacagcaaa atgcacaatg actggcttggc taccgtctcc gagatgtacc tggaaacac 1080
gtgatttatcc agacattaaa catggaggc tataatgttca gaatatgcgt agaccatact 1140
ttccagtagc tgttagaaaaa tattactctt attactgttca tgaacatctt gagactccgt 1200
caggaagtta ctgggatcac attcattgttca cacaagatgg atggctccca gcaatccat 1260
gcctcagaaaa atgttatctt ctttttttgg aaaaatggata taatccaaat catggaaagaa 1320
agtttgtaca gggttaatctt atagacgttg cttgccttc tggcttacgt ctccaaaaag 1380
cgccagaccac agttcatgtt atggagaatg gttggcttc tactccaga tgcattccgt 1440
tccaaacatg ttccaaatca agtatacgat ttttttttgc gatctcgt 1500
atacatatgc ttatggaaat aaagcggaaat atcaatgcac actaggatat gtaacagcgg 1560
atggtgaaaatc atcaggatca attacatgtt gggaaatgg atggcttacgt caacccacgt 1620
gcattaaatc ttgtgtatcc ccaatgttca tgaatggccag aactaaaaat gacttcacat 1680
ggttttaagctt gatgtacaca ttggactatg aatggccatgtt tggttatggaa agcaatactg 1740
gaagccaccac tggttccata gttgtgggtt acaatgggtt gttgttgcattt cccatatgtt 1800
atggaaagaga atgcgttacgtt ctttttttgc gatctcgtt agttcctgtt gcaagaaaag 1860
accaggataa atgtggagag gtgttgcattt ttcctgcattt accaggattt acaatagttt 1920

gacctaattc	cgttcagtgc	taccactttg	gatttgtctcc	tgaccccca	atatgttaaa	1980
agcaagtaca	atcatgggt	ccacccctcg	aacttctcaa	tgggaatgtt	aaggaaaaaa	2040
cgaaaagaaga	statggcac	agtgaagtgg	tggaatatta	ttgcaatct	agatttctaa	2100
tgaaggggacc	taataaaaatt	caatgtttt	atggagagtg	gacaacttta	ccagtgtgt	2160
tttgtggagga	gagkaccigt	ggagatatac	ctgaacttga	acatggctgg	gcccaagctt	2220
cttccccctcc	tttattactat	ggagattcag	tggaaattca	trgctcagaa	tcatattacaa	2280
tgattggaca	cagatcaatt	acgtgttac	atggagtatg	gaccacaactt	cccccaagtgt	2340
tggcaataga	taaacttaag	aagtgc当地	catcaaattt	aattataactt	gaggaacatt	2400
taaaaaaaca	gaaggaattc	gatcataatt	cteacataag	gtacagatgt	agaggaaaag	2460
aaggatggat	acacacagtc	tgcataatag	gaagatggga	tccagaagtg	aactgctcaa	2520
tggcacaaat	acaattatgc	ccacccctccac	ctcagattcc	caattctcac	aatargacaa	2580
ccacactgaa	ttatcgggat	ggagaaaaag	tatctgttct	ttgccaagaa	aattatctaa	2640
ttcagggagg	agaagaaaatt	acatgcaaag	atggagatg	gcagtcaata	ccactctgtg	2700
ttgaaaaaaat	tccatgttca	caaccacac	agatagaaca	cggaaccatt	atttcatcca	2760
ggtcttcaca	agaaagttat	gcacatggg	ctaaattttag	tttactttgt	gagggtgggt	2820
tcaggatatc	tgaagaaaat	gaaacaacat	gotacatggg	aaaatggagt	tctccacctc	2880
agtgtgaagg	ccttccttgc	aaatctccac	ctqagattt	tcatggtgg	gtatgc当地	2940
tgtcagacag	ttatcagttat	ggagaagaag	ttactgtacaa	atgttttggaa	ggttttggaa	3000
ttgatgggcc	tgc当地ttgc	aaatgtctag	gagaaaaatg	gttccaccc	ccatcatgca	3060
taaaaaacaga	ttgtctcagt	tttacccatgt	ttgaaaaatgc	catacccatg	ggagagaaaga	3120
aggatgtgt	taaggcgggt	gagcaagtg	cttacacttg	tgcaacat	tacaaaatgg	3180
atggagccag	taatgtaa	tgcatttaata	gcagatggac	aggaaggccaa	acatgcagag	3240
acacccctcg	tgtgaatccg	cccacagtg	aaaatgttta	tatagtgtcg	agacagatga	3300
gttaaatatcc	atctggtgag	agagtagctt	atcaatgttg	gagcccttat	gaaatgtttt	3360
gggatgaaga	aytgatgtgt	ttaaatggaa	actggacgg	accacccctca	tgcaaaagatt	3420
ctacaggaaa	atgtggcc	cctccacca	ttgacaatgg	ggacattact	tcattccctgt	3480
tgtcagttata	tgc当地ccatgt	tcatcagtt	agttaccaatg	ccagaactt	tatcaacttgc	3540
agggtaacaa	ycgaaataaca	tgttagaaatg	gacaatggtc	agaaccacca	aaatgtttac	3600
atccgtgtgt	aatatcccga	gaatattatgg	aaaattataa	catagcatta	aggtggacag	3660
ccaaacagaa	gctttattcg	agaacagtg	aatcagttga	atttgbgtgt	aaacggggat	3720
atcgctttc	atcacgttgc	cacacattgc	gaacaacatg	ttgggatggg	aaactggagt	3780
atccaaacttgc	tgc当地aaaga	bagaaatcaat	cataaaagtgc	acacccctt	tcagaactttt	3840
agtattaaat	cagttctcaa	tttcattttt	batgtattgt	tttactccct	tttatttcata	3900
cgtaaaatcc	tggattaatt	tgtgaaaatg	taattataag	ctgagacccgg	tggctcttatt	3960
cttaaaaacca	ccatattaaa	tcctggaaaa	ctaaaaaaa	aaaa		4004

<210> 2
<211> 1292

212 DNA

<233> Home

www.ijerph.org

えまひじふ と だいせせせん

3 / 64

caggaagtta	ctgggatcac	attcartgca	cacaagatgg	atggtcgcga	gcagtagccat	1260
gcctcagaaa	atgttatttt	ccttatttgg	aaaatggata	taatcaaaat	catgaaagaa	1320
agtttgtaca	gggttaaatct	atagacgtt	cctgccatcc	tggctacgct	cttccaaaag	1380
cgcagacccac	agttacatgt	atggagaatg	qctggcttcc	tactccccaga	tgcatccgtg	1440
tcagctttac	cctctgaact	tctgatcgaa	ggtcatccct	ctccagcttg	agtggatcaa	1500
agatgacaagg	ggccaatgga	accagggtt	agtcttgcca	ggtaataact	tgggtctgaa	1560
gtatggtgac	tagtatctgt	tttggtagt	gtgttattatt	ccagccagaa	tggaaaatgc	1620
taatttcagct	cctccaggca	gccccatggg	gctggtggt	tttagattat	taaactcttt	1680
ctatgtqca	aaaaaaaasa	aa				1702

<210> 3

<211> 4252

<212> DNA

4233> Mus musculus

<400> 3

gagagattcc attgagtc ca gcagtcatga acatggaa acttacgt atgtctgtga 2820
 tcatgtttc aggataacctg aagaaaatag gataaccgtc tacatggaa aatggagcac 2880
 tccacccctgc tgggttggac ttccctgtgg acctccaccc tcaatccrc ttggtaactgt 2940
 ttctctttagt ctatggaggat accaacaatgg ggaagaggat acataaccatt gtctiacagg 3000
 ctttggaaatt gatggaccatg cattttat atgcgaaggg ggaaagtggt ctgacccacc 3060
 aaaatgcata aaaacggatt gtgacgtttt acccacagtt aaaaatgcata taataagagg 3120
 aaagagcaaa aaatcatata ggacaggaga acaagtgaca ttccatgtc aatctcccta 3180
 tczaatgaat ggcctcagaca ctgtgacatg tgtaatagt cggtggatg gacagccagt 3240
 atgcaaaatg aattccctgt tggatccacc acatgtgcca aatgctacta tagtaacaag 3300
 gaccaagaat aaatatctac atggtgacag agtacgttat gaatgtataa aacccccc 3360
 actatttggg caagtggaa tgatgtgtga aatggataa tggacagaaa aacccaaagtq 3420
 ccgagactca acagggaaat gtggggctcc tccacccatt gacaatggag acatcaccc 3480
 cttgtcatta ccagtatatg aaccattatc atcagttgaa tatcaatgcc agaagtattt 3540
 tctccctaag ggaaagaaga caataacatg tacaaaatgg aagtggctcg agccaccaac 3600
 atgcttacat gcatgtgtaa taccggaaaa cattatggaa tcacacaata taatctcaa 3660
 atggagacac actgaaaaga ttatccccca ttccaggggag gatattgaat ttggatgtaa 3720
 atatggatataataaagccaa gagattcacc gccatttcgt acaaagtgc ttaatggcac 3780
 catcaattat cccacttgc tataaaatca taatacattt attagttgt tttattgttt 3840
 agaaaggcac atgcgtgtga ctaatataact ttcaatitgc attgaagtat ttgttaactc 3900
 atgtcttcataaataatataa acatttttgt tatatgtgtaa tttaacttgc acatttaaaaa 3960
 ctattggccaa aatgcggaaag cagtaattca aacatccata ttaataatataat gatatgtccca 4020
 aggacaaaactt attcataatca agaaagttaga tgtaatgtc tcaacatctg ttcttattca 4080
 gaacttccatc agattttcctt ggataccctt tgatgttaagg ttctgattta cagggatataa 4140
 agatataattt gactgattt tcaaaataat atgatttccc aaagcatgt acaacccaaac 4200
 tatacatatata tataatgtacta atgcatacaaa ttaattacta tataatactt to 4252

<210> 4

<211> 4250

<212> DNA

<213> Rattus norvegicus

<400> 4

acagcacata cttcttccatc agtcaactgc tcccaagatag atccaaagaca tgagactgtc 60
 agcaagaattt atttgggtta tattatggac tggatgtgtaa gcaagaaatgtt gtaaagggtcc 120
 tccatccaaaga gaaaattcag aaatttctc aggttctgtgg tctgaacaatc tatattcaga 180
 aggcacatcag gcaacccata aatgcggccccc tggataccga acacttgcata ctattgtaaa 240
 agtacgtcaag aatggagaat gggtaacctc taacccatca aggatatgtc ggaaaaggcc 300
 atgtgggcat cccggagaca caccctttgg gtcctttagg ctggcagggt gatctgaattt 360
 tgaatttggt gcaaaagggtt gttataatcgt tgatgtggg tcccaactct taggtgaaat 420
 tgattaccgtt gaaatgtgtatc cagatgggtt gaccatgtat gttcaatataat gtaaggttgt 480
 gaagtgttttgc ccaatgttgc aactggggaaat tggaaagaaatgtt gtagtgggtt cagccgaaacc 540
 agaccaggaaat tatttttttgc gacagggtt acgtttgtaa tggcaactccg gttcaatataat 600
 tgaaggacag aaagaaaatgc actgcgtcaga aatggccctt tggagcaatg aaaagccaca 660
 gtgtgtggaa atttttttgc tggccaccacg agttgaaaat gggatgttgc tttatctgaa 720
 accatgttttgc aaggagaatg aaagatttca atataaatgtt aagcaagggtt ttgtgtacaa 780
 agaaaagggg gatgtgttgc gcaatgggtt tggatggaaat cctccatccctt cctgtgttgc 840
 aatgcacatgt ttgactccat atattccaaa tggatgttgc acacccatca ggattaaaca 900
 cagaattgtat gatgttgc gatgttgc taaaatggc ttctatccatc caacccatc 960
 acctgttca aagtgttgc ttactggctt gatccctgtt gcaatgttgc gttgaaacc 1020
 ttgtgttttccatccatc aacatggacg tttgttattat gaaagaaagcc ggagaccctt 1080
 cttccatccatc cttataggaa aggatgttgc ctattactgt gacaacccgtt ttacaaccc 1140
 ttcacatgttca tactggggactt accttgcgttgc cccatgttgc gggatgggtt cttgtgttgc 1200
 atgccttcagg caatgttgc tccatgttgc gaaatgttgc gaaatgttgc gttgaaacc 1260
 aagatataataat gggatgttgc tttgttgc tttgttgc gttgaaacc 1320
 tggatgttgc tttgttgc tttgttgc gttgaaacc 1380
 tttatccatc tttatccatc tttatccatc tttatccatc tttatccatc tttatccatc 1440
 ttatccatc tttatccatc tttatccatc tttatccatc tttatccatc tttatccatc 1500
 tttatccatc tttatccatc tttatccatc tttatccatc tttatccatc tttatccatc 1560
 atgcatttgc tttgttgc tttgttgc tttgttgc tttgttgc tttgttgc 1620
 atgcatttgc tttgttgc tttgttgc tttgttgc tttgttgc tttgttgc 1680
 tttatccatc tttatccatc tttatccatc tttatccatc tttatccatc tttatccatc 1740
 tttatccatc tttatccatc tttatccatc tttatccatc tttatccatc tttatccatc 1800

5 / 64

agttaaaaatac	aaagtgtggag	attcgtttag	tttcttgc	cgttcaggac	acagagtttg	1860
agcagattta	gtgcaatgtct	accactttgg	atggccccc	aatttcccaa	cgtgtgaagg	1920
ccaagtaaaa	tcatgtgacc	aacctcttga	aatcccgaat	ggggaaataa	agggaaacaaa	1980
aaaagtggaa	tacagccatg	gtgaogtgg	ggaatatgtat	tgcaaaccta	gatttctact	2040
gaaggggaccc	aataaaaatcc	agtgtgtga	cggaaagtgg	acaaccttgc	cgatatacg	2100
tgagtatgag	agaacatgtg	gagaccttcc	tgcacttgag	catggcttg	tccagttatc	2160
tgtccctccc	taccaccacy	gagattcagt	ggagttcaact	tgtgcagaaa	cottcacaat	2220
gattgggcat	gcagtagttt	tctgcattag	tggaaggtgg	accgagctc	ctcaatgtgt	2280
tgcaacagat	caactggaga	agtgtaaagc	cccgaagtca	actggcata	atgcaattca	2340
tccaaataaag	aatgaattt	atcataactt	tagtgtgagt	tacagatgt	gacaaaagca	2400
ggagtatgaa	cattcsatct	geatcaatgg	aagatggat	cctgasccaa	actgtacaag	2460
aatgagaaa	agattctgc	ctccctcccc	acagattcca	aatgcccagg	tgattgaaac	2520
cacagtggaa	tacttggatg	gagagaaagt	atctgttctt	tgccaaagat	gttaccta	2580
tcaggggccc	gaagaaatgg	tgtgtaaaca	tggaaggtgg	cacgttac	cacgtgcac	2640
ggaaaaaaatt	ccatgttccc	agccccctta	sattgaadat	ggatcttatta	agtcgcccag	2700
gtctctcagaa	gagagagatt	taattttagtgc	cacgacttat	gaacacggaa	ctacattcag	2760
ctatgtctgt	gatgttggat	tcaaggatata	tgaagaaaat	ggggtaact	gcaacatggg	2820
aaaatggago	tctctgcotc	gttgtgttgg	aataccctgt	ggaccccccac	cttcaattcc	2880
tcttggatt	gtttctcatg	aactagaaaag	ttaccaatst	ggagaggagg	ttacatacaa	2940
ttgttctgaa	ggctttggaa	ttgtatggaco	agcattttat	aaatgtttag	gaggacagt	3000
gtctgaacca	cccaaataatgc	taaaaactga	ttgtgacaac	ttgcccacat	ttgaaattgc	3060
caaaccgaca	gaaaaagaaaa	aaaaatcata	caggtcagga	gaacaagtga	cattcagatg	3120
tccacctccg	tatcgaatgg	atggctctga	cattgtcaca	tgtgttaata	cgaagtggat	3180
tggacagccg	gtatgc当地	ataattctgt	tgtgaatcca	ccacatgtgc	caaatgtctac	3240
tataactaaca	aggcacaaga	ctaaatatcc	atctgttgac	aaagtacgtt	atgactgtaa	3300
taaacctttt	gaatttattt	gggaagtgg	agtgtatgtc	aaaaacggga	tttggacaga	3360
accacccgaaa	tgcaaaagatt	caacaggaa	atgtgggcct	cctccacota	ttgacaatgg	3420
agacatcacc	tccttgcata	taccagtata	tgcaccat	tcatcagtt	aatatcaatg	3480
ccagaactat	tatctactta	agggaaataa	gatagttaca	tgttagaaat	gaaagtggc	3540
tcagccacca	acctgtttac	atgcatgtgt	gataccagaa	gatattatgg	aaaacatata	3600
tatagtctc	agatggaggg	aaaatgcaaa	gatttattcc	caatcagggg	agaatattga	3660
attcatgtgt	aaacctggat	atagaaaaatt	cagaggatca	cctccgtt	gracaaaatgt	3720
cattgggggt	cacatcaatt	atcccacttg	tgtataaaaat	cgctatacaa	ttatttagta	3780
accttattgg	tgaacccctt	ttttagaaat	cacatgtata	ttactaatac	agtttgaat	3840
tacatttgaa	atattttt	getcatttct	tctaataat	atataaactt	tttttatatg	3900
gtgggttaatc	agtaactttt	cagactttt	ccacaaagca	agaacattgc	atcaaaaact	3960
cctaataccaa	aatatgatat	gtccaaggac	aaactatgtc	taagcaagaa	aataaaatgtt	4020
agttttccaa	tgtctgtttt	tattcagac	ttttcagat	ttcttggata	cctttgttg	4080
tttagttctg	attcacagtg	agtggaaagac	acactgactc	tgacttcaaa	tratgattac	4140
ttgcaataac	ataacaaccca	aactatcata	atatcacaat	tgtatacagc	taattactgt	4200
gtcttacatt	tgtatcaata	aaqaatctt	agaaagttct	tgcttbatgaa		4250

5310 v 13

<211> 1231

<312> PPT

<213> Homo sapiens

400 55

```

Met Arg Leu Leu Ala Lys Ile Ile Cys Leu Met Leu Trp Ala Ile Cys
      1           5          10          15
Val Ala Glu Asp Cys Asn Glu Leu Pro Pro Arg Arg Asn Thr Glu Ile
      20          25          30
Leu Thr Gly Ser Trp Ser Asp Gln Thr Tyr Pro Glu Gly Thr Gln Ala
      35          40          45
Ile Tyr Lys Cys Arg Pro Gly Tyr Arg Ser Leu Gly Asn Val Ile Met
      50          55          60
Val Cys Arg Lys Gly Glu Trp Val Ala Leu Asn Pro Leu Arg Lys Cys
      65          70          75          80
Gln Lys Arg Pro Cys Gly His Pro Gly Asp Thr Pro Phe Gly Thr Phe
      85          90          95
Thr Leu Thr Gly Gly Asn Val Phe Glu Tyr Gly Val Lys Ala Val Tyr
      100         105         110

```

Thr Cys Asn Glu Gly Tyr Gln Leu Leu Gly Glu Ile Asn Tyr Arg Glu
 115 120 135
 Cys Asp Thr Asp Gly Trp Thr Asn Asp Ile Pro Ile Cys Glu Val Val
 130 135 140
 Lys Cys Leu Pro Val Thr Ala Pro Glu Asn Gly Lys Ile Val Ser Ser
 145 150 155 160
 Ala Met Glu Pro Asp Arg Glu Tyr His Phe Gly Gln Ala Val Arg Phe
 165 170 175
 Val Cys Asn Ser Gly Tyr Lys Ile Glu Gly Asp Glu Glu Met His Cys
 180 185 190
 Ser Asp Asp Gly Phe Trp Ser Lys Glu Lys Pro Lys Cys Val Glu Ile
 195 200 205
 Ser Cys Lys Ser Pro Asp Val Ile Asn Gly Ser Pro Ile Ser Gln Lys
 210 215 220
 Ile Ile Tyr Lys Glu Asn Glu Arg Phe Gln Tyr Lys Cys Asn Met Gly
 225 230 235 240
 Tyr Glu Tyr Ser Glu Arg Gly Asp Ala Val Cys Thr Glu Ser Gly Trp
 245 250 255
 Arg Pro Leu Pro Ser Cys Glu Glu Lys Ser Cys Asp Asn Pro Tyr Ile
 260 265 270
 Pro Asn Gly Asp Tyr Ser Pro Leu Arg Ile Lys His Arg Thr Gly Asp
 275 280 285
 Glu Ile Thr Tyr Gln Cys Arg Asn Gly Phe Tyr Pro Ala Thr Arg Gly
 290 295 300
 Asn Thr Ala Lys Cys Thr Ser Thr Gly Trp Ile Pro Ala Pro Arg Cys
 305 310 315 320
 Thr Leu Lys Pro Cys Asp Tyr Pro Asp Ile Lys His Gly Gly Leu Tyr
 325 330 335
 His Glu Asn Met Arg Arg Pro Tyr Phe Pro Val Ala Val Gly Lys Tyr
 340 345 350
 Tyr Ser Tyr Tyr Cys Asp Glu His Phe Glu Thr Pro Ser Gly Ser Tyr
 355 360 365
 Trp Asp His Ile His Cys Thr Gln Asp Gly Trp Ser Pro Ala Val Pro
 370 375 380
 Cys Leu Arg Lys Cys Tyr Phe Pro Tyr Leu Glu Asn Gly Tyr Asn Gln
 385 390 395 400
 Asn His Gly Arg Lys Phe Val Gln Gly Lys Ser Ile Asp Val Ala Cys
 405 410 415
 His Pro Gly Tyr Ala Leu Pro Lys Ala Gln Thr Thr Val Thr Cys Met
 420 425 430
 Glu Asn Gly Trp Ser Pro Thr Pro Arg Cys Ile Arg Val Lys Thr Cys
 435 440 445
 Ser Lys Ser Ser Ile Asp Ile Glu Asn Gly Phe Ile Ser Glu Ser Gln
 450 455 460
 Tyr Thr Tyr Ala Leu Lys Glu Lys Ala Lys Tyr Gln Cys Lys Leu Gly
 465 470 475 480
 Tyr Val Thr Ala Asp Gly Glu Thr Ser Gly Ser Ile Thr Cys Gly Lys
 485 490 495
 Asp Gly Trp Ser Ala Gln Pro Thr Cys Ile Lys Ser Cys Asp Ile Pro
 500 505 510
 Val Phe Met Asn Ala Arg Thr Lys Asn Asp Phe Thr Trp Phe Lys Leu
 515 520 525
 Asn Asp Thr Leu Asp Tyr Glu Cys His Asp Gly Tyr Glu Ser Asn Thr
 530 535 540
 Gly Ser Thr Thr Gly Ser Ile Val Cys Gly Tyr Asn Gly Trp Ser Asp
 545 550 555 560
 Leu Pro Ile Cys Tyr Glu Arg Glu Cys Glu Leu Pro Lys Ile Asp Val
 565 570 575
 His Leu Val Pro Asp Arg Lys Lys Asp Gln Tyr Lys Val Gly Glu Val
 580 585 590
 Leu Lys Phe Ser Cys Lys Pro Gly Phe Thr Ile Val Gly Pro Asn Ser
 595 600 605

Val Gln Cys Tyr His Phe Gly Leu Ser Pro Asp Leu Pro Ile Cys Lys
 610 615 620
 Glu Gln Val Gln Ser Cys Gly Pro Pro Pro Glu Leu Leu Asn Gly Asn
 625 630 635 640
 Val Lys Glu Lys Thr Lys Glu Glu Tyr Gly His Ser Glu Val Val Glu
 645 650 655
 Tyr Tyr Cys Asn Pro Arg Phe Leu Met Lys Gly Pro Asn Lys Ile Gln
 660 665 670
 Cys Val Asp Gly Glu Trp Thr Thr Leu Pro Val Cys Ile Val Glu Glu
 675 680 685
 Ser Thr Cys Gly Asp Ile Pro Glu Leu Glu His Gly Trp Ala Gln Leu
 690 695 700
 Ser Ser Pro Pro Tyr Tyr Gly Asp Ser Val Glu Phe Asn Cys Ser
 705 710 715 720
 Glu Ser Phe Thr Met Ile Gly His Arg Ser Ile Thr Cys Ile His Gly
 725 730 735
 Val Trp Thr Gln Leu Pro Gln Cys Val Ala Ile Asp Lys Leu Lys Lys
 740 745 750
 Cys Lys Ser Ser Asn Leu Ile Ile Leu Glu Glu His Leu Lys Asn Lys
 755 760 765
 Lys Glu Phe Asp His Asn Ser Asn Ile Arg Tyr Arg Cys Arg Gly Lys
 770 775 780
 Glu Gly Trp Ile His Thr Val Cys Ile Asn Gly Arg Trp Asp Pro Glu
 785 790 795 800
 Val Asn Cys Ser Met Ala Gln Ile Gln Leu Cys Pro Pro Pro Gln
 805 810 815
 Ile Pro Asn Ser His Asn Met Thr Thr Leu Asn Tyr Arg Asp Gly
 820 825 830
 Glu Lys Val Ser Val Leu Cys Gln Glu Asn Tyr Leu Ile Gln Glu Gly
 835 840 845
 Glu Glu Ile Thr Cys Lys Asp Gly Arg Trp Gln Ser Ile Pro Leu Cys
 850 855 860
 Val Glu Lys Ile Pro Cys Ser Gln Pro Pro Gln Ile Glu His Gly Thr
 865 870 875 880
 Ile Asn Ser Ser Arg Ser Ser Gln Glu Ser Tyr Ala His Gly Thr Lys
 885 890 895
 Leu Ser Tyr Thr Cys Glu Gly Gly Phe Arg Ile Ser Glu Glu Asn Glu
 900 905 910
 Thr Thr Cys Tyr Met Gly Lys Trp Ser Ser Pro Pro Gln Cys Glu Gly
 915 920 925
 Leu Pro Cys Lys Ser Pro Pro Glu Ile Ser His Gly Val Val Ala His
 930 935 940
 Met Ser Asp Ser Tyr Gln Tyr Gly Glu Glu Val Thr Tyr Lys Cys Phe
 945 950 955 960
 Glu Gly Phe Gly Ile Asp Gly Pro Ala Ile Ala Lys Cys Leu Gly Glu
 965 970 975
 Lys Trp Ser His Pro Pro Ser Cys Ile Lys Thr Asp Cys Leu Ser Leu
 980 985 990
 Pro Ser Phe Glu Asn Ala Ile Pro Met Gly Glu Lys Lys Asp Val Tyr
 995 1000 1005
 Lys Ala Gly Glu Gln Val Thr Tyr Thr Cys Ala Thr Tyr Tyr Lys Met
 1010 1015 1020
 Asp Gly Ala Ser Asn Val Thr Cys Ile Asn Ser Arg Trp Thr Gly Arg
 1025 1030 1035 1040
 Pro Thr Cys Arg Asp Thr Ser Cys Val Asn Pro Pro Thr Val Gln Asn
 1045 1050 1055
 Ala Tyr Ile Val Ser Arg Gln Met Ser Lys Tyr Pro Ser Gly Glu Arg
 1060 1065 1070
 Val Arg Tyr Gln Cys Arg Ser Pro Tyr Glu Met Phe Gly Asp Glu Glu
 1075 1080 1085
 Val Met Cys Leu Asn Gly Asn Trp Thr Glu Pro Pro Gln Cys Lys Asp
 1090 1095 1100

8/64

Ser Thr Gly Lys Cys Gly Pro Pro Pro Pro Ile Asp Asn Gly Asp Ile
 1105 1110 1115 1120
 Thr Ser Phe Pro Leu Ser Val Tyr Ala Pro Ala Ser Ser Val Glu Tyr
 1125 1130 1135
 Gln Cys Gln Asn Leu Tyr Gln Leu Glu Gly Asn Lys Arg Ile Thr Cys
 1140 1145 1150
 Arg Asn Gly Gln Trp Ser Glu Pro Pro Lys Cys Leu His Pro Cys Val
 1155 1160 1165
 Ile Ser Arg Glu Ile Met Glu Asn Tyr Asn Ile Ala Leu Arg Trp Thr
 1170 1175 1180
 Ala Lys Gln Lys Leu Tyr Ser Arg Thr Gly Glu Ser Val Glu Phe Val
 1185 1190 1195 1200
 Cys Lys Arg Gly Tyr Arg Leu Ser Ser Arg Ser His Thr Leu Arg Thr
 1205 1210 1215
 Thr Cys Trp Asp Gly Lys Leu Glu Tyr Pro Thr Cys Ala Lys Arg
 1220 1225 1230

<210> 6

<211> 449

<212> PRT

<213> Homo sapiens

<400> 6

Met Arg Leu Leu Ala Lys Ile Ile Cys Leu Met Leu Trp Ala Ile Cys
 1 5 10 15
 Val Ala Glu Asp Cys Asn Glu Leu Pro Pro Arg Arg Asn Thr Glu Ile
 20 25 30
 Leu Thr Gly Ser Trp Ser Asp Gln Thr Tyr Pro Glu Gly Thr Gln Ala
 35 40 45
 Ile Tyr Lys Cys Arg Pro Gly Tyr Arg Ser Leu Gly Asn Val Ile Met
 50 55 60
 Val Cys Arg Lys Gly Glu Trp Val Ala Leu Asn Pro Leu Arg Lys Cys
 65 70 75 80
 Gln Lys Arg Pro Cys Gly His Pro Gly Asp Thr Pro Phe Gly Thr Phe
 85 90 95
 Thr Leu Thr Gly Asn Val Phe Glu Tyr Gly Val Lys Ala Val Tyr
 100 105 110
 Thr Cys Asn Glu Gly Tyr Gln Leu Leu Gly Glu Ile Asn Tyr Arg Glu
 115 120 125
 Cys Asp Thr Asp Gly Trp Thr Asn Asp Ile Pro Ile Cys Glu Val Val
 130 135 140
 Lys Cys Leu Pro Val Thr Ala Pro Glu Asn Gly Lys Ile Val Ser Ser
 145 150 155 160
 Ala Met Glu Pro Asp Arg Glu Tyr His Phe Gly Gln Ala Val Arg Phe
 165 170 175
 Val Cys Asn Ser Gly Tyr Lys Ile Glu Gly Asp Glu Glu Met His Cys
 180 185 190
 Ser Asp Asp Gly Phe Trp Ser Lys Glu Lys Pro Lys Cys Val Glu Ile
 195 200 205
 Ser Cys Lys Ser Pro Asp Val Ile Asn Gly Ser Pro Ile Ser Gln Lys
 210 215 220
 Ile Ile Tyr Lys Glu Asn Glu Arg Phe Gln Tyr Lys Cys Asn Met Gly
 225 230 235 240
 Tyr Glu Tyr Ser Glu Arg Gly Asp Ala Val Cys Thr Glu Ser Gly Trp
 245 250 255
 Arg Pro Leu Pro Ser Cys Glu Glu Lys Ser Cys Asp Asn Pro Tyr Ile
 260 265 270
 Pro Asn Gly Asp Tyr Ser Pro Leu Arg Ile Lys His Arg Thr Gly Asp
 275 280 285
 Glu Ile Thr Tyr Gln Cys Arg Asn Gly Phe Tyr Pro Ala Thr Arg Gly
 290 295 300

9/64

Asn Thr Ala Lys Cys Thr Ser Thr Gly Trp Ile Pro Ala Pro Arg Cys
 305 310 315 320
 Thr Leu Lys Pro Cys Asp Tyr Pro Asp Ile Lys His Gly Gly Leu Tyr
 325 330 335
 His Glu Asn Met Arg Arg Pro Tyr Phe Pro Val Ala Val Gly Lys Tyr
 340 345 350
 Tyr Ser Tyr Tyr Cys Asp Glu His Phe Glu Thr Pro Ser Gly Ser Tyr
 355 360 365
 Trp Asp His Ile His Cys Thr Gln Asp Gly Trp Ser Pro Ala Val Pro
 370 375 380
 Cys Leu Arg Lys Cys Tyr Phe Pro Tyr Leu Glu Asn Gly Tyr Asn Gln
 385 390 395 400
 Asn His Gly Arg Lys Phe Val Gln Gly Lys Ser Ile Asp Val Ala Cys
 405 410 415
 His Pro Gly Tyr Ala Leu Pro Lys Ala Gln Thr Thr Val Thr Cys Met
 420 425 430
 Glu Asn Gly Trp Ser Pro Thr Pro Arg Cys Ile Arg Val Ser Phe Thr
 435 440 445
 Leu

<210> 7
 <211> 1234
 <212> FRT
 <213> Mus musculus

<400> 7
 Met Arg Leu Ser Ala Arg Ile Ile Tryp Leu Ile Leu Trp Thr Val Cys
 1 5 10 15
 Ala Ala Glu Asp Cys Lys Gly Pro Pro Pro Arg Glu Asn Ser Glu Ile
 20 25 30
 Leu Ser Gly Ser Trp Ser Glu Gln Leu Tyr Pro Glu Gly Thr Gln Ala
 35 40 45
 Thr Tyr Lys Cys Arg Pro Gly Tyr Arg Thr Leu Gly Thr Ile Val Lys
 50 55 60
 Val Cys Lys Asn Gly Lys Trp Val Ala Ser Asn Pro Ser Arg Ile Cys
 65 70 75 80
 Arg Lys Lys Pro Cys Gly His Pro Gly Asp Thr Pro Phe Gly Ser Phe
 85 90 95
 Arg Leu Ala Val Gly Ser Gln Phe Glu Phe Gly Ala Lys Val Val Tyr
 100 105 110
 Thr Cys Asp Asp Gly Tyr Gln Leu Leu Gly Glu Ile Asp Tyr Arg Glu
 115 120 125
 Cys Gly Ala Asp Gly Trp Ile Asn Asp Ile Pro Leu Cys Glu Val Val
 130 135 140
 Lys Cys Leu Pro Val Thr Glu Leu Glu Asn Gly Arg Ile Val Ser Gly
 145 150 155 160
 Ala Ala Glu Thr Asp Gln Glu Tyr Tyr Phe Gly Gln Val Val Arg Phe
 165 170 175
 Glu Cys Asn Ser Gly Phe Lys Ile Glu Gly His Lys Glu Ile His Cys
 180 185 190
 Ser Glu Asn Gly Leu Trp Ser Asn Glu Lys Pro Arg Cys Val Glu Ile
 195 200 205
 Leu Cys Thr Pro Pro Arg Val Glu Asn Gly Asp Gly Ile Asn Val Lys
 210 215 220
 Pro Val Tyr Lys Glu Asn Glu Arg Tyr His Tyr Lys Cys Lys His Gly
 225 230 235 240
 Tyr Val Pro Lys Glu Arg Gly Asp Ala Val Cys Thr Gly Ser Gly Trp
 245 250 255
 Ser Ser Gln Pro Phe Cys Glu Glu Lys Arg Cys Ser Pro Pro Tyr Ile
 260 265 270

10/64

Leu Asn Gly Ile Tyr Thr Pro His Arg Ile Ile His Arg Ser Asp Asp
 275 280 285
 Glu Ile Arg Tyr Glu Cys Asn Tyr Gly Phe Tyr Pro Val Thr Gly Ser
 290 295 300
 Thr Val Ser Lys Cys Thr Pro Thr Gly Trp Ile Pro Val Pro Arg Cys
 305 310 315 320
 Thr Leu Lys Pro Cys Glu Phe Pro Gln Phe Lys Tyr Gly Arg Leu Tyr
 325 330 335
 Tyr Glu Glu Ser Leu Arg Pro Asn Phe Pro Val Ser Ile Gly Asn Lys
 340 345 350
 Tyr Ser Tyr Lys Cys Asp Asn Gly Phe Ser Pro Pro Ser Gly Tyr Ser
 355 360 365
 Trp Asp Tyr Leu Arg Cys Thr Ala Gln Gly Trp Glu Pro Glu Val Pro
 370 375 380
 Cys Val Arg Lys Cys Val Phe His Tyr Val Glu Asn Gly Asp Ser Ala
 385 390 395 400
 Tyr Trp Glu Lys Val Tyr Val Gln Gly Gln Ser Leu Lys Val Gln Cys
 405 410 415
 Tyr Asn Gly Tyr Ser Leu Gln Asn Gly Gln Asp Thr Met Thr Cys Thr
 420 425 430
 Glu Asn Gly Trp Ser Pro Pro Pro Lys Cys Ile Arg Ile Lys Thr Cys
 435 440 445
 Ser Ala Ser Asp Ile His Ile Asp Asn Gly Phe Leu Ser Glu Ser Ser
 450 455 460
 Ser Ile Tyr Ala Leu Asn Arg Glu Thr Ser Tyr Arg Cys Lys Gln Gly
 465 470 475 480
 Tyr Val Thr Asn Thr Gly Glu Ile Ser Gly Ser Ile Thr Cys Leu Gln
 485 490 495
 Asn Gly Trp Ser Pro Gln Pro Ser Cys Ile Lys Ser Cys Asp Met Pro
 500 505 510
 Val Phe Glu Asn Ser Ile Thr Lys Asn Thr Arg Thr Trp Phe Lys Leu
 515 520 525
 Asn Asp Lys Leu Asp Tyr Glu Cys Leu Val Gly Phe Glu Asn Glu Tyr
 530 535 540
 Lys His Thr Lys Gly Ser Ile Thr Cys Thr Tyr Tyr Gly Trp Ser Asp
 545 550 555 560
 Thr Pro Ser Cys Tyr Glu Arg Glu Cys Ser Val Pro Thr Leu Asp Arg
 565 570 575
 Lys Leu Val Val Ser Pro Arg Lys Glu Lys Tyr Arg Val Gly Asp Leu
 580 585 590
 Leu Glu Phe Ser Cys His Ser Gly His Arg Val Gly Pro Asp Ser Val
 595 600 605
 Gln Cys Tyr His Phe Gly Trp Ser Pro Gly Phe Pro Thr Cys Lys Gly
 610 615 620
 Gln Val Ala Ser Cys Ala Pro Pro Leu Glu Ile Leu Asn Gly Glu Ile
 625 630 635 640
 Asn Gly Ala Lys Lys Val Glu Tyr Ser His Gly Glu Val Val Lys Tyr
 645 650 655
 Asp Cys Lys Pro Arg Phe Leu Leu Lys Gly Pro Asn Lys Ile Gln Cys
 660 665 670
 Val Asp Gly Asn Trp Thr Thr Leu Pro Val Cys Ile Glu Glu Glu Arg
 675 680 685
 Thr Cys Gly Asp Ile Pro Glu Leu Glu His Gly Ser Ala Lys Cys Ser
 690 695 700
 Val Pro Pro Tyr His His Gly Asp Ser Val Glu Phe Ile Cys Glu Glu
 705 710 715 720
 Asn Phe Thr Met Ile Gly His Gly Ser Val Ser Cys Ile Ser Gly Lys
 725 730 735
 Trp Thr Gln Leu Pro Lys Cys Val Ala Thr Asp Gln Leu Glu Lys Cys
 740 745 750
 Arg Val Leu Lys Ser Thr Gly Ile Glu Ala Ile Lys Pro Lys Leu Thr
 755 760 765

Glu Phe Thr His Asn Ser Thr Met Asp Tyr Lys Cys Arg Asp Lys Gln
 770 775 780
 Glu Tyr Glu Arg Ser Ile Cys Ile Asn Gly Lys Trp Asp Pro Glu Pro
 785 790 795 800
 Asn Cys Thr Ser Lys Thr Ser Cys Pro Pro Pro Gln Ile Pro Asn
 805 810 815
 Thr Gln Val Ile Glu Thr Thr Val Lys Tyr Leu Asp Gly Glu Lys Leu
 820 825 830
 Ser Val Leu Cys Gln Asp Asn Tyr Leu Thr Gln Asp Ser Glu Glu Met
 835 840 845
 Val Cys Lys Asp Gly Arg Trp Gln Ser Leu Pro Arg Cys Ile Glu Lys
 850 855 860
 Ile Pro Cys Ser Gln Pro Pro Thr Ile Glu His Gly Ser Ile Asn Leu
 865 870 875 880
 Pro Arg Ser Ser Glu Glu Arg Arg Asp Ser Ile Glu Ser Ser Ser His
 885 890 895
 Glu His Gly Thr Thr Phe Ser Tyr Val Cys Asp Asp Gly Phe Arg Ile
 900 905 910
 Pro Glu Glu Asn Arg Ile Thr Cys Tyr Met Gly Lys Trp Ser Thr Pro
 915 920 925
 Pro Arg Cys Val Gly Leu Pro Cys Gly Pro Pro Ser Ile Pro Leu
 930 935 940
 Gly Thr Val Ser Leu Glu Leu Ser Tyr Gln His Gly Glu Glu Val
 945 950 955 960
 Thr Tyr His Cys Ser Thr Gly Phe Gly Ile Asp Gly Pro Ala Phe Ile
 965 970 975
 Ile Cys Glu Gly Lys Trp Ser Asp Pro Pro Lys Cys Ile Lys Thr
 980 985 990
 Asp Cys Asp Val Leu Pro Thr Val Lys Asn Ala Ile Arg Gly Lys
 995 1000 1005
 Ser Lys Lys Ser Tyr Arg Thr Gly Glu Gln Val Thr Phe Arg Cys Gln
 1010 1015 1020
 Ser Pro Tyr Gln Met Asn Gly Ser Asp Thr Val Thr Cys Val Asn Ser
 1025 1030 1035 1040
 Arg Trp Ile Gly Gln Pro Val Cys Lys Asp Asn Ser Cys Val Asp Pro
 1045 1050 1055
 Pro His Val Pro Asn Ala Thr Ile Val Thr Arg Thr Lys Asn Lys Tyr
 1060 1065 1070
 Leu His Gly Asp Arg Val Arg Tyr Glu Cys Asn Lys Pro Leu Glu Leu
 1075 1080 1085
 Phe Gly Gln Val Glu Val Met Cys Glu Asn Gly Ile Trp Thr Glu Lys
 1090 1095 1100
 Pro Lys Cys Arg Asp Ser Thr Gly Lys Cys Gly Pro Pro Pro Pro Ile
 1105 1110 1115 1120
 Asp Asn Gly Asp Ile Thr Ser Leu Ser Leu Pro Val Tyr Glu Pro Leu
 1125 1130 1135
 Ser Ser Val Glu Tyr Gln Cys Gln Lys Tyr Tyr Leu Leu Lys Gly Lys
 1140 1145 1150
 Lys Thr Ile Thr Cys Thr Asn Gly Lys Trp Ser Glu Pro Pro Thr Cys
 1155 1160 1165
 Leu His Ala Cys Val Ile Pro Glu Asn Ile Met Glu Ser His Asn Ile
 1170 1175 1180
 Ile Leu Lys Trp Arg His Thr Glu Lys Ile Tyr Ser His Ser Gly Glu
 1185 1190 1195 1200
 Asp Ile Glu Phe Gly Cys Lys Tyr Gly Tyr Tyr Lys Ala Arg Asp Ser
 1205 1210 1215
 Pro Pro Phe Arg Thr Lys Cys Ile Asn Gly Thr Ile Asn Tyr Pro Thr
 1220 1225 1230
 Cys Val

<210> 8
<211> 1235
<212> PRT
<213> Rattus norvegicus

<400> 8
Met Arg Leu Ser Ala Arg Ile Ile Trp Leu Ile Leu Trp Thr Val Cys
1 5 10 15
Val Ala Glu Asp Cys Lys Gly Pro Pro Pro Arg Glu Asn Ser Glu Ile
20 25 30
Leu Ser Gly Ser Trp Ser Glu Gln Leu Tyr Ser Glu Gly Thr Gln Ala
35 40 45
Thr Tyr Lys Cys Arg Pro Gly Tyr Arg Thr Leu Gly Thr Ile Val Lys
50 55 60
Val Cys Lys Asn Gly Glu Trp Val Pro Ser Asn Pro Ser Arg Ile Cys
65 70 75 80
Arg Lys Arg Pro Cys Gly His Pro Gly Asp Thr Pro Phe Gly Ser Phe
85 90 95
Arg Leu Ala Val Gly Ser Glu Phe Glu Phe Gly Ala Lys Val Val Tyr
100 105 110
Thr Cys Asp Glu Gly Tyr Gln Leu Leu Gly Glu Ile Asp Tyr Arg Glu
115 120 125
Cys Asp Ala Asp Gly Trp Thr Asn Asp Ile Pro Ile Cys Glu Val Val
130 135 140
Lys Cys Leu Pro Val Thr Glu Leu Glu Asn Gly Arg Ile Val Ser Gly
145 150 155 160
Ala Ala Glu Pro Asp Gln Glu Tyr Tyr Phe Gly Gln Val Val Arg Phe
165 170 175
Glu Cys Asn Ser Gly Phe Lys Ile Glu Gly Gln Lys Glu Met His Cys
180 185 190
Ser Glu Asn Gly Leu Trp Ser Asn Glu Lys Pro Gln Cys Val Glu Ile
195 200 205
Ser Cys Leu Pro Pro Arg Val Glu Asn Gly Asp Gly Ile Tyr Leu Lys
210 215 220
Pro Val Tyr Lys Glu Asn Glu Arg Phe Gln Tyr Lys Cys Lys Gln Gly
225 230 235 240
Phe Val Tyr Lys Glu Arg Gly Asp Ala Val Cys Thr Gly Ser Gly Trp
245 250 255
Asn Pro Gln Pro Ser Cys Glu Glu Met Thr Cys Leu Thr Pro Tyr Ile
260 265 270
Pro Asn Gly Ile Tyr Thr Pro His Arg Ile Lys His Arg Ile Asp Asp
275 280 285
Glu Ile Arg Tyr Glu Cys Lys Asn Gly Phe Tyr Pro Ala Thr Arg Ser
290 295 300
Pro Val Ser Lys Cys Thr Ile Thr Gly Trp Ile Pro Ala Pro Arg Cys
305 310 315 320
Ser Leu Lys Pro Cys Asp Phe Pro Gln Phe Lys His Gly Arg Leu Tyr
325 330 335
Tyr Glu Glu Ser Arg Arg Pro Tyr Phe Pro Val Pro Ile Gly Iys Glu
340 345 350
Tyr Ser Tyr Tyr Cys Asp Asn Gly Phe Thr Thr Pro Ser Gln Ser Tyr
355 360 365
Trp Asp Tyr Leu Arg Cys Thr Val Asn Gly Trp Glu Pro Glu Val Pro
370 375 380
Cys Leu Arg Gln Cys Ile Phe His Tyr Val Glu Tyr Gly Glu Ser Leu
385 390 395 400
Tyr Trp Gln Arg Arg Tyr Ile Glu Gly Gln Ser Ala Lys Val Gln Cys
405 410 415
His Ser Gly Tyr Ser Leu Pro Asn Gly Gln Asp Thr Ile Leu Cys Thr
420 425 430
Glu Asn Gly Trp Ser Pro Pro Pro Lys Cys Val Arg Ile Lys Thr Cys
435 440 445

Ser Val Ser Asp Ile Glu Ile Glu Asn Gly Phe Phe Ser Glu Ser Asp
 450 455 460
 Tyr Thr Tyr Ala Leu Asn Arg Lys Thr Arg Tyr Arg Cys Lys Gln Gly
 465 470 475 480
 Tyr Val Thr Asn Thr Gly Glu Ile Ser Gly Ile Ile Thr Cys Leu Gln
 485 490 495
 Asp Gly Trp Ser Pro Arg Pro Ser Cys Ile Lys Ser Cys Asp Met Pro
 500 505 510
 Val Phe Glu Asn Ala Met Thr Lys Asn Asn Asn Thr Trp Phe Lys Leu
 515 520 525
 Asn Asp Lys Leu Asp Tyr Glu Cys His Ile Gly Tyr Glu Asn Glu Tyr
 530 535 540
 Lys His Thr Lys Gly Ser Ile Thr Cys Thr Tyr Asp Gly Trp Ser Ser
 545 550 555 560
 Thr Pro Ser Cys Tyr Glu Arg Glu Cys Ser Ile Pro Leu Leu His Gln
 565 570 575
 Asp Leu Val Val Phe Pro Arg Glu Val Lys Tyr Lys Val Gly Asp Ser
 580 585 590
 Leu Ser Phe Ser Cys Arg Ser Gly His Arg Val Gly Ala Asp Leu Val
 595 600 605
 Gln Cys Tyr His Phe Gly Trp Ser Pro Asn Phe Pro Thr Cys Glu Gly
 610 615 620
 Gln Val Lys Ser Cys Asp Gln Pro Leu Glu Ile Pro Asn Gly Glu Ile
 625 630 635 640
 Lys Gly Thr Lys Lys Val Glu Tyr Ser His Gly Asp Val Val Glu Tyr
 645 650 655
 Asp Cys Lys Pro Arg Phe Leu Leu Lys Gly Pro Asn Lys Ile Gln Cys
 660 665 670
 Val Asp Gly Lys Trp Thr Thr Leu Pro Ile Cys Val Glu Tyr Glu Arg
 675 680 685
 Thr Cys Gly Asp Leu Pro Ala Leu Glu His Gly Ser Val Gln Leu Ser
 690 695 700
 Val Pro Pro Tyr His His Gly Asp Ser Val Glu Phe Thr Cys Ala Glu
 705 710 715 720
 Thr Phe Thr Met Ile Gly His Ala Val Val Phe Cys Ile Ser Gly Arg
 725 730 735
 Trp Thr Glu Leu Pro Gln Cys Val Ala Thr Asp Gln Leu Glu Lys Cys
 740 745 750
 Lys Ala Pro Lys Ser Thr Gly Ile Asp Ala Ile His Pro Asn Lys Asn
 755 760 765
 Glu Phe Asn His Asn Phe Ser Val Ser Tyr Arg Cys Arg Gln Lys Gln
 770 775 780
 Glu Tyr Glu His Ser Ile Cys Ile Asn Gly Arg Trp Asp Pro Glu Pro
 785 790 795 800
 Asn Cys Thr Arg Asn Glu Lys Arg Phe Cys Pro Pro Pro Gln Ile
 805 810 815
 Pro Asn Ala Gln Val Ile Glu Thr Thr Val Lys Tyr Leu Asp Gly Glu
 820 825 830
 Lys Val Ser Val Leu Cys Gln Asp Gly Tyr Leu Thr Gln Gly Pro Glu
 835 840 845
 Glu Met Val Cys Lys His Gly Arg Trp Gln Ser Leu Pro Arg Cys Thr
 850 855 860
 Glu Lys Ile Pro Cys Ser Gln Pro Pro Lys Ile Glu His Gly Ser Ile
 865 870 875 880
 Lys Ser Pro Arg Ser Ser Glu Glu Arg Asp Leu Ile Glu Ser Ser Ser
 885 890 895
 Tyr Glu His Gly Thr Thr Phe Ser Tyr Val Cys Asp Asp Gly Phe Arg
 900 905 910
 Ile Ser Glu Glu Asn Arg Val Thr Cys Asn Met Gly Lys Trp Ser Ser
 915 920 925
 Leu Pro Arg Cys Val Gly Ile Pro Cys Gly Pro Pro Pro Ser Ile Pro
 930 935 940

14/64

Leu Gly Ile Val Ser His Glu Leu Glu Ser Tyr Gln Tyr Gly Glu Glu
 945 950 955 960
 Val Thr Tyr Asn Cys Ser Glu Gly Phe Gly Ile Asp Gly Pro Ala Phe
 965 970 975
 Ile Lys Cys Val Gly Gly Gln Trp Ser Glu Pro Pro Lys Cys Ile Lys
 980 985 990
 Thr Asp Cys Asp Asn Leu Pro Thr Phe Glu Ile Ala Lys Pro Thr Glu
 995 1000 1005
 Lys Lys Lys Ser Tyr Arg Ser Gly Glu Gln Val Thr Phe Arg Cys
 1010 1015 1020
 Pro Pro Pro Tyr Arg Met Asp Gly Ser Asp Ile Val Thr Cys Val Asn
 1025 1030 1035 1040
 Thr Lys Trp Ile Gly Gln Pro Val Cys Lys Asp Asn Ser Cys Val Asn
 1045 1050 1055
 Pro Pro His Val Pro Asn Ala Thr Ile Leu Thr Arg His Lys Thr Lys
 1060 1065 1070
 Tyr Pro Ser Gly Asp Lys Val Arg Tyr Asp Cys Asn Lys Pro Phe Glu
 1075 1080 1085
 Leu Phe Gly Glu Val Glu Val Met Cys Gln Asn Gly Ile Trp Thr Glu
 1090 1095 1100
 Pro Pro Lys Cys Lys Asp Ser Thr Gly Lys Cys Gly Pro Pro Pro Pro
 1105 1110 1115 1120
 Ile Asp Asn Gly Asp Ile Thr Ser Leu Ser Leu Pro Val Tyr Ala Pro
 1125 1130 1135
 Leu Ser Ser Val Glu Tyr Gln Cys Gln Asn Tyr Tyr Leu Leu Lys Gly
 1140 1145 1150
 Asn Lys Ile Val Thr Cys Arg Asn Gly Lys Trp Ser Gln Pro Pro Thr
 1155 1160 1165
 Cys Leu His Ala Cys Val Ile Pro Glu Asp Ile Met Glu Lys His Asn
 1170 1175 1180
 Ile Val Leu Arg Trp Arg Glu Asn Ala Lys Ile Tyr Ser Gln Ser Gly
 1185 1190 1195 1200
 Glu Asn Ile Glu Phe Met Cys Lys Pro Gly Tyr Arg Lys Phe Arg Gly
 1205 1210 1215
 Ser Pro Pro Phe Arg Thr Lys Cys Ile Glu Gly His Ile Asn Tyr Pro
 1220 1225 1230
 Thr Cys Val
 1235

<210> 9
 <211> 150626
 <212> DNA
 <213> Homo sapiens

<400> 9
 gatcataatg gtataacaaca attaacatca gaataaaaact tggaaacttt acaaaacactt 60
 ggsaaattaaa caacatgtac atttaaaaacc aatggctcaa tgaaggaact aaaaaaaaaatt 120
 tggaaagttt ttgagacaaa tgacaatgga agcacagcat actataatag atgagataca 180
 gcaaaaccag ttctaaagg aaattttata acaataaaatg ccttatcaaa aagaataaaat 240
 ctctccaaata aacaacccaa cattgcacct taaggagcta aaaatattaag aacaacattt 300
 ctaaaaaacaa gtcgaaaaag aaataataas gatcagagca gaaacaaaca acgcagagac 360
 taaatgtaaag tatgacaaaa tcagtaaagc aaagattttt aaaaaaaaaattt acaaaacattt 420
 tcttagacta agaaaaataa gggagacgtat ccaaaatataat aaaaatcgag agggaaaagg 480
 agacattaca tctggttcta cagaaacaca aaggatcata aaaaactataa ggaacaattt 540
 tttgccaata aatttgtata cctggaaagaa atggacaaaat ttttgacacat atacaacata 600
 ccaagattga attaggaata aatagaatac taaaacagaca aataatgtat aagttgatta 660
 aatcgttaat aaaaattcacc catcaaaaaaa gccccaaaaacc tggatcgat actgtgtaat 720
 tctaccaat attaaaaaaa aaaaaactca gagtaatttt tctcaacta tgccaaaagc 780
 aaagaaaaatg gaatttttcc aacttattgt agcgtccag cattgcctg atacccaaaac 840
 ccaaacaagga aacaacacaa aaagaaaaact acaggctgtat gtcctgttg aacagaggtg 900
 ttaaaaattct taataaaaata cacaacacaa aaagaaaaag tgaatttctg ttcctttgtt tgggggttt 960

tgagaagagg tctctctctg tcagccccgtt tggAACGcAG gggTGCCATC ctggCTGGCT 1020
ctatctcaga ctcctttggc tcasgcAATC ctttcacetc atcccccaga gtagcigsga 1080
ctataggcct gggtaaacac acccagctaa ctcaaaagct aactcgatTT ttaaaaata 1140
gagtataatt aaaacaagggt ttgtatgtac aatgttgaat catacaactt aaaacgtgga 1200
gggctcagaa gagatcaact ctcttacccc caccggcAC ataggcAAat atccgtata 1260
gtcacacttt tagaaaatcA cttgacactt gattcgatgt tggataatac tgTTACCTGC 1320
ttcaCTGACT gtgacAGTCC tcataAAAAG ctaacttact ccccccata aatgttttGA 1380
aatatctcaa gacagtcatT ataatgtot aactctatct ttttgcATGC ttcttatgtct 1440
ataatTTCTT taactcttca actatctata tattcttctt tatgcCATGA tagttggaa 1500
ccaaatcatTT taaaacgtgg taggctaagt acggtatatt attacagaca tgatatttgg 1560
tgggcaaaacc acacagttGA gagtaCTTtG ttgacactGA aaaacatcat ttccatGA 1620
agoctgaaaag agatagatgt ttcctcagt accaccatttG tctattaata tttagggTT 1680
taatgaaaat cttcatTTTC ctccacttAA tttaacttta aagctaaata caaatgttGT 1740
ttccactaAG taaatctGCC aacaaaaaaa taaaatttCT tttttgactt gaatgcctCA 1800
tgaatgatTT atctgttCTT aacagataaa taaaaaAGAC tttttttttt ttttgagaca 1860
gaatottgtC cagttGCCA ggctggagtG cagtGactCG atctcogCTC acrgcaagCT 1920
ctgccttcTG gattcAcGcA ataatcccgc ctcagecctc CGAGTAGCTG ggactacaga 1980
cggcccccac cacGCCAGA taatTTTTTT tttatTTTT tttagtAgAGA cggggTTG 2040
ccctgttagc caggatggc ttgatctt gacctcgtGA tggccctcc tggccctccc 2100
aaagbtgtgg gattacAGGT gtgagcact gtGCCGGcC aaaaAGACat ttitgaAGGA 2160
agttaaaatt ttaatTTAAAC acatgttGCT gatttttttG gctttaAGGA tttagtctCT 2220
tgagataat gtatAGATG aatatttttG gaatgttata tGtaatttCA gtatAGACat 2280
aggTTTGTG taatAGATt ttTcgttGAG tcaGtataa aatatttCA tgcTCTtattt 2340
gttcatataA tagtaatttG tgacagaACA ttttttggg gaaatttcatG tcaatcatTC 2400
tcattaccTC tctcaataat aactgaaCTt ctgcaatttG ggtgtccCT ttcaCTcaat 2460
tttttCTGT caaaacgAAC aaacaaACAG gCgcaaaaaa accctggcAA taacctttGA 2520
taaACatCTG ctctcaacca ttttCTGT agatttGAGC aatcataact agtttccG 2580
tcctgacCTC tcataCTTGT aacttatttC cctgtgtata aattaatGAC ttccatCTG 2640
gtcattttat ttctccactt AAAATCTTA arggatctca agtcaGCTAA caggacaAGA 2700
accttatttC acTTTCTCTA ctTCTactAA catAGTatGg tctctcAGC aatttGAG 2760
gttttatacAG cattaatttA aactgagCTt atctacaact ataccaAGtT aagctcaAGC 2820
tgccAGtCA gggTGCACGc attAGAatG attttttttt ggaAAAGAGA gacaAGAAAT 2880
atgactgtAA cataaaaaat ctgatAtGtA gcaAAatttAC tccAGATA aAACATTTG 2940
tttagTTTtG tggatTTtG ttTGTatGcG atggcatGcA ttcttaccat agttAGAAT 3000
catgtgtcAG ataAGAtATA ttattGACat AAAAAtAAAG tgcataGACy aatgtacAA 3060
tatgtatATA ttcttacat ctatAGGTtG tGatacCTtG agaaatGtGA acaacatCAC 3120
aattttAAAGtG ccatatCATT tatGTTTACT ctataatttG ggaacaAGtG atagaAAATA 3180
gtatttACat totatttttGt atgaaaaACTt aagaAtATAA ttAAAtAAAAA gttAGTTG 3240
aatcatcata AaccAGAGAG aactAGAAAG arGCTAGtGg cacaACAGtG tttagtGtGcA 3300
gatgagaAGA ctaAGtCAG agaAGtGACA ttTTTACTtT gaggGAAGcG ttGtGtAGtT 3360
acagaactGG atccAGAGcC ttGTTGGGcG acGcatGAcA ccttctcGA cccAGTCCt 3420
caAGcatGGA tgcACAGtT tctGtGAGtG tGtCCTCtG tattGAAAAC tGtAAACtTC 3480
ccggccCTGT gtaacCTCt GAGAtACTt tacatttttG tattGtGcA ggatAtttG 3540
tccgaggtag AAAGGGACat AAACtAAAGG AAAtCATTtA aatCTTtTT ttttttCTCA 3600
tttttattttt tatttttAAT agtcttGtC tGtCtCCAAA gctAGAGtGc agtGGcACTA 3660
tattGGCTCA cgtcaacCTC tGtCtCCeGG gttcaAGtGtA ttctctGcC tcaGtCtCt 3720
gtgaAGtGtG aattACAGtG tGtGcCGcC acatCCAGtGtG tttttttAA actTTttagtA 3780
gagACAGCAT ttcAtCATGt tGGCoAAActC tGgCcCtCA gtaGtCtGcG CGCtTGGcC 3840
ctcgAAAGtG ctgggattAA tGtGtGAGcC AtCtGtCtGtG gCCAAAAtt ttttttCTtA 3900
gtcaACGATA atttcGAACC tgaAGtGAGt ttttcatGtGtG ttagGTTtGtG ttttttCTtA 3960
cgtttCTtCCC actAAAGcC actGGAAAttC catAGAGAAA ttattGAAAC ttGtCtGtGtA 4020
gttaggAAAAG tcaAGGAAAG tattGGGtCt tattGtAtGtG caaAGttaA tGGGGcACcA 4080
tgAAAtAtAtAC acAGAAGcCA tcttCttagt gagAtGtGAA acAAAttCtCA gcatCCCCAA 4140
gaAGtACAtA GGCtAAAtAAAC tGtAAtGcAt tGtGtACTGt aAtGAtCAGt tAAAAGGGa 4200
tttAAAGcA ACCtCtGtCt acAAAtGttaA tGtGtACTtG tGACAtTTG tAtGcAc 4260
tctAGtGAt GAAtAtAtAA ttttAtAtAtCAt tctGAAAGGA tAttCAtAtAt tAAAAtAtAt 4320
gttAtGAC ACtAtTTtGtGAt tAAAtAGtGAt AAAtAAActtA tGactGAtG tGAGGAAAtAt 4380
tggccaAtAC AAAttCAAtG AACtAtAtAA tagtGtACAA ttaACAttI tctGtCAAtG ttttttCTtA 4440
ttGtCtTtCA AtAGtGtGtG tttccAAAAG AtTGGtGtGtG CCGAtTTtG tGtGtAGAAC 4500
tGAAAtAtCA AtAccAttCA AAAAAttI AtAGtGAtAA GCAAttCACA AGtAtGtCtC 4560
ttcAttaAtG AtAtGAAAtAA tcttCttagt AtttGAttA tGAttCtG AtAtAGAtGtG 4620
AAAtACAGAtA tAtAtACACAtA tAAAGtAttC AAcAGAGAcA AAtCAGcAG gAAAtAtACAC 4680

17/64

accccaacccc taacccccagg cttcacattt cacagctcca aaagaaaaccc cttccttctg 8460
cttgaggaga ggagagggaa gaacggggaa gacttgtct tacatcttgg atatccatgc 8520
agacaaagca ggatagggca actgtcaag gaatgaggcc cctgctttaa gcccttagctc 8580
ccagatgaca ttcttcttqaca taccctgaac caaaagggaa cccaatgccc tgaaggaaat 8640
gatgcagtcc tggcagcatt actgtcaag gaatgaggcc cctgctttaa gcccttagctc 8700
gcagtgtatac ccagatacta caccctggct aactgaagag tttttagggc ctttaggttag 8760
caggtaaccag catggccaca ggggatagag aaccacctgg gttttagggc ctttaggttag 8820
ctggacttga ctgggtgggtg gcatttttgg acataccatg gttttagggc ctttaggttag 8880
cccagaaggg tgaatcttag aacccctttaagg gaacatcago gttttagggc ctttaggttag 8940
gaccataggg tgaggctctt ctgactttgg aaaggggagg gttttagggc ctttaggttag 9000
tttttattatt atactttaag gtgtgtgtaa cccatgtca aaccccttccccc ccacccccc 9060
tgtatacatg tgcatgttg atctccaaat gttttagggc ctttaggttag 9120
atatgcactgc cagccccatg acatgttcc cccatgtca aaccccttccccc ccaccaacatt 9180
aaactggte cctggaaacc atcatgttcc cccatgtca aaccccttccccc ccaccaacatt 9240
tagagtaccc cccatgtca aaccccttccccc ccaccaacatt 9300
gggatttttga caccctgtaa acatgttcc cccatgtca aaccccttccccc ccaccaacatt 9360
gagaagttaca gttttaggtca agaaggatgg ttacaattaa gtgtgtgtaa cccatgtca aaccccttccccc ccaccaacatt 9420
aaataatacc taacttctca tccagggaaa cccgacctca aactgtgatgttcc cccatgtca aaccccttccccc ccaccaacatt 9480
aaactgtgatgttcc cccatgtca aaccccttccccc ccaccaacatt 9540
aaagaaaatca agataacaca agattgaaaat aattttaaaa tactgaagaa gatattacac gttttagggc ctttaggttag 9600
gatttggta gcttgaagac aaagaattaa aaacaatgaa atcttaagagt attcacctta cccatgtca aaccccttccccc ccaccaacatt 9660
aaatggata atcacaaga gaaatgttcc cccatgtca aaccccttccccc ccaccaacatt 9720
aaatggata atcacaaga gaaatgttcc cccatgtca aaccccttccccc ccaccaacatt 9780
aaatggata atcacaaga gaaatgttcc cccatgtca aaccccttccccc ccaccaacatt 9840
aaatggata atcacaaga gaaatgttcc cccatgtca aaccccttccccc ccaccaacatt 9900
gtgttatttc ttaatagcag aagctatgtg aaaatcacaca gtatgttcc cccatgtca aaccccttccccc ccaccaacatt 9960
aaataacotc cccatgtca aaccccttccccc ccaccaacatt 10020
aaataacotc cccatgtca aaccccttccccc ccaccaacatt 10080
aaataacotc cccatgtca aaccccttccccc ccaccaacatt 10140
aaataacotc cccatgtca aaccccttccccc ccaccaacatt 10200
aaataacotc cccatgtca aaccccttccccc ccaccaacatt 10260
aaataacotc cccatgtca aaccccttccccc ccaccaacatt 10320
aaataacotc cccatgtca aaccccttccccc ccaccaacatt 10380
aaataacotc cccatgtca aaccccttccccc ccaccaacatt 10440
aaataacotc cccatgtca aaccccttccccc ccaccaacatt 10500
aaataacotc cccatgtca aaccccttccccc ccaccaacatt 10560
aaataacotc cccatgtca aaccccttccccc ccaccaacatt 10620
aaataacotc cccatgtca aaccccttccccc ccaccaacatt 10680
aaataacotc cccatgtca aaccccttccccc ccaccaacatt 10740
aaataacotc cccatgtca aaccccttccccc ccaccaacatt 10800
aaataacotc cccatgtca aaccccttccccc ccaccaacatt 10860
aaataacotc cccatgtca aaccccttccccc ccaccaacatt 10920
aaataacotc cccatgtca aaccccttccccc ccaccaacatt 10980
aaataacotc cccatgtca aaccccttccccc ccaccaacatt 11040
aaataacotc cccatgtca aaccccttccccc ccaccaacatt 11100
aaataacotc cccatgtca aaccccttccccc ccaccaacatt 11160
aaataacotc cccatgtca aaccccttccccc ccaccaacatt 11220
aaataacotc cccatgtca aaccccttccccc ccaccaacatt 11280
aaataacotc cccatgtca aaccccttccccc ccaccaacatt 11340
aaataacotc cccatgtca aaccccttccccc ccaccaacatt 11400
aaataacotc cccatgtca aaccccttccccc ccaccaacatt 11460
aaataacotc cccatgtca aaccccttccccc ccaccaacatt 11520
aaataacotc cccatgtca aaccccttccccc ccaccaacatt 11580
aaataacotc cccatgtca aaccccttccccc ccaccaacatt 11640
aaataacotc cccatgtca aaccccttccccc ccaccaacatt 11700
aaataacotc cccatgtca aaccccttccccc ccaccaacatt 11760
aaataacotc cccatgtca aaccccttccccc ccaccaacatt 11820
aaataacotc cccatgtca aaccccttccccc ccaccaacatt 11880
aaataacotc cccatgtca aaccccttccccc ccaccaacatt 11940
aaataacotc cccatgtca aaccccttccccc ccaccaacatt 12000
aaataacotc cccatgtca aaccccttccccc ccaccaacatt 12060
aaataacotc cccatgtca aaccccttccccc ccaccaacatt 12120

gcaaaaaaaa ttgcataatat ttattatgtta aaacatattt tgttgaataa tgtatatacatt 15900
agatagtggc taaatcaagg taataaaatat atgttttct tcacataactt ctcatttttg 15960
tgtgtggta gactgtttaa aatctacact aagttagttt caagaataaca acatattatt 16020
gttaactaaa gtcaccatat ttacaaacgg attgtcatgtta taagtcaat catgtggtt 16080
tgtctgtctt atccaccta acttaatgtc ctcctgttt attcatagtt cttgaaaatg 16140
caggattcc tttttcaaa gctgaatagt attacattgt gstatatagac cacatttct 16200
ttatcttatt atctgtaatg gatacttaag ttgattccat attttggta ttataaaataa 16260
tgctgtaatg aagatggaa tgcaagataac bctttgacat actgatccct ttttcttgc 16320
acatatatto agtagtagga ttactggatt gattataatgt tctgctttc attttgaca 16380
aactctatag tatttccat aatggctata otaatataca ttccatcaa caatgtgca 16440
gtgtgtcctt ttatccacat gttgataac acttgatgtt ttttgtt gttgataata 16500
atacttggtg gccattggta cgtctttt tgagaaatgt cattcggt acattgccta 16560
tttttaatt ggttaattcc atattaacgc ttttacatgg cttttag ccattgagtt gagttccta tattttga 16620
atattaacgc ttttacatgg atatggctt caaatatttt tccaaactcat gagttgtc 16680
tttacactgg gcaattttt cttttgttgc cagaagcttt ttagttgt gtaatacaat 16740
gtgtgtatgtt ttctttttgt tgcctatgt tggggaccac atccaagaaa tcatagccc 16800
gaccatgtc atgtattttt ttctcttttta ttttctctca gcaagttttt agttcaagc 16860
tttacatgtc agtcttacat aatattctg tagttttatg tagtgtgaaa cagtggatca 16920
attacatctt tctatgtgtg aatatacogat ttccacagca ttgtcatctt tattgaaaat 16980
tattttccat atgtgagttt gccaatgtca tgcitatcgta atattgaatt ctattctgtt 17040
ttatttggtgt ctgtttttat taatgcctcc agctttgtt ctttataatca aaatttactt 17100
taatbcaaaa tttagaagtgg atttcataca tatttttggaa ttgttttca tttttctgt 17160
gacccctggg atctcttgc aaaaatgaca tttagaattttt gatggggact gcattgaatc cttacatctt tttgtgtaat 17220
atgaacatctt tattccatatt gaaatcttgc gtcctgtca atgggctatt ttctgttta 17280
tgtgtgtctt ttcaattttt tttcatcaat attgttattgt taaaatata tagatttttg 17340
agatcttggg ttaatatttac ttttgcata tttttttgtt acagtttatt gttgtatataa 17400
tcttttaattt tcttttgcag ttttgcata ttttgcata ttttgcata ttttgcata 17460
ctaaagcatga agaacacaaag ttttgcata ttttgcata ttttgcata ttttgcata 17520
gaaccagaga taagaagtat ctttttgcata ttttgcata ttttgcata ttttgcata 17580
ctatcttaggg gcaaaataaa aatagcaacg trtcattaca ttttgcata ttttgcata 17640
aataagcaacg ttttgcata ttttgcata ttttgcata ttttgcata ttttgcata 17700
gagaagaata tatttaatgt ttttgcata ttttgcata ttttgcata ttttgcata 17760
tttgatagca caacagggtt agggataattt ggatttttttgcata ttttgcata ttttgcata 17820
tcattttacc ttttgcata ttttgcata ttttgcata ttttgcata ttttgcata 17880
tcatacacatac atagacgtac gtttttgcata ttttgcata ttttgcata ttttgcata 17940
gttttgcata gtttttgcata ttttgcata ttttgcata ttttgcata ttttgcata 18000
atattttatt tatttttgcata ttttgcata ttttgcata ttttgcata ttttgcata 18060
caaaagtattt gacattttccaa ttttgcata ttttgcata ttttgcata ttttgcata 18120
atttgcata ttttgcata ttttgcata ttttgcata ttttgcata ttttgcata 18180
gataaaatattt gtttttgcata ttttgcata ttttgcata ttttgcata ttttgcata 18240
gagtttttgcata ttttgcata ttttgcata ttttgcata ttttgcata ttttgcata 18300
gagaaatattt gtttttgcata ttttgcata ttttgcata ttttgcata ttttgcata 18360
gagaaatattt gtttttgcata ttttgcata ttttgcata ttttgcata ttttgcata 18420
gaaatattt gtttttgcata ttttgcata ttttgcata ttttgcata ttttgcata 18480
tccagagata tccagattga acaacaatctt ttttgcata ttttgcata ttttgcata 18540
acaacaacaa aaaaacctttt ttttgcata ttttgcata ttttgcata ttttgcata 18600
aagtaatattt ttgttccatt ttttgcata ttttgcata ttttgcata ttttgcata 18660
ccccataaaaa statcattgg ttttgcata ttttgcata ttttgcata ttttgcata 18720
tttgcata ttttgcata ttttgcata ttttgcata ttttgcata ttttgcata 18780
ctcaccctgt tacctttttgtt atttcaaaaata tataatataat ttttgcata ttttgcata 18840
atgttttgcata ttttgcata ttttgcata ttttgcata ttttgcata ttttgcata 18900
tgcacccctt ggttaactata ttttgcata ttttgcata ttttgcata ttttgcata 18960
ttttttttttttt ttttgcata ttttgcata ttttgcata ttttgcata ttttgcata 19020
ttttttttttttt ttttgcata ttttgcata ttttgcata ttttgcata ttttgcata 19080
ggcagaattt aatgttccaa ttttgcata ttttgcata ttttgcata ttttgcata 19140
tgacagaaac ataaatgtttt gtttttgcata ttttgcata ttttgcata ttttgcata 19200
gagagtgcag atatttttgcata ttttgcata ttttgcata ttttgcata ttttgcata 19260
tttgcata ttttgcata ttttgcata ttttgcata ttttgcata ttttgcata 19320
tttgcata ttttgcata ttttgcata ttttgcata ttttgcata ttttgcata 19380
tttgcata ttttgcata ttttgcata ttttgcata ttttgcata ttttgcata 19440
tttgcata ttttgcata ttttgcata ttttgcata ttttgcata ttttgcata 19500
tttgcata ttttgcata ttttgcata ttttgcata ttttgcata ttttgcata 19560

gttcacatta tttttgtcca tacttgccac ctgtatggg taggcttgc 30780
aatatctcaatc ttaataataata atctccagggt gttgagagag agacactgtgt 30840
ggatcategtt ggcagttcc cacaatgtgt ttcacatgtg ggaagtgtatt 30900
tatgtatgtatt taataactgtt tttagaaggta eterttcaact tgtagtgatgt 30960
ccttgyaag aagggtccctg cttcccccttc agcggtaaatg gtaagttca 31020
tcagtcatgt ggaactgtga tcaattaaaa ttttttcttt tataaattac 31080
gaaggtctttt acacgagtgt gaaaacgaa taatacacca cactcccttc 31090
ccaaattttt tgcittctatc aaatgtgaaa tacttataat tctctttttt 31140
aaaatgtact tataggcaga ttgttgataa actgacagaa gttttttttttt 31200
gtgagtaga ggcagctgtg ccctaagaac agagatgaga agtctgagaa 31260
aggatgtctt aaggtaacac aagatgtgt gaaaatgaaac tataattttt 31320
aatgttttaa ttactacago tataatttcc cacacgtc tataattttt 31380
tatgaatttc tagagttccct tttttttttt tttttttttt 31440
aatattttatc atacatataa taaaatttcaa tgacccatad cagaatattt 31500
gaccattttt ctcttaagca tccataactga taactgtctg cacttacact 31560
catttgcacg taacttcttc tgagaaatct cttttttttt 31620
tgagaaatct cagttggaga atttttatgt cttttttttt 31680
ttcacttaact cataaattta aaataaaacaa tacaggagct aactgaagaa 31740
actagccctc tgggtctgt cttttttttt 31800
ctaaaaatag caatacattt aaataaaacaa tacaggagct aactgaagaa 31860
aaacttacta gtgataataa atattgttagg aaataagaag gggcatttgc 31920
gtggcaaaagc aaacatgaca atcgtgaattt gcaatttgc 31960
ttgaatcatg agggcgattt tttttttttt 32040
tgagatctga tgggtttata agtagttttt 32100
catcatgtga agaaggacat gtttgcattt cccaaatctc 32160
cctcccagcc atgttggatt tggttgc 32220
cttgggttagt tcttfatagc tgataactgcttcc 32280
gagtaggggtg ctgtgtaaa aggagctttt ctgtttttt 32340
aggcagggggt tagaaccatt gtttgcatttcc 32400
ggaacttctt agggagttgg gtttgcatttcc 32460
tagaggcttg ttgaatggct gggcatttgc 32520
ggatgggggt gtcacatgtg gtttgcatttcc 32580
cacttctgt attcggaaatg gtttgcatttcc 32640
ttgaacttga gagagatgtt gtttgcatttcc 32700
ctcaagagga agcagagcat gtttgcatttcc 32760
ataaaacttc atttttctgg ggatgggggtt gtttgcatttcc 32820
aaggagccaa agttaatbc acggatgggtt gtttgcatttcc 32880
cttcatgaca ccccccaccca gtttgcatttcc 32940
gacctggatc aggttccctgc gtttgcatttcc 33000
ctccagctgt ggttaaaaagg ccccaagccct tgggttgc 33060
ccccaagccct tgggttgc 33120
tgaggtttgg gaaacctacaa gtttgcatttcc 33180
gcagaagttt gctgcagggg gtttgcatttcc 33240
ggaaatgtgg ggtcagagcc gtttgcatttcc 33300
gtgagaacag gaccacaatc tttttttttt 33360
tatgttctgt gaaaagccac gtttgcatttcc 33420
acaaagccac attcgcacaa gtttgcatttcc 33480
gtgagacatg ggtttttttt 33540
aaatttcaga cttccatcaatc agttaatcc 33600
aatggaaagca tttttttttt 33660
tttgatrrta caggttcata agttaatcc 33720
atgaactttt gaggtaatgc gtttgcatttcc 33780
atttggtttt gaatttgtgag gtttgcatttcc 33840
tgactgtatc tccaaacccaa gtttgcatttcc 33900
tgggaggggac tcagtaggaa gtttgcatttcc 33960
ctcaggatag tgagtgtgtt gtttgcatttcc 34020
ggtcaagaact totttttttt 34080
tttcttaaga cttccatcaatc gtttgcatttcc 34140
ataaaatttac caatattttt 34200
caatattttt gtttgcatttcc 34260
ccctccacca tgatttgcatttcc 34320
ttttttttttt 34380
agaataatac agataggttt 34410

aatttcacta gatattattt ttaatgoca gaatacacaag tgactctatc atgaacaaat 34500
 aaaattaaca taaatagaat agattcaatc atycaaaaag tattttaatg gtataatata 34550
 taaaattatcc tatatatgcg gtaatctcaa ttatccccct cacttgata acaagagatt 34620
 attttatga attctactat aaacagaaaat tgtagtattca tattgccta accttcacac 34680
 tgagggtggag aactccatrr tcccatgttag catgttgtt cattttctc agatatcctg 34740
 aaaccacccct cacaagatata actcaattta gtcacatgtc cataacttcc ttgtgaagac 34800
 ctggatgaat taaatggttcc gtgttatac tgagggtgggt gtgaacatgg aattttttct 34860
 aaatgaagaa taaaatcaa agggtaaaaa acaaataaaa tacttaaatt gaaatataaa 34920
 actaaactat attccggatt ttaaagttag tataatttg acaaataaaa ttatTTaaaa 34980
 acaaaaaacat attagaaact cgcaaaagata tattccctca ccatactat gtiaccatcc 35040
 tcttgc当地 taatcatctt cattcatgtc ttgttcatca caaggattaa aatatgcattg 35100
 aatggaaatg ttatctgaca tttacataat attccaaaga ttttggctgt attttgttca 35160
 aaaaactgaa agagtggtag tttgatataat tgcccttaggtc ctaatTTattt ttgtcaggat 35220
 aaagtaatag acacagagaaa agaacttcc tcttggttac scgaagcaca agagaatatt 35280
 aacccatTT gaaagaattt tgtaaaaacaa attatacact actgaccaac acagagtgg 35340
 attgactgcc atcttccatc tttgcataatc atttcttctc cttccgtatc tagataattt 35400
 tttttggccaa gaacagatac ttttcttcc tcccgataat tcagtggtt tgcataattt 35460
 tgagaatttgg gaatctgagg tggaggtggg cataattgtt ttttgcacac taaaatTTat 35520
 taaaatata attaattgtt taataaaaaaa taaaatTTat aatattttaa attagaattt 35580
 ttgatgaaaa attaattttat tgattttaaaat agaataaaa gaaagatcaa taactgtttc 35640
 ataaattatc acatattatc tatgtatgtt ttgtatgtcaaa atattataact tttagctgt 35700
 gtaacagtta cattaaacaa tagaattttt gccttgcattt cttcatagact ttcttgcatt 35760
 tttttccatattt attttttgtt taataattttt gataattttt tttttttttt attttttat 35820
 ttttggccct ttagatgtt ttaatggat tacacactt taattacatg cattaaatata 35880
 aaatttgcattt cttatattca atgtatcagg attggattaa aacactcaca aatttttgc 35940
 caatggatc tgatttagcga gaagtgataat tttttttttt tttttttttt tttttttttt 36000
 acacttgacc aatataagca tttttttttt tttttttttt tttttttttt tttttttttt 36060
 acttgaaact cccctagago tttttttttt tttttttttt tttttttttt tttttttttt 36120
 aatggatgtt atgcaccccg tttttttttt tttttttttt tttttttttt tttttttttt 36180
 atataaagac acctttgttaa actcacatgtt aagttttttt tttttttttt tttttttttt 36240
 atatcttattttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 36300
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 36360
 gttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 36420
 agtgcgttgc atttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 36480
 gttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 36540
 aaatTTttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 36600
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 36660
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 36720
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 36780
 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 36840
 aacaattaaag aaaaatTTttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 36900
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 36960
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 37020
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 37080
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 37140
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 37200
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 37260
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 37320
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 37380
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 37440
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 37500
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 37560
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 37620
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 37680
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 37740
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 37800
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 37860
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 37920
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 37980
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 38040
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 38100
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 38160

cccgttcaac tgcaccacac sattagaaaa ggaatctcaa aaaccagggt ttccttg 38220
 gagaagtttt tggatctcat ataaagcattt ctgtgtttttt gcccrttaatt cactaattttt 38280
 ggaagcagag gagattaaac acatgagagt ctctcttagat cacagaaaa atgggtggtat 38340
 gatacaagtg ctgaagagat tccagaaaact tcattctta atagcagttc agagaagggg 38400
 ctgaaaacaaac agtccccctgt ttctcccgag aagttttatg atatattttt cctgtggcta 38460
 ctttagaggtc tgaattctaa aaaacttgcg gtctggattc taatgasctt gcatcaggca 38520
 cttctcttgc cggttcccggt ggctcacccccc agtgcatacat ccaggatcat taatcactct 38580
 tagacaactt ttgtccacac aaacttqagt gcocttaactt ttacaacttt cattcaggga 38640
 ctgttatttca aagctttagt ttctgggagt agagggcaca aaatataatcc agagtcttac 38700
 tagaccactg aaaaaaagaaa tggcgaaaa tatgggtgtg taagcactt caggagcttc 38760
 attggccaag agcagtgcag agaaaaagggtt tttaaaatgc agtcccccctg tttaatccctca 38820
 aaaagggtttg tgcateccat caagtgcac aaccccttaca gttacccctca aaaggactcc 38880
 tttaaaaactt cttaaacttgc acagcagata tttagaaaaat accagtctcc atagatogta 38940
 aagcaaataag atggtctttaa aatgcataatgta aaaaacttccg ggcgcgtatgc caaatggag 39000
 cagtgcagaa aaggaaaagag aaagtcaat ttccattttt ctgtcgaaag ggcttagggc 39060
 acataacttcc actggctact taatgaactt gcctctatcg agtgcacca gggtatctaa 39120
 tgacgcacaaac aaaaaataat ttcccccgcag cccaaagccaa agtttgcac ttcatgagtc 39180
 tccgcaccaat gataaaattca gatttatcc ttcttcctgg accaagtttca gccatgcatt 39240
 cccaaaggcat cacttctata gctccaaactt aagagatctgtt cttcttaca aactcacact 39300
 gggagatgtt agagatctgc attegtaaa ggccttacat cacagaataac aaaaagctgg 39360
 taatcataatc gactcttccat aagcagatccat ttcccttgcgg tccagacatg cagcctgaat 39420
 atttagtacag tttagtagccg cagattttt acttgggtgtt atacagagag agagtggag 39480
 ataaacacacgc acatttccat ttcaatgtaa aatagaagata agtaatataca cagccaaatgc 39540
 ttcaatattttt tcagtcataat ttccatccat tggcttctaa ttgttggc ccaggctctg 39600
 aaaaagatgtg gcacattcttta acctccaggg ggccacaaaaa aataaagagac agcagtccgc 39660
 acaaaagactt gagaggcaca tggaaatctt tggctggaaa aatragttagt gttttctcc 39720
 tataatgacg cagtctgtata agactgagaa aggccattgtt cttatcttattt gcatagaaaac 39780
 actgtgagtt aaaaagaaaataa aagaaacaag atatcataac tccaaacaaa agaacaagat 39840
 gagtttccatg aaatttgaccc tggggaaatgtt gatataagggtt ttttacttca gaaagaattt 39900
 aaaaataatgg tcaataaaatgat acttacttgcg accaagagag caatgcaaaaa acaaattaac 39960
 tacttcaaca aagaggtaga aagtattttt aaaataccaa acasaaatca caaatggag 40020
 aataactataa ctgaacggaa aagttttaaa gaggttatttca tcagcagact agatgaaggg 40080
 gaagaaggaa ttagtgaact tgaagtccaa ttactgaaaaa tcacccaaatc tgagaaccaa 40140
 aataaaacaca taaataaaataa aaagtgaaga tagcttaaga tccagatgg aatactaccat 40200
 gtggaaataao gtagtgcattt tcaccatgtt aaaaadagaa agaaacacaa cgatacagaa 40260
 aatatatttca aaaaatataat gacagaaaaac ttccatccat tggggaaagaa atagaaaaccc 40320
 acacccagaa atctcaaaagg aaatcaataa agttttatgtt aagatagtca cttaagaca 40380
 taaccaatac aaatttataatc aagtttataatc ccaaggatting aaaaagccaa atgaaaatgt 40440
 aatgttttca taaaatggaa ttccacaaatc actatcatgtt gattacttca cagaaaacctt 40500
 gcaggccata aaaaaggatgtt aatgtataact cccaaatttgc aagaaaaaca actgccaagg 40560
 aataatttca gattccactt ttctgttcaaaaacaaagg agtgataatc gctttcttgc 40620
 aatggaaaaaa agctgagaga gatataaggac acttttccctgc cttacaaagg atgtttaagg 40680
 gagtttcttgc aggtgaaaagg aagggatgtt aatgtataatc atgaaatgtt taaaatgtt 40740
 aacttacttag taaaatgtt aatgtataatc aatccatccat ctcttataatc gtaatgtt 40800
 tgggttaataa cagcttagcat aaggtttaaa aggccaaaagg ggttggaaaca gctgaagctt 40860
 caaaactttgtt taagagatccat gatattttca aatgttccatc gtttccatccat gtttccatccat 40920
 catggggagga gcaagatccat attttgcataat tttatatgtt atccaaatccat gtttccatccat 40980
 agctttaataatc acctgttata aatgttccatc tggccatccat aggataacta caacttccaa 41040
 tagcttttca taaggtatgc tatgttccatc taaggatgtt cccaaacccaa acatcttata 41100
 gatacacaatc aatgttccatc aatgttccatc aatgttccatc aatgttccatc aatgttccatc 41160
 atgttccatc aatgttccatc aatgttccatc aatgttccatc aatgttccatc aatgttccatc 41220
 aaatatttccat aatgttccatc aatgttccatc aatgttccatc aatgttccatc aatgttccatc 41280
 ctataatccat aatgttccatc aatgttccatc aatgttccatc aatgttccatc aatgttccatc 41340
 gtttccatccat aatgttccatc aatgttccatc aatgttccatc aatgttccatc aatgttccatc 41400
 aaaaacccatc aaaaataaaa acttccatccat aatgttccatc aatgttccatc aatgttccatc 41460
 aatgttccatc aatgttccatc aatgttccatc aatgttccatc aatgttccatc aatgttccatc 41520
 gtcattttgtt caagatccat aatgttccatc aatgttccatc aatgttccatc aatgttccatc 41580
 actaaatataa taaatgttccat aatgttccatc aatgttccatc aatgttccatc aatgttccatc 41640
 atgttccatccat aatgttccatc aatgttccatc aatgttccatc aatgttccatc aatgttccatc 41700
 caataatccat aatgttccatc aatgttccatc aatgttccatc aatgttccatc aatgttccatc 41760
 aagaaatccat cacataatccat aaaaacccat aatgttccatc aatgttccatc aatgttccatc 41820
 cagaatatgtt tttatgttccat aatgttccatc aatgttccatc aatgttccatc aatgttccatc 41880

tgtaaaaaca tgatgtatgt gttttagata caaaataccaa aagttttgcg aagtttaaat 45560
attaatattt tatacattac caatacacac tggtaaagggtt gtccacttc catcaacaca 45720
ttgaattttt ttaggtccct tcattagaaa tctaggatttgc ceataatattt ccaccacttc 45780
actgtgtcca tattttttt tcttttttgc cttaacatcc ccatgtggaa gtteaggagg 45840
tggaccacat gattgtactt gctctatagt agaaatacta tcttttttgc ceataatattt ccaccacttc 45900
tctgttttac aatataaaaaa ttcaagtttttgc tggaaagatttgc tcttttttgc ceataatattt ccaccacttc 45960
tcttcattat gtaacttatt atagcatcc aaacaatcaa ttttttttgc ttttttttgc ceataatattt ccaccacttc 46020
tacttatact aaattgtcat attgaagtg tatttttttgc ttttttttgc ceataatattt ccaccacttc 46080
tagatatatctt aaagatgc当地 gaaaaccat ttttttttgc ttttttttgc ceataatattt ccaccacttc 46140
tttttacatt tcatggaaaac atttttatcat aacatttttgc ttttttttgc ceataatattt ccaccacttc 46200
aagcatttga tcaacataaaat gtttgc当地 tcaatacaag ttttttttgc ceataatattt ccaccacttc 46260
tgcttaataa ttgttttagac acacccgggtq aaacttaagt ttttttttgc ttttttttgc ceataatattt ccaccacttc 46320
atgtcccgaaa tggafgttga ttttttttgc ttttttttgc ceataatattt ccaccacttc 46380
ttgtcagccca ctgtatgtt ccccaatgtt ttttttttgc ttttttttgc ceataatattt ccaccacttc 46440
ttaaatgtttt ttttttttgc ttttttttgc ceataatattt ccaccacttc 46500
tgaacagatg aatgeccctt ttttttttgc ttttttttgc ceataatattt ccaccacttc 46560
ggttctttaaa aagagccigt ttttttttgc ttttttttgc ceataatattt ccaccacttc 46620
tttctcttgc cacagttggct ccttttttgc ttttttttgc ceataatattt ccaccacttc 46680
tgcagatgcc cgatotttga tttttttgc ttttttttgc ceataatattt ccaccacttc 46740
tacaatcat ccagactcag ttatttttgc ttttttttgc ceataatattt ccaccacttc 46800
ccgacaacac ctgtgtgtct gggaaatattt ccagcacatc ttttttttgc ttttttttgc ceataatattt ccaccacttc 46860
taacttaagt gactgaatet caggtattca gtactcaata ttttttttgc ttttttttgc ceataatattt ccaccacttc 46920
atttgacttta attcatttga ttacaggcaat ttttttttgc ttttttttgc ceataatattt ccaccacttc 46980
agttggattt caaagtttca atttttttgc ttttttttgc ceataatattt ccaccacttc 47040
catattgggaa ggtcaggaga caatccaaat ttttttttgc ttttttttgc ceataatattt ccaccacttc 47100
attgttaatcc ctgggttgc当地 ggagaatttgc aacacccatc ttttttttgc ttttttttgc ceataatattt ccaccacttc 47160
ttgogatcag gaactaagtgc ttttttttgc ttttttttgc ceataatattt ccaccacttc 47220
aggtaaaaata atttcatgag aatataat ttttttttgc ttttttttgc ceataatattt ccaccacttc 47280
ccacaataaa gtgaggttga ttttttttgc ttttttttgc ceataatattt ccaccacttc 47340
ctgtasagaa ttttttttgc ttttttttgc ceataatattt ccaccacttc 47400
ataaattgttta ttttttttgc ttttttttgc ceataatattt ccaccacttc 47460
ttacaatgaa ttttttttgc ttttttttgc ceataatattt ccaccacttc 47520
aaaaacatgaa aattacttcc ttttttttgc ttttttttgc ceataatattt ccaccacttc 47580
gcttttttgc当地 aacaaatgatg ttttttttgc ttttttttgc ceataatattt ccaccacttc 47640
gaacccaaatg tacaggtaaa ttttttttgc ttttttttgc ceataatattt ccaccacttc 47700
ctgtatagag aaaccatggaa gagaaggccaa ttttttttgc ttttttttgc ceataatattt ccaccacttc 47760
acaaaggttg actaggaccc ttttttttgc ttttttttgc ceataatattt ccaccacttc 47820
ctccctgc当地 ctcacccgtt ttttttttgc ttttttttgc ceataatattt ccaccacttc 47880
cacacactgg ttttttttgc ttttttttgc ceataatattt ccaccacttc 47940
ttgaataggg ttttttttgc ttttttttgc ceataatattt ccaccacttc 48000
cagtgactc atgtggggac ttttttttgc ttttttttgc ceataatattt ccaccacttc 48060
accagagccg cacaatattt ccctgtc当地 ttttttttgc ttttttttgc ceataatattt ccaccacttc 48120
ctggacccaa aggagttaca ttttttttgc ttttttttgc ceataatattt ccaccacttc 48180
tggaaagtgc aacaaaggaa ttttttttgc ttttttttgc ceataatattt ccaccacttc 48240
gtgtgc当地 gcaacccgtt ttttttttgc ttttttttgc ceataatattt ccaccacttc 48300
agacgggtg ttttttttgc ttttttttgc ceataatattt ccaccacttc 48360
ccagcgtt当地 ggcacggatg ttttttttgc ttttttttgc ceataatattt ccaccacttc 48420
atagctgtgg ttttttttgc ttttttttgc ceataatattt ccaccacttc 48480
gggttattttt gggggctt当地 aactccactg ttttttttgc ttttttttgc ceataatattt ccaccacttc 48540
gaaagacaag ctacgggtt当地 ttttttttgc ttttttttgc ceataatattt ccaccacttc 48600
gtttgtgtt当地 atcccttggat ttttttttgc ttttttttgc ceataatattt ccaccacttc 48660
tgtccccc当地 ttttttttgc ttttttttgc ceataatattt ccaccacttc 48720
gagagtctt当地 cataaaatgtt gacaaggatc ttttttttgc ttttttttgc ceataatattt ccaccacttc 48780
tacctgtcoo ttttttttgc ttttttttgc ceataatattt ccaccacttc 48840
gacactaggg catgtatgtt当地 aacaaggatc ttttttttgc ttttttttgc ceataatattt ccaccacttc 48900
tcaggaggca gtaagccgtt当地 ttttttttgc ttttttttgc ceataatattt ccaccacttc 48960
aaagccatca tacaaaatgtt atcttcaatcc aaggtactca ttttttttgc ttttttttgc ceataatattt ccaccacttc 49020
aagaacccag aacccatccatc aataatgtt当地 attttccatc ttttttttgc ttttttttgc ceataatattt ccaccacttc 49080
agggaaaaaaa aaaatcttgc当地 ctgttggaaa ctggactt当地 aaataagaag ggtatgtt当地 49140
tctggatgag aagaaaccac ttttttttgc ttttttttgc ceataatattt ccaccacttc 49200
aacactcgca aaggatcaca ttttttttgc ttttttttgc ceataatattt ccaccacttc 49260
tgaatataccaa aacaattttt当地 aatattt当地 ttttttttgc ttttttttgc ceataatattt ccaccacttc 49320

gttgaaaagc aacacaaaaga aattaaaaaa aaaaactcagg atatgaatga aaaatgtact 49380
 aaaaatattt tttaaaaaac aaatagaact tatggaaaatt aaaaattcat tgaagaatta 49440
 caaaatatag tgaaaagatt taattacaga ttacatcaag cagaaaaaact tgctctcaga 49500
 gtttgaagac aggtctttcc aattaaccct gtcagacaaa aataaagagc aaataaacatt 49560
 ttttaatgag caaagggtttt gagaaaaatg acgttctaaa aaatgagaaa acttaagsgt 49620
 tatacatat ttttgaggag aagaaaaagc taaaaaaacc tttttgagga aatatttatct 49680
 ccttttgcctt ttttgtaga gacatagaaa tcottataca agaggcicag ataaacaccag 49740
 gaagatgcat tgcgagatga acttctacaa acatatagtc atcaggctat ctasagtcaa 49800
 tgtgaacggg aaaaattata aaatcagcaa gagaaaaagca tctaatac tataacggaa 49860
 atctcttaag actaacatgt gacttctcag casasactgt acaagccaga agatatttgt 49920
 gtcttattttt caggggtctt aaagaaaatg tagttcatat ttattaaaa aacatataatt 49980
 agagatatat tttgtatccc gctaaactaa acttcataaa tgaagaatatt ataaagtctt 50040
 tccccaaacaa gctaatacta aggaagttca tbaaccacta aatccactt taggaatcca 50100
 ccccccacaaga aatgtccag ggagtcttga acatggaaat agatgtcaa tactcactat 50160
 cataaaagaca tgcaaaagta caaaactcad aggtcttattt aaaaattac acaatggga 50220
 ctacaaaacca gcttaggtacca aactacata atgacaagaa caaaacctca catgacaata 50280
 ttaacttttia acataaaatag attaaatgtt ccactaaaa gatatagatt tttggaccas 50340
 atatggaaaa cagaaaccaa ccacatgtc ctcasaasgaa scccacctaa cttagagaaaa 50400
 cctataaaaa ctcatggtaa aggtatggag acatgttattt tgaacaacag aacaaaaaaag 50460
 cattttgtat agttatattt atataaaaaa asagatttca aatcaacaag aaaaaaaaaa 50520
 caagaagttc attacacaaat gataaaaggaa gcaagaagat ataaacattt taaatataata 50580
 tgcactcaaa acctcagcac tcagattcat aatgaaaatg ctactagagc taatgtagsaa 50640
 gataaaacagc aataataatg gggcaagcaa ctccacacc cccaaatgact atactagaca 50700
 gattgcaggg aaaaaaaaaa aacaaagaa acctcataact taaatggac tttttttttt 50760
 atggacctaa cagacatattt aacgcattt caccacaaat ctcagaata tttttttttt 50820
 tcacccgtgc atggaacattt ctccaaaata gaccatattgc taggttacag ctacaaagca 50880
 agttccaaa atttttaaagg tttagaaatata batcaagtat ttatccat tttttttttt 50940
 tataactata aatcaatatac ataaagaattt ttcacaaacta tccatataca tggaaaaattaa 51000
 atgacctgtc totgggttat tttttttttt actaaaaattt ttttttccat caaaggaaat 51060
 aataaaacaga gtaaacagac aacctcagaa tggaaaaaaa tttttttttt ctatgaatct 51120
 gaaaaaggc taatatcrag aatctgcaaa gaactgaaaac aacacaacaa gaaaaaaaaa 51180
 taataatccc atgaaaaatg ggacaaaagga batgaagaga ttttttgcattttt 51240
 gaaaatgacc aagaaaatatg aaataaaaaac tcaatatacg taatcatcg agaaatgcga 51300
 attaaaaaaa tgatgtatca tcttacatta gacacagtgg ccactgtcaa atagtccaaaa 51360
 aataataaat gttgggtaca gtgaggagaa agaagaatgc ttatacgctg ttgggtggaa 51420
 tgtaaatttag tacaacccctt atggaaaaaca gaatggacat ttcccaaaaactaa 51480
 gaactaccat ttcacccaggc aatccacta ctgtgtatct acccaaaagga aatcaatttat 51540
 catatcaaaa tgatatacccg actcatatgt ttatagccctc actactoaca gtgcaataaa 51600
 batggaatca aactaattgt ccaccaacac agtattttttt aagaatatg tttttttttt 51660
 atatgcata gaataactact cagccaaaac aaaaaataaa aaaaaaaa aagaataaaa 51720
 tcatgccttc ayaagcaacca tttttttttt aaaaatatttccat tttttttttt 51780
 agattcagaa agttaaaatcc cacatattgt cacttataag tttttttttt 51840
 catatggaca gagagtgtcg agtaacagac attggagact cagaatgtg gcaggatagc 51900
 aggaggggtga ggaataaaaaa attacctaattt ggggtcaatg tttttttttt 51960
 tacactaaaaa gtacagactt caccactatg caatataatcc atgcaacaaa actgcatttt 52020
 gaccatctaa acatataaaa catagaaaattt aaaaattttttt aaaaaaaa aacacatcata 52080
 aaacaccatg gaaatatctt aaaaatgtttt aaaaatataata gaaactggggg ggttcccgag 52140
 aataatgtg gtataatatac tttttttttt tttttttttt 52200
 taaaacaaacctt caaatgattt tttttttttt 52260
 acatcacaaa aaggtaaattt tttttttttt 52320
 attaattttttt attttttttt tttttttttt 52380
 ttcttaatata tttttttttt 52440
 aagaaaaacaa accaagataa atttttcaagt tttttttttt 52500
 gaatattttt tttttttttt 52560
 taaaattttt tttttttttt 52620
 ataattttttt aaaaatcagca acattactas atattatccca aatattttt tttttttttt 52680
 agaactccccc tttttttttt 52740
 tactaaaaag aaaaatattt acatcataac tttttttttt 52800
 gatTTTTTTT tttttttttt 52860
 tttttttttt aatgagttttt gcaatgtttt tttttttttt 52920
 gggattttttt tttttttttt 52980
 gggattttttt tttttttttt 53040

aaaagcatta tcttaaaaaag gaaagttaag accttgcatta ttgggttata ttcaaattgt 53100
gtatttatat agaggtataa acttacaaaa cgtgatTTAG agaagaatgt gaatggacac 53160
tccatgaatt agaaaatattt ttcttcatct aaaactcaaa accctaagtc ctagtactag 53220
atatgtgaaa tgttaatatac aatTTTAAc tctgagatAC atactccttA tttagctta 53280
gtgcTCCATA ataacaattc tGTggAAAacc tticcacAAAa gaagagacct octaggacac 53340
ttgaaatata ctcagatgtc tgcatacCA cAtgcAGTT tctgttACat ggctgagaga 53400
agaatatttg aaaagaatAC taagCTGGTA tttCTTCGTT taatgtttgg aggCCTGTAC 53460
tataCTAGCA aAtTCCTAGT tatgtgttCA aAtgtatCCTA aGTCCTTGTA caatttgCAA 53520
tagaaAGACA ttttCTACAT cAgCTCTAC tGCTATGTCC GccACTCCAA CTTCCTCTCC 53580
tttaggtttt catttcatgt ctgggtgattg gaaagactac tgaAGCAATA tATTCACAA 53640
tttGTGTTCT ttTTTGAAGA AGACCCCTCA AAATTGTAAA AGCTTCCTGGC TTCAATAAAAC 53700
ctaaatttac ctatcatCAC AGAAAAGAAA ttTATGAGTC tCTTAAATA AGCTCCCCC 53760
tCTCAATTAG AGCAAAAATC AACCTCTTCA TGATCCATGC CTACTCTTC AATGTATCA 53820
aatgttCTC tCTTCCACTA AATCCAGGAT TCAgATTTA TGATCTTGA ATTTTATTAA 53880
aaAGGTCAAG tCTCTCGT CCTCAGCTGT TGCACATAAC CTTCTCACTA TAACAAATGG 53940
ctttcaacca tCTCTTGCA tGATGACTTC CTATGTAaaa CAGATCTCCA GTTCTTCCC 54000
tCTTATTTTC tATCTCAATT ATTGGATTTT CTATTCCTCT GTACACAGTG ATACATAAAA 54060
tATTTTAA ATATTTTAT TACTTGGATA TTGGGTCTT ACCTTTTAG TTTCCTCAGTG 54120
tCTTATTTA GAATAAAATC TCTGGATAAG TAGACCTGTG CTTGTGTTT CACCATTTC 54180
tCCTGTCTA TGATAGGTGT ttAcAACAGC AGGAATGAGT CAAATTAAAC TGGACCTTG 54240
ACACTGCCTT TCACTACAA TGTACTCATT CTCTTCTCA GCTGTGACTA TTTCAAAAAC 54300
tttCTATTCT ACCTAGTACT CTTCTCTCTC CTGCCCCAC ACACTATTCA ATCTCAGATG 54360
ACCATGTCTC ATACTCAAA ACAGAACCA TCAgCTTCAT CCATTTCAC ACgttACTGC 54420
tCATTTCCT TCCATCTCC TGTACACAAAG TTGTAAAGCAG CCTTGTGTC ACCTGTCAAC 54480
AGGTGTAAAG CAGTCTGTT GCCACCAAAAG CACAATACCT CCACAGTAGC TGTGAGTCCT 54540
ttCCCTCTGC ATTTCTAG GGCAACTATG TAAGTCATGT GTTCAGCCTT TGCAgCTCCC 54600
tTTTGTCTGT ATCTGCTCTG GTGTCTTCCA TTCTTTCTT TTAAATTAC CTTCTAGTGC 54660
ACAACCTTCC TCAAGCAATA TTCTGATCTT CCTATTAGAT TCAAAGCCAG AATCTTGA 54720
GAGTTATGTC TACAGTCTGT ATTGAATGTC TAGCTCATT TTCTTATTGG CAGATTCTAT 54780
GTAGGGTCTG TCTCTCTAC TCTATTAAA TCCATTTTTG TTACACTGTG CATTGGCTTG 54840
TACCTTACCT ATCCATCAC AATTTCTGAA CAGAAATATAA TAACTAAATT AGAAATATT 54900
ATCACTTGA TAATGATATT AAGGTAAATT ATTACAACt TCTTGTACTT TATTATATAA 54960
GGCACTATGG CAFAAAATAT TTATAAAATAT TTAGTCTGC TAACTAACAC AATCCTTGT 55020
AATATTAGAA CTGTTGAA ATATGTGACA TTTCACCAAC AAGAAAGAGT CAACAAAGGT 55080
TCAAATAGAC TTGOTGTGTT GGCCAAAAGAT ACATGCCAG CAAGCAGTGG AATTAGAATC 55140
CAGACAGGAT GACTTAAAGC TCAAGCTGTG ACACTACCT TTCTATAA ATTCTCTTAT 55200
TTTTATGTT ATGGCAACAT TCTAGTTT TTCTCTGTG TTCTCTGGC CTCCTTTTT 55260
CCCCATTTC TTCTACTCT ATTGTCTTC TGTCTTATST ATAAATGTGG TAATGTTCA 55320
GGGCTCTAC TTGAGCTCT TGCCTTTTC ATTCTGTCTT CTTATCCTA TTAGCGTCAT 55380
CATTATATG ATGATATCC GAAATGCAATA TCTCTCTCT AGATGCTAT CCAACTCCAC 55440
ACTTCACATC TCCAGTTTG ATTTCCTTGC GGCAGCTCAA TCTATAATGTG TCCAAGTC 55500
AAGTGCAAA GCCCTCTAA ATATGCTCT ATCCAGTCAG TACCATTTA CAAAATGGT 55560
ATTGCCATTt ACCTACATAC TTGTGAGAAA ACAATTGAAA ACAACATGT GAGTCCTTA 55620
ATCTCCTCT TTTCACACC CAACATTAG TAACATCACC TGTACTTTG ATCACCTAA 55680
TGTCTTCAA ATAGCCCTC TGCTCTGCAC CTCCTCTATE ATCACTCTC CTCAGTCCCC 55740
ACACTTCTC ACCCTACCTG GACTCATGGT GTGCGCTCTT GCCTACAAAAA AGTACAGCAT 55800
CCAGGAAAAC AATCCAACAA AACTAGAAAAT CAAATTATAC CATTCCCTT CTAAAACCTC 55860
TTTATGGGT TTTCTTCTAGT CATAAAATGA ATCCAAATGA TATGATGCT TGAGCTGATC 55920
TGGATAATTG TTCTCTGCC TCCCATCTAG CTCAGCAGG ATAGACTCTG CTTTACCAAC 55980
TTGAAATATA TTGTTTGTt TTACAGCTT TGCACATATT TTCTCTGCC TTGGAACACT 56040
CTGCATATAAC TTGTTTCCC ACAGAGCCAA TCCCTCTCTT AACCTGAAA AATAGATGGC 56100
TGATTGAGAA ACGTAAATGA GATTCTATGTA ATGGTCTTCA GAACTTTCA AATTTAGAAA 56160
ATAAAGAATC ACACTCAGAA AGTACAGAAA TTAACACACA AGATAGAAGA TGTAAAGTAG 56220
AAATTAAAAA SACAAATTAG CTGAGGAAGT TGTAAACCAAC TATAATTTG GTAAATAAGTG 56280
CTAGTTCTA ATAATTTGA AAGCTTTAT TTAGGGTAAC AAAAGCAATI ATATTATAAT 56340
CACAAATCTG GAAGGTAGGT GGCCTCTAGG AAGTATTAA TTAATGCACT ACTTTAGAGA 56400
TATTTCAAA ACTCCCTCT TTTCCAGTT TATGTCATAAT CAGGAGATAT CTTGATTTA 56460
ATCAACATC CTTAACAACT CCTCTATATA ATTCTAAATT TTAAAATGG AAAACAGATT 56520
TATTTCTTCTT TTGAAATATA ATTCTCTGAA ACCAGTACT TACCATTAACA TATGGTAA 56580
TCAGACCAAC CATTGTAACC ACACACTATG GAACCACTGG TGCTTCCAGT ATTGCTTCA 56640
TAACCATCAT GGCATTCTCA GTCCAAATGTG TCACTCAGT TAAACCATGT GAAGTCATT 56700
TTAGTTCTGG CATTCTATAA TACTGGATA TCACAAAGATT CTAGTCATA AAAAATTTAG 56760

aatgtcattt ctaatgtcat ctaataaaaca atctgaggat ttccccatttc aagaagaaaa 56820
agctttatgg attagatcta ctaataaaata ggtaccgtac aaaaataatc tatgactgg 56880
gagaatttgt tgcgtaaaa tagttgtca aagtgaagg aratcttct acacaacatt 56940
ttttttoatt gettaagccc caaaatatat tttsaasasc tttttcttaa ttcatttata 57000
ctaaagcatt tatgacaatg ctagtaataa aacaggccat tacaggata cattatttt 57060
taaagaaaaat cataacagaa ttttgtaaat taagagtcca aactaatcg tagtgagac 57120
atatgtaaaa aggagaaaaa gactgaaaat ataaattctt atgttataca agacatttc 57180
tctttaataa taagaaaatc taaaagaat aattaataaa aattagtat aaaatgtat 57240
tttttatgag gactaacatt ttttgtaaac tagacctcat attaagcaca gacattaaaa 57300
aatgaaaaca gtatacatga ataccttatt cacttactt aacatggta tattaaatat 57360
tacttcaaat atattactga gaggcaggag gatcattga gattaagggt tagagaccag 57420
cctggctaac atgcaaaac cttgtctta ttaaaaatac gaaaatbagg caggcatgt 57480
ggagggtgtcc tgtaatccca gaaaatggag gttcagtgtca gggaaatgg cttgaaaacg 57540
gagcaagact ccattctctt ctctatataat atataatatac atataatatac ttgtgtt 57600
ctctatataat atataatatac acacacacac acacatattttt aatatctaga tagtgtggta tggtaccatc taggaatatt 57660
gttcccggaa aattttcata tagatagtgt ggtaggaaaa ttgtctctt actacctaa aatctacaaa ttatagagtt tggaaaaatctt cttatctttt 57720
agacatatcc tacagtgtca cactaggcat ccatatcttc aataaaaaaca ttgtttttgt aataatctt 57780
atgtaaaatg ctaatcttta aaaaacagata tatattaaca gggaaatctt cttatctttt 57840
agcaaaatca gttaaacca aaatctttagtggta tccatacaaca gggaaatctt cttatctttt 57900
aatgttttag agtagggaaa ttgtctctt actacctaa aatctacaaa ttatagagtt tggtaccatc taggaatatt 57960
tggatgtgtt ttgaaaaaaa aatctttagaa aaatttctaa aatctacaaa ttatagagtt tggtaccatc taggaatatt 58020
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 58080
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 58140
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 58200
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 58260
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 58320
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 58380
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 58440
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 58500
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 58560
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 58620
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 58680
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 58740
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 58800
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 58860
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 58920
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 58980
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 59040
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 59100
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 59160
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 59220
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 59280
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 59340
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 59400
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 59460
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 59520
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 59580
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 59640
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 59700
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 59760
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 59820
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 59880
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 59940
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 60000
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 60060
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 60120
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 60180
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 60240
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 60300
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 60360
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 60420
ttgtctctt actacctaa aatctacaaa ttatagagtt aataaaaaaca ttgtttttgt aatctttaggtt 60480

aactccccaa gaaatggacaa aggataccta ttagatgaag aacactacca gagaacaaaa 60540
 aggttaaagga tteccagagc acacacacaa cacaggaga catttaaatg gaatcaatca 60600
 gagtagaaaag actcgtttga acatctaggc cacgttagt agscatcaga agcagctta 60660
 tatttcgtaa aactatctc tggtttttt taagctttt aasagcttaa aataaagcc 60720
 tggaaagaact aagttagccc aaaacaaacc taaacttaa aaaaaattaa aacaagtaat 60780
 cttggggtc tcacagatgt acagacttgc ggagtccaa agctgcttc tttagccaa 60840
 atacagaatg gagttaaaaaa aaaatccaca ttttggtaat aatacccttc tcacaccc 60900
 ctccaaaaat cacagtaat ctttatggc atactcaccc tactccagcc aaacactgtat 60960
 tggatatacta tatataaaa gttggaaat ggcacttagag cgtatgaaa taaattggtg 61020
 tcactaaata cctgggatag aaaatgacgg tggccactt caataaccc agcctctacc 61080
 attagatatt agtaaaaatg gaaaaattt atctcaaagt aagcagaaga aataactacaa 61140
 taaagatccag agatgaaata ataaagaatg aatatgtat ataaacaagg aaacccaaaag 61200
 cttgttattt tagatctcta taatttgaaa accttttagac agactasatc agaaaaaaaata 61260
 acacaaaattt cttataaacag caatgacaga aatgacatca ttatgtttt tacatataatt 61320
 aaaagaaaaaa taaaatattt tctgatataat ggcatgtcaa taaatcaag aacttgaatg 61380
 aattaaaaaa ttactgaagc cacaactat catggcttc tcaagaagga ttaggttagca 61440
 ttaatataattt ctgttcttata aacaaatttgc attttttgtt gatggatgaa atacaaaata 61500
 ttttagttata aatctagaa aatacaggat ctgtatgtt aaaaataaaaaa aacttaggg 61560
 aagactgtat gatcttacta aatcaagga tatataat tcatgatgtt aaaaattttaa 61620
 tactttraca tattcgatcc ccccgatttgc atctgtgatg gtgtccagg tctagtgaat 61680
 aaccaagcac aatgttttgc acatacgeac atgctgatcc taaagtccata tggasaggta 61740
 aaggggctaa aacagctaaa caattttca aaagataaga gaagtgaaa aactcacatt 61800
 accaaatttt aagacttaaa aaaagctaca gtgatgtt aatctcatgatg tactggttaa 61860
 aggacaaaaca cgtggaaagaa tagaagagaa aacgggtgtcc agaaatagac tcacatgcat 61920
 ggtatcgatcc tataaatagc ttctatttca ttttggttata agactatcg gttcacatgc 61980
 ccactgtttt gcaatagacc aatacgttgc gacagttaggg ttgcagccaa agaaaggctt 62040
 taatcascac aagggcacc aacaaggaat tggaggatt ctcaagcccc agatctgttc 62100
 tgagaagggg ctatgtgcaaa gagaccttaa ggggatcatg ggggtgacg ggctagsaaa 62160
 tttgggttgc caatttggtca gggtaagggg gatgaagtca ccaggatgtg gaacctgcat 62220
 tatttcgtca gtcagtttt tgctggctc tttagaccag ctgatgtgtg tgcgtgtgt 62280
 tctgtgtgtg tatgtttgtg tgcgtgtgtg ttgtttgtt ttgagcaaga tgatctgt 62340
 ctgtgtccca tctggatttc agtagegtgc tcacagctca ctgcacttc tgccctccag 62400
 gtcacagtgg tccctccacc tcagatctcc tgagoagctg gtactacaga cctgtgccc 62460
 aatgcccggc taattttttta atttttgtg aaaaatggat tttgccttgc tgaccaggat 62520
 gttgttaggt ttttttttca tatgagaacac cttaaggaga aactcatgca gaaagattat 62580
 catctcacaa tgcgtttagat ttatcttata gaaaggaaaa ggacaaaaat gtcttgc 62640
 aagggttctt ttatccagg gtagtataatca atgaccaggat acagagaatg tggacaaaatg 62700
 gaaagctgtat ttagtgcattt ctgtgttgc tccgttgcattt atagttgaat ttttcccc 62760
 taatcaattt tatataactt tccatggac agtttgcgtt cttccggcc ttgatcoct 62820
 ctcaattctg aggtgtaaaa gtcataatgg tatgaatcc gcaatggcc ttctagctt 62880
 ttttgcgtca caccggccac agagagagag tcaggattag aggaatgaaa ccgtcttgc 62940
 acaacctgca agctgttata cccagcttgc ggtgtggat gaacatgttgc tgcacttgc 63000
 ctatggttt attgtatata ttaatgtat aatgttaattt ataaatcccta taaacagaat 63060
 tgtgagcttgc aacttcaaaa gtcctgaaa aatggactgg aaaacatggc gtatgcaggc 63120
 gggaaagctca aaaaactatt cagacatagg gtctgtggta gagacatatg gtctccaggc 63180
 agactgttgc aatatttttt ttagtttgc ttttattttca ccagaaggcat tgatataatg 63240
 acaacagggtg gtattgtatca ctgtacagac tccctcttgc aaagccaaga gaaaatcaag 63300
 tgttagttccg ttgtcaagaa ctatctggcc aagtaatattt gaagagttt ctgcgcctca 63360
 atgttcttag cagcttctt tgcattattt tctgtgttgc ccaataatgtt tctgtatgc 63420
 tccctgttag tgcgttactcc atagcttaga ctgtgtatgc ctgcaggctt ctgcaccagg 63480
 atatattgtat atatgccttg cagtccttgc tggagtcggt gggaaaatgg gcagaatattt 63540
 ttgtcatttag gatggacttgc gaagtatcc agtaatgtgc agcccttaat atacagggtt 63600
 ttgagacacc agtggcttgc cccttacaga ggagggtctg atccatgtcc acaaataaaac 63660
 atgttaccaag ggggcacaca ggttaagccc tcaagggtgc attttttgtat gatttttttc 63720
 atggggata tagacaatgc gaatttgcactt agggatctt ttttacaggc tccccc 63780
 trgtgtgtata ttccccactt taaatattt tggcatatgc aggagaaaact tttagttt 63840
 ttcccttctt ccttagtgcg ttgtgtgcg cagttatgc tggccatgg agggcctatg 63900
 taatggatg actttccattt ttttccattt ttttccattt ttttccattt ttttccattt 63960
 ttttgggtgtat ttttccattt ttttccattt ttttccattt ttttccattt ttttccattt 64020
 gtgtatgtat ttggaaatcc ttttccattt ttttccattt ttttccattt ttttccattt 64080
 ttttggatag ttttggggag ttttccattt ttttccattt ttttccattt ttttccattt 64140
 gcaataccctt gaaacagttt aactacatgc ttttccattt ttttccattt ttttccattt 64200

agagagaggtta taattttagaaat tttttaaaaca agagtgacca ttctctaatt tttagaatgtc 64260
cacataatga gtggcatgag actatgttag catggcatag aatgtctsga aaatctataa 64320
gtcttaacaat tgttattgacc aaggcaatta tgaagtaatg tctataaggg tagcaattgt 64380
aatttatccat gcaattataa tgaccaagta aatatatggc attataataa caascatcc 64440
gyaataagaca ggaaggatc tcaccccttt atataaaata ttaagcatc agtaaggcag 64500
tgtttatgctc aaagtaacta ttgttagtgt caagaagaca aggcccata aagatttact 64560
taaagttaact tatctgtat ttttcctcaa aagatattg agtgcctctc tacattttt 64620
tatccatca gatagggttg agacagtctc tgaagttgaa gtggcctctc 64680
gataggacaa gaatctggcg ggggggggtt tataatggctg tggtaatcc agggctcaag 64740
tccttcaagc tgaacagagg aatgggtcact cagtcatgtt tgcattgtcc tctttcaotg 64800
tgttttaagt ggtccccagg atgtcgactt ttcctggct tgagcagaac ccagtctgt 64860
gsttggatgg gatgaaagag aatgtcagtt ggataccaca atctgtcgga accacaaact 64920
cgtgaatagt agttaaagta caacccaaag attgtgtat ttgtataata totaatttt 64980
ttatgtgtat gttattggca ttcccttagtc tgagaaggta acggaagaat gatccccat 65040
gtaaaatttt taaaggcctt aatttaagcc cacttttagg yaccacccctt actctgagca 65100
ggcaatggc cagaatgtt stccaggtt ttagtttctt ggcaaatctt agctaaaatt 65160
tgtttttt tataatgtat gatttatctt ttgagtttt tcagtagact tcagtcgtca 65220
ggctgtatga agattccaga ttatgtctg ggccttggaa atatgggtc ctaggttaca 65280
gaaattgcac tatgttcaca ctggatggag acaggccacc baaacctgtg ggttaatctt 65340
tctaccaagg ctctcattttt ctcagacatt ctcttggct tgccagoggaa tgattttgtt 65400
tatcttgcata atgtatcttca aataacaago aegtattttaa aatttccgtc taccottggc 65460
atcacggtaa aatcaattttg ccagtcctct aatagccctg caccctctgc ttgaatccctt 65520
ggtactgggg gtggaggacc attatttttt ggatagtctt agtcttaaga ttgttctggg caccaggatg gtatttttaa 65580
agggtggcat gcctgccata ctgtgtgtt tcatgtatgtt catagtctgt gatcaattga 65640
agatacttgg gcaccagaac cttttcttcc gtgtcacata gtttgbatgt atctgtcaca 65700
tgattggagt caaagtctca tccatgttccat ctcatttttccat tccacttattt 65760
tttttaggtt aagtttattt cagggattaa tggcatttagg cttttttcttccat tccatgttccat 65820
ctctgttcaac ctcttttagt gctgtctgtt cctagtgtattt aaggctttgg gcatttttt 65880
ttgtccatcc actgtatgtcc atggtagtgtt attatagcta tttttttttt ttaatcatca 65940
gccttttagt aggtcaatggat ttcttttagca tqcttaatttgc aatggacaaac aataaaaaaca 66000
saggttaaga gcccgttttcc tttccaaacg gccccatggat ttttttttttcatca 66060
tacottggaaat cagagtaatc ggtgacttcag gagtttttac catggacaaac aataaaaaaca 66120
aggactctaa gtttgcetttt atctgtcaca ggggttacaaat ctatgttccat tccatgttccat 66180
atctgtcaca ttttccatca ttttttttttcatca 66240
cttttccatca tgaatattttt ttttttttttcatca 66300
tgaatagaac acatgtgtcc ttttttttttcatca 66360
atttaaagca gaaacagetc tcaatgttccat ttttttttttcatca 66420
cttattoagt ctcttagagg agttaattttt atctgttccat tccaggagggaa tgacctgtata 66480
acagttatggg gtgtgtacag ttttttttttcatca 66540
aagatcacaat gtggtgcacag ttttttttttcatca 66600
cagctgtttt gaaaaatgttccat ttttttttttcatca 66660
tccttaaaccat atcccttccat ttttttttttcatca 66720
gggtctcaagt agccagatcc ttttttttttcatca 66780
atcccttgc ttttttttttcatca 66840
tataagccca aaataagaaat ttttttttttcatca 66900
acagctgtcc ttttttttttcatca 66960
ccggacgggtt agtgagttttt ttttttttttcatca 67020
agcttttagt ttttttttttcatca 67080
ggggataacag atgaaggcat ttttttttttcatca 67140
taaagtcatg aataatgtat ttttttttttcatca 67200
ctttagtgc ttttttttttcatca 67260
cctatgttccat ttttttttttcatca 67320
caagacgggtt attttttttcatca 67380
gttttttttcatca 67440
ggccactcc ttttttttttcatca 67500
tgaccaaaaac ttttttttttcatca 67560
tccatgttccat ttttttttttcatca 67620
ggccatcc ttttttttttcatca 67680
gttttttttcatca 67740
ctcttcagggg ttttttttttcatca 67800
acatgttccat ttttttttttcatca 67860
ctttagtttcatca 67920

tgccatgaat ttttttttct
tcccaggatg gagtgactgt
aagtattct ccacgcctcg
ctggcaact trrttatttc
cgagctctg acctaagta
tgtgagccat catgtctgg
cctgtgtgc agcaacagaa
ttgcaaggtc accaaacaag
aagtttctg ggcaagaatc
attgggtaa ggggctgaa
tttctgtca agccttcag
aaggagaaac tcaaattggaa
cagaaaaaga acaaagattc
accagotata aggaagtggg
acaaggctag ttgaaattta
gttttcaatt taaaaaggg
agtataactg gaacagtaac
tacctcatac aaaaattaac
tatggccctg gttaggc当地
aaaatgtgt aacatcaaaa
azgttaaagct acagatgca
agccacaata tattcatgttag
tggcaaaat ttagacagt
aagatgttaa gcagcattag
gataattaa tggaaaaaaaa
ggatotcaca tacactgagt
gtctatttct tataaaaaatg
aatagctctt ataatittga
catgaagggg tigtgaattt
ttttttgtca ttacatttt
atggogactt gctcatggtg
atrrtattga ggatttttgc
tctgttggtc ctgtgcagg
aggaggagac cttttttt
tcttagtacc tctggtagaa
ggcaggctat taattactac
acrttcttct tctgtttag
tccagatttt ctactttt
atttctctgg gatcagiggt
tctgtctttt ctcttttatt
ccagctctg ggtcattga
ctgatcttag ttatcttctt
aattctttt ttattttatt
ttagttacat atgtatacat
acatttagta tatctcttaa
ggtgtgtgtat gttccccctt
gtgagagcat gegatgettg
ccagcttcat ccatgtccct
ttctatggtg tatatgtgcc
ttggttccaa gtcttgcata
tttatacgag catgatttt
aaatggtatt ttactgttata
actagtttac agtccacca
cacctgttgtt ttcctgactt
atgttgttt tgatgttca
tttttggctg cataaatgtc
ttgatggggt tttttttttt
attagccctt tgcagatga
ttcaacttgc tggtagttt
ttgtcagttt tggcttgcgt
atgocatgtt octgaatgg
ctaaccattt aqctttlaat

ttttttttttt tttttttttt
gcacgatctt ggctcaactgc
cctcccaagt aactgggatt
tagtagagac agggtttca
atctgcctc ctttgcctcc
tgcttgcctt gaatttttat
tataccaaga cagtgagtt
gacatgagaa gaatttctca
tttgaagggg gagtggtctgg
atcatcgga targggaaagt
aatggctggc atcaqtagtt
aqtrtgcattt ctcattttgt
tagtgccaa gattatgtta
tcaatggaaa gctagctaa
cttttcttc ctttaactgtt
gcaaaaggca ttcaataaaag
gcatccaaat goaaaaataat
tcatataact aagtgtaaaa
gaaatttta gatgacacaa
ttacataott ttgctcatga
gaaaaatatt tgcaaaatatt
tctcaaaatt ccgtaatgg
ttcaccaaaag gaggtacata
tcaactaggaa atgcaatacc
aacacattat ctcaaaggct
atgtgaaggt acaatgtat
aacacatatt tagtgata
gatatgttcc atcaatact
tattgaaggc ctttctgya
tgattttgtat atgtgaaac
aataagctt tagatgtct
attqatgttc atcaggata
tittggatc aggatgtgc
tattgttga aatgtttcc
tttgcgtta aatccatctg
cacaatttca gaacctgtgt
tggggagc gtgtatgtgt
tggtagagg tyttatagt
gataccctt ttatcatttt
agtatggcta gtagtgtact
ttttttaaag ggttttcaty
tcttgcata gctttgaat
tataccttaa gttttaggt
gtgccatgtt ggtgtctgc
tgcttatecct cccccctcc
ctgtgtccat gtgttctcat
gtttttgtc attgcccatt
acaaaggaca tgaacttcc
acattttttt aatccagtct
ttgtgaatag tgcgcataa
aatcccttgt gtatatacc
gatccccctg gatcttagaca
acagtgtaaa agtggctcta
tttaatgtc gecattctaa
ttcttotaatg accagtgtat
ttcttgcata gttttttttag
aagttgtctgt tttttttt
tttcttgcata attttttt
gttagattgca aaaaattttt
ttttgtctgt cagaagctct
tgccattgtt tttttttt
atgocatgtt octgaatgg
ctaaccattt aqctttlaat

agacggaaatc tcaatctgtc
aacctctgtcc tcccagggtt
acaggcatgt gccaccatgc
catgttggcc agcctggct
taaagtgttggg ggtttt
aagattgtaa ggtttgtat
tgcaacagag agttaacc
gactcaaacc catttcaact
aaaatgttggg tcatcaattt
acatttcttc ctaagttgag
ttgttagtat gcagaaacct
cttaatattt aactaaagaa
tccctggactt gtaatcagtg
tgattaccat tgattgttct
ttttaaaaatt ttttggaggat
aaaacatagt cttttaaaca
aaccctctac atatcctca
tgtaacttc tagaactgt
agagcttaat catabaaatg
aaagagacta ttagagagaa
ttactcagtg aaggcttgc
agaaacaact caatggaaag
gatggtsat aagtacaaag
atcacacaca tattagaatg
ggcaagggtt cgaasacaact
atcgctcagg aaaacagttt
tttgcgtatgg gttttttaaaa
agttttatgtt gtttttttac
tctattgtt taattatgt
ageccttgcat cccagagata
gtctggattt ctttgcctgt
tttgcgtatgg atttttttt
tggctccata aataggtta
aaaggaatgg taccactcc
gtccctggct atttttgg
ttggcctatt cagggtttt
ccaggaattt atcoatttt
attctctgtat ggtatgtt
tattgrgtct atttgattt
ttgttaatct ttcttaaaaa
tctctatctc caggctctgt
ttgtttgtt atgttttct
acatgtgcac tccgtgcagg
acccatttaac tcttctattt
ccccccccc aacaggcccc
tgttcaattt ccacccatgt
tttgcgtgaga atgtatgg
ttttttatgg ctgcataatg
atcatgttgc gacattttgg
aacatagctg tacatgttgc
agtaatggga tggcttaggt
atgacttcca caatgggt
tttctccaca tccctccgg
ctgggtgtt gatgtatctc
tttgcgtt tttcatgtt
tcatatctt caccctt
gttcattgtt gattctgg
cccttctgtt aggttgcct
tttagtttaat tagatccat
tagacatgaa gtccttgc
gggtttttat ggtttttagat
tataagggtt aacgaaggga

tatggcttgc ttgttttccc agcaccattt attaaataag 75420
gttttttcga ggttgtccaa agatcagatg gtttgccata 75480
ctctgttctg tccatttggt ctgcacatct gttttggta 75540
taactgtggc ttgttagtata gtttgaagtc aggttagcatg 75600
ttgtctttagg attgacttgg caatgcggc tctttcttgg 75660
agtttttcc sattctytaa agaaaggcat tgccatcccc atcaagct 75720
aaggtaattt atagattcaa tttccactt tctgtatgtgg 75780
taggggtgtca agtttagatc ttatggat tctgtatgtgg 75840
tctctaaag actgtttaa ctgtgtccca gatattctgg 75900
attgggttca aggaactrat ttacttctgc cttactttca 75960
cagtagcagg ttgttcagt tccatgtatgtt 76020
gatrtctaat ttgatattcac tgggtgttgg gagaactgttt 76080
ggtttgttgg gggagtgttt tttccactt tataatggtcg 76140
tagtgcctaaag aagaacactt gacttctgt ggagagttt 76200
gttggtcag agtttagttc aaatbggaa tatctttgtt 76260
tgtcttagat ggacatagta ttgggagggtt tggaccagac 76320
taaggagat tcaatagga agagaggaag tcaaattgtc 76380
tggtatattt agaaaacccc actgtctcaa cccagaaact 76440
tcagggaaatg otcagggatgc aaaatcaara tgcaaaaatc 76500
gtaatagaca gaaagccaaa tcatgatgtt 76560
asasatacgta gaaatacaac ttacaaggga tgcgaaggaa 76620
accactgtc agggaaataa gataggaaga atcaatatca 76680
tgcatttccc atctagctat tgatttcaaa ctatactaca 76740
ttcatatgaa accaaaaaaa agctgtatca gatatatata 76800
accatggtact tgbaccagaa ccaittgtate ttcacagaa 76860
ataacaccac acatctacaa ggttttttttggtgc agggaaaatt 77040
ggaaaagatt ccotattgaa taaatggtgc tacacctaataaaatata 77100
ctgaaaactgg accctttccct cattatctt ttttttttttgg 77160
ttaaatgtaa gacctaaaac gatctcatgtt 77220
aggacatagg catggycaaa ccaaaatgtt 77280
ccaaaatgtt caaaatggat ctaattaaac taaaagagctt 77340
tcatcagat gaataggcaa ttttttttttgg 77400
agactacatg aatatcaaga acaaccctat 77460
aattttataag aaagaaaacaa atctacaaggaaat 77520
cttctcaaaaa gaagacattt gtgttactt 77580
ggtcattttaga gaatgtcaas gtgttactt 77640
geogatcatt aaaacatctg gaaaccacag ggttttttttgg 77700
gttttactt gtttgtggta gtgttaattt ggttttttttgg 77760
ctcctcaaaag atcaagaacc agagatacca ttttttttttgg 77820
tacccaaagg aatataaattt attctactat 77880
gcaccattt ctagtagcaaa gtttttttttgg 77940
ataaaagaaaa ttttttttttgg 78000
tgcgttccctt tgcaggggaca ctttttttttgg 78060
aggaacagaaa aacaaaacac ttttttttttgg 78120
cacatggaca tagggggggg ggttttttttgg 78180
gggagagaga gcatcaggac gtttttttttgg 78240
gtttaggggt gcagcaaaacc atgttactt 78300
otgcacatattt atcccaagaac aacacacaca 78360
cacacacaca cacacacccat tagatatgtt 78420
ataaaatttgc gtttatataa ttatcttaca 78480
aatgcaaaaa acaatgcaaa ttttttttttgg 78540
tgcatttttttgc gtttttttttgg 78600
tatgcatttgc ctttttttttgg 78660
agtttttttttgc acctgttctgt ttttttttttgg 78720
gttttttttgc gtttttttttgg 78780
gttttttttgc ttttttttttgg 78840
tttttttttgc ttttttttttgg 78900
tttttttttgc ttttttttttgg 78960
tttttttttgc ttttttttttgg 79020
tttttttttgc ttttttttttgg 79080

tttcataaaagg atacactccca tttttttttt
tctgcattt ctcacaacat ggttatgagg aatttagatt tttaattttt 79140
gtgattcaact gacaatttgac tgtacatggaa aatataacgt tttaattttt 79200
gaagctaaga cttgttaatt atatgacaaac cgtraaaagtag tgatatactca atctgttggaa 79260
acaggggtcta goatgaagag taaaatagta acattcttaa tgatatactca atctgttggaa 79320
acttgggaca aaaggaaaaga aggaaggaag gaaggaagga gaaaaacttg agccagacaa 79380
agggagggag ggaggtgaca gaggyaggg gggagggag ggagggaggg agggagggaggg 79440
gaagggaaaaga gaaagaaaaga aagaagaaa gaaagaaaaga aaaaaacttg agccagacaa 79500
aagaaaagaaa gaaagaaaaga gaaagaaaaga aaaaaacttg agggagggaggg 79560
gaaaagaaa ggaagggaaa agaaaagaaa aaaaaacttg agggagggaggg 79620
gtagacaaag aaaggaaaaga aaaaaacttg agggagggaggg 79680
aaggaaaagaa agaaaagaaa aaaaaacttg agggagggaggg 79740
gaaaagaaa ggaagggaaa aaaaaacttg agggagggaggg 79800
ttccaaaatca aaccaagagg catacataat caaggcatat gttttttttt 79860
atgggatcat ctgacactga ggggtgaagg tcatgattt gttttttttt 79920
ataaaaattt cttttttttt 79980
atgggtacaga gtgagattt atgtgagac aaaaaagaga gttttttttt 80040
tactgcaatg ctgtttttt 80100
atttgttgt tgatatacaca aattgttac taatagtgc gttttttttt 80160
gaaaggtact ataaaaattt aattgttac taatagtgc gttttttttt 80220
aaatacagcc attatcatga aggttaactt taactttttt 80280
tcccttaaat agaaacaaga atgagcaact tatgttcata aattgttac taatagtgc gttttttttt 80340
atacatttgc attacgtata caactaataa taccaaaact aacattcattt aattgttac taatagtgc gttttttttt 80400
agattagaag cattaaatac taaaagaaaat gttttttttt 80460
atattaaaat gcaaaatttac atattaaaat gttttttttt 80520
aatgratgtt ggaataaataa attttttattt attgtttttt 80580
agaataccca tttgtactt attttttattt attgtttttt 80640
tcatataact gctgaaatattt attttttttt 80700
actataattt tttttttttt 80760
atataaggat tgagaaaaaaa attttttattt attgtttttt 80820
ggtttttttt 80880
tggatattt gttttttttt 80940
tggatattt gttttttttt 81000
tggatattt gttttttttt 81060
tggatattt gttttttttt 81120
tggatattt gttttttttt 81180
tggatattt gttttttttt 81240
tggatattt gttttttttt 81300
tggatattt gttttttttt 81360
tggatattt gttttttttt 81420
tggatattt gttttttttt 81480
tggatattt gttttttttt 81540
tggatattt gttttttttt 81600
tggatattt gttttttttt 81660
tggatattt gttttttttt 81720
tggatattt gttttttttt 81780
tggatattt gttttttttt 81840
tggatattt gttttttttt 81900
tggatattt gttttttttt 81960
tggatattt gttttttttt 82020
tggatattt gttttttttt 82080
tggatattt gttttttttt 82140
tggatattt gttttttttt 82200
tggatattt gttttttttt 82260
tggatattt gttttttttt 82320
tggatattt gttttttttt 82380
tggatattt gttttttttt 82440
tggatattt gttttttttt 82500
tggatattt gttttttttt 82560
tggatattt gttttttttt 82620
tggatattt gttttttttt 82680
tggatattt gttttttttt 82740
tggatattt gttttttttt 82800

ttcatcacag taataggagt satattttcc tacagctact ggaaagtatg gtctacgcat 82860
 attcctcatga tatagacctc catgttaat gtctggataa tcacaagggtt toacttgca 82920
 taaaaatttt aaaaaaaaaaaga taaagaaaattt tractgtaat aaacactcat attagagata 82980
 aatttttatac actgaatttat atttccttct tagtataattt acacattcca ttagggtttc 83040
 taggtcaaaa caaatgatag aactcagatg actgagatata gtaacaagaa ggtctttgtt 83100
 aatgaagatg aaatttatgto ttgtgatca catgtatggtt aatgttgcataa gaggctctc 83160
 cagaaagaaa aatgcacsga ctatataat atatttccct taaaatcacaca taccctatcc 83220
 ctggtaastt aaataagctt ttcggtttag aatatatgcca attttaccgc ttagctcatg 83280
 tattttttc tttttttttt ctatttctat cagtaaacaa gagccctgca 83340
 tttttttctc agaacaatcc aatgtttagga agtagtatttt tgagggattt aaggttttta 83400
 ttgttttagt attgaattca tgggtgggccc gcagttggctc acgcctgtaa tcccagcact 83460
 ttggaaaggct gagacaggca gatcaatcg aaggagttcg agaccagctg ggccaacatg 83520
 gtgatactcc gtctctacta aaaaatacaaa aaaaatttagc cgggcctgtt ggtgccc 83580
 tgaatccca gctactttaga aagcagagggc aggagaatcg cttaacccca ggaggcagag 83640
 gttgcagtga attgagatg tgccttgcctt ccacccatggt ggttacagag tgagactccca 83700
 tctcgaaaaaa tataaataag taaataataa aatttaggctt ttcoctattt attgcagaca 83760
 acgtaaaaat atagagaaaac acaaaaattt ttctttgtt ataccggcga gaaaaataaac 83820
 atagttattt catgcctcaa acaatttattt aagcccaatgtt ctccatctgtt batitaacca 83880
 gagaaacaga cttagaaatatttccat ccaaatagttt aatgttgcataa ttaactttttt 83940
 tggtttatttc taatttttaat tggagagaaa aataattttt atgttgcataaa atatatttaa 84000
 gtaaggtaca atataatttac attttactgat ttgtttatattt attaattttt acaaaatacat 84060
 ttgagttgttca ttgttttttat tatatttaaca gttttatata tttttcagaa aatttgctct 84120
 ttccatggga ttattttgtttagt attatattttt acttttcaata acaaaatgtt attaatgttt 84180
 tccatggaaat atgttttctat ttcaataaaac ctatgcataa aggtttaaaaaa gaatttcaat 84240
 acacacatac acacacacac atataaataat ttcttttcat ctccatctttt cttaaattct 84300
 gtgttattttt ttctttttgtt ttgtttttttaga gaaattttca tttttttttt acatttatta 84360
 tttttttttttt aactgttataa attgttataat tttaatgtt atttttttttt aagacttagt 84420
 aatgatactt ttccatgtt agtttttttgg cttacaatcc atataatccaa taatttgatag 84480
 atttttttcc ttatattatctt gaagctccca gtgttgaat taaaacattt acttagtctt 84540
 atttttttta agtaacattt tacatttttcc ctcaccactt tttaaagattt tggaaatattt 84600
 ttatatttacc attggattttt acaaaatttca tcatgtatgtt ttgagacatg tattatatttaa 84660
 caataatttctt gcatgggaa agctttagtgc ttggattttgtt gggagctgtg cttttttttt 84720
 ctcaatttgc ttccatattt aatgtttagag tagatatttcc aatgttgcataa 84780
 aagcaagtat ggttccat ctttttttttgg tttttcccg aagggttccaa aataaaattt 84840
 ttccaccggaa ttcttttccaa aagggaaataa aaggaggggca taattttttttaa catataacat 84900
 taccacaggc tccatgtttagtatttttccat ctttttttttgc cacatttaca tttttttttt 84960
 tcccttttttac aatgttgcataa ctttgcataa attttgcataa ccacacatgg tttttttttt 85020
 gctgaaatggaaatggacttccat aatgttgcataa attttgcataa ttttttttttt 85080
 tttttttttttccat ctttttttttttgc aatgttgcataa tttttttttttgc acaaaatgtt 85140
 aatgttgcataa attttgcataa attttgcataa attttgcataa attttgcataa attttgcataa 85200
 attttgcataa attttgcataa attttgcataa attttgcataa attttgcataa attttgcataa 85260
 gtttttttttttgc aatgttgcataa attttgcataa attttgcataa attttgcataa attttgcataa 85320
 attttgcataa attttgcataa attttgcataa attttgcataa attttgcataa attttgcataa 85380
 tcaatgttgcataa aatgttgcataa attttgcataa attttgcataa attttgcataa attttgcataa 85440
 gatgttttttttgc aatgttgcataa attttgcataa attttgcataa attttgcataa attttgcataa 85500
 ctttttttttttgc aatgttgcataa attttgcataa attttgcataa attttgcataa attttgcataa 85560
 agtttttttttttgc aatgttgcataa attttgcataa attttgcataa attttgcataa attttgcataa 85620
 taaaatatttttgc aatgttgcataa attttgcataa attttgcataa attttgcataa attttgcataa 85680
 atgttgcataa attttgcataa attttgcataa attttgcataa attttgcataa attttgcataa 85740
 attttgcataa attttgcataa attttgcataa attttgcataa attttgcataa attttgcataa 85800
 tatgttgcataa attttgcataa attttgcataa attttgcataa attttgcataa attttgcataa 85860
 aggggttttttttgc aatgttgcataa attttgcataa attttgcataa attttgcataa attttgcataa 85920
 atgttgcataa attttgcataa attttgcataa attttgcataa attttgcataa attttgcataa 85980
 caacacttccctt ccctccaaat aatgttgcataa attttgcataa attttgcataa attttgcataa 86040
 ttgttgcataa attttgcataa attttgcataa attttgcataa attttgcataa attttgcataa 86100
 tgatgttttttgc aatgttgcataa attttgcataa attttgcataa attttgcataa attttgcataa 86160
 tgagggatgttgc aatgttgcataa attttgcataa attttgcataa attttgcataa attttgcataa 86220
 tgagtttttttgc aatgttgcataa attttgcataa attttgcataa attttgcataa attttgcataa 86280
 ctcttccttgc aatgttgcataa attttgcataa attttgcataa attttgcataa attttgcataa 86340
 aatgttgcataa attttgcataa attttgcataa attttgcataa attttgcataa attttgcataa 86400
 taacttccctt ttttttttttgc aatgttgcataa attttgcataa attttgcataa attttgcataa 86460
 acactaatac atgttgcataa attttgcataa attttgcataa attttgcataa attttgcataa 86520

gccccatttata aactcatggc aaggccatcg tggtaaggac ctgaggccctc ctgacaacag 86580
ccatgtgtgt cagtaatgtt agaagoagat cctccctccc agccaaggct tctgatca 86640
gtagccctggg ccatgatcc gattgcaaca caagaagaca gtctgatca caactacta 86700
tataagccat tttagagatc ctgaccgata gaaactgtaa gataataaag gtttagttgt 86760
ttaagtaat atgttttgg ggtattttgt tacaatgca taaaatacta atatagtstg 86820
tgttagatga cattattttt atctagtggt ttaattcaga tattggaata atttattaat 86880
tagggaaaca tacattcata aacacacata cacatttaat tttagatgc aaaaaatatg 86940
agtticggca acttcgaaaa ctaaagaatg cttccaaacag ctttactttg tatatacaat 87000
aagacaataa ttgggtttt a tttttttatg tggttaaagg aaatttcaga 87060
attraagaaat gggtcaagat atgaatgaa cttacaggta catctcgag caggatcc 87120
gccagttactt gtgcattttt ctgttattcc cggggttgc ggataaaaac catttctaca 87180
ctggtagctg attcatcoto cagttctgt ttaatcctt aaaggtgagt agtcaccatt 87240
tggaaataaa ggattatcac atgattttc tgaaagaaaa aaggatataat ggataatgc 87300
gaaataagta tccggtttt ttaatcattt ataraaacat taaaagttgg gtgttattt 87360
tttgcctta gcataataca aatggcatt aaaaatgaaca tatactatatt ctcatctgac 87430
tatactcattt atttttcctt ttaatcattt ataraaacat tatactatatt ctcatctgac 87480
cttaatccct tcttctccaa tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 87540
totcatcaca tataacttca tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 87600
gtictcataa ggattgtttt ctttctttt ttaatcattt ataraaacat tatactatatt ctcatctgac 87660
ctgcgcacc acc ctttctttt ttaatcattt ataraaacat tatactatatt ctcatctgac 87720
aaaagrggas gtaataatcattt tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 87780
ttatgttcc tttcccaaaag tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 87840
ctgtcacttg attttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 87900
gtgaacatga atgaaaataaa tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 87960
cattttttttt actataatag gataaaaatag cagagggttt tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 88020
ggccagataa aatgtctctg tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 88080
aaaaaacaat acataaaacaa tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 88140
agggggcaag ttgtattttt tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 88200
ttaatctata aggacaccc tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 88260
tccatttgca asattcgttt tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 88320
tatatgacca ctttttattgg tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 88380
tcagcatgtc ttgaaaatcca tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 88440
gtaaaatgate catagttcc tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 88500
aacagataat aagtctccat tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 88560
tacttcttc cagcactctt tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 88620
agtcttcagt gyttaaagtgt tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 88680
cctgtatttt aaaccattgt tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 88740
aaattgtat ggaagttttt tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 88800
agctaataatg tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 88860
aattgtgttc tccactttcc tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 88920
tgaccttotat ttgttgtccaa tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 88980
tcagaaatgc ttgcatttc tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 89040
tatttattga actgaacaga tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 89100
ttgggtgtct ccattaccc tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 89160
gtgatgttt tcttttstat tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 89220
ttgtacttta cttaattttt tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 89280
gccatttttc racettttct tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 89340
tcaaacataa aattttataa tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 89400
atacttccac tgggtccatt tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 89460
taatataatct statagctaa cggataata tatttagatt agcaataatt atatgaaaaa 89520
caatatgtat gtgacttaat tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 89580
tttatgtaaa aatatgttt tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 89640
tgtattccct tttttttttt tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 89700
cattaaagtt cagtttatgt tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 89760
accaattttt gaagtcaaaa tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 89820
ataaaaataat atgaaacaat tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 89880
caagcagtag acataaaatcc tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 89940
aaatcacatca tggatttttt tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 90000
agactatcca tattttccaa tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 90060
aattcaaggt tagcaactcta tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 90120
gatagattcg gatcaaaagat tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 90180
ataaataact ttgtgttaca tttttttttt ttaatcattt ataraaacat tatactatatt ctcatctgac 90240

aacatgttta attggaattc taacaataga gaagaaaatg aacataggca atatttgaag 101460
aaacaatago tcaaagggtt ccaaatttgc tgaaaagaaaat cagtcacaa aatcaaaaatt 101520
tctaaaaacc cccasaatgc tgtataccaa gaaaacctat actgataactc tgctgaaaac 101580
caaagataaa gcacaaatct taaaagcaga ttgttattatg ccattttgc acagctatga 101640
aaaaatactc aagactgggt aatttataaa gaaaagagat ataattgact cacaattcca 101700
catggttggg gaggcctcag gaaaggatca gtcatgggg aaygggaagg aaagacctct 101750
tcacatgtatg gcaagagaga agtgccaaaca gggaaaatgc cagatgttia taaaaccatc 101820
aaacccatcg agaactcatt cactatcagc agaatacgat aggagaaaact gccccatgt 101880
ccaagcacgt cccactgggt ccttccctca acacacaggg attalgggtga ttacaattta 101940
agatgagatt tggtagggc cacagaccc aaccatatta ttctgcccct tgcccttccc 102060
aaatotcatg tcctcacatt taaaacata arcatgcctt cccaaacagtc cccccaagtc 102060
ttaactcact acagcattaa ccctaaagtc catgtccaaa gtctcatctg agacaaggca 102120
agtccttcc acataatgagu ttgtaaaatc aaaagaaaat tagtcatttt caagatacaa 102180
tgggataaca ggcattgggtt aaatgtcccc atcccaatgc ggatgaattt gctaaaaacaa 102240
agggacccaa ggctccatga aagtcaaaaa tccaaataggg aagtcaattaa aactcaaaagt 102300
tccaaaacag tcccccttgc ttccatgtct caccattcagg tcacactgtatg gcaagagggt 102360
agctcccaca gccttggca gacgtcccc aatgggtttt caaggtatgg ccccttgc 102420
tggctacttt cactgttgcg attgagatc tttgtttt ccaggcaca ggtcaaccc 102480
gtcagtgaat ctaccattt gggatcttggg ggtatgttgc cccttttctc acagctccat 102540
taggtatgtc cccactgggtt cctctgtgtt ggggtttccaa tccatcattt cccttgc 102600
ttgccttgcg agagggttctc catgggggtt cttcccttgc agcacaccc tgcctggaca 102660
totaactcata tataatcatt ttctgaatct aggtgggggtt tttgtattt tttgttccac 102720
aggaccaaca ccatgtggaa gtcgcaagg cttagggtct tcattatctg aagcaatggc 102780
ccaagctgtt tttttttttt ttttagacat ggctgcagct ggtgcagcta ggatgc 102840
cacaactcc ttagactgca tacagcgtt gggcccgaggc ctgcaaaacc sttttttctt 102900
ccgaggcaac caggccttgc atggggagg ctgcctttaaa gatcactaacc attccctgg 102960
gacatttttcc ttttgtcatg gtgatataaca ttggcttccct catttcatttcc acagatttct 103020
ccagbgggtt tgcatttttcc acaagaaaaat tgggtttttt ttcttatttgc atcatcaggc 103080
tgc当地tcccaactttt ccaactttt atgtctgttcc tccctttttaa acataatgc caatttcaga 103140
ccaaactttt caaagttcaaa agttccacag atctcttaggg aagggcaaa atgttgc 103200
tctcttgcgtt aaaaacacagt tagatgtatc tttgtatccat cttccatataa gttcccttgc 103260
cccatctgag accacccctcag cttggacttc atattccaga tcactatcag cattttggc 103320
taaagcatcc aacaaatgttcc taggaagttc caagctttcc cccatcttcc tttttttttt 103380
ttagacactcc aactgttcc aacctcttgc cattacccat tttccaaatgc acttccacat 103440
tttgaggat ttttataataa gtgccttact accttgcgttcc caatttactt tttttttttt 103500
ttttgcactt ctataaagaa ttacctgaga ctgggttagt cttttttttttaaa gaagttttaaa 103560
ctgatttcata ctttcacatg gttggggagg ctttcaggaaa ctttccatca tagtggaaagg 103620
tgaagaagaa gagaggatgt tttttccatgtt gtagcaggag agagaatgtc aagttgggg 103680
aatggccatgtt gttttttttttaaaatca taagaactca ctttccatca tgagaacagg 103740
atgggacccaa caaccccccattt gatccatgtt cttccctactt agttctccat tttttttttt 103800
atgatttatgg agattataat ttaatgtatg gtttttttttgcggacacagag cccaaaccata 103860
tcacagacatg agggaaacatt ttttttttttgcg gagaatagta aaaatataatgc ccaagttttttt 103920
ggaagttttt actgtatgtt gtttttttttgcg gtttttttttgcg gtttttttttgcg 103980
aaatgtcacttca gagaacttca ttttttttttgcg gtttttttttgcg gtttttttttgcg 104040
aacacattttt ttttttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg 104100
aaaatactaa aaaaatgttccat ttttttttttgcg gtttttttttgcg gtttttttttgcg 104160
acaaaaaggaa ataaaggatgtt gtttttttttgcg gtttttttttgcg gtttttttttgcg 104220
aaacatgtatc ttttttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg 104280
tttttttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg 104340
atagtagccaa aagtgttccat ttttttttttgcg gtttttttttgcg gtttttttttgcg 104400
tagtcttgcgtt gtttttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg 104460
gttttttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg 104520
tacatgtatgtt aatgtatgtt gtttttttttgcg gtttttttttgcg gtttttttttgcg 104580
agagagaaaa atttggggccaa aatgtatgtt gtttttttttgcg gtttttttttgcg 104640
agtaatttaca ttttttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg 104700
ctggataaaa gtttttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg 104760
atataaatttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg 104820
aatgtatgtt gtttttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg 104880
tttttttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg 104940
gcaatgttccat ttttttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg 105000
atacacatot ttttttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg 105060
atattgttagt aattttacacc atgtatgtt gtttttttttgcg gtttttttttgcg 105120

tttaaaatgtta agagaaaagt ttgactaatg atatctgagg aaagaaaatta taacaaagta 108900
gtcagcatt ttaaaaagaa ccaaataatac ttctaaaaaa tgaaaaaaaaacc catttaato 108950
atcaatggac agcttaatag cagataaac acgttgtaaaa agaattcggt gacaggaggg 109020
caggtcaaaa gaaataatac aggtgcac acgttgtaaaa agaattcggt gacaggaggg 109080
agatgagcta agagtcaarg aggatagaaa agccagagca acatgtgtgg aaaatacaca 109140
aaaatgaatg gaacatacca attaatatat ccaagaattt aaaaatttcc aycagtaaaa 109200
aaacacaccc statgcata taaggaatat gcagaaasacc aaagagaaaa tatcttaacc 109260
ttgttagaga aaaatattaa tttaaaagca gtaatggta gattacaaa gacttcata 109320
tagcaatagc agacgccacc aggtattaa cacttccatt ttccaggaga aataactatc 109380
tatataaaat tctatataca gaaataattt ttggagaata aagttttgtat tcataaaaatt 109440
tatttttattt tatttttttgca caagatctt atggccagg tggaggtgtca gtgtgtgtat 109500
tttagctcg tgcgaccctg accccctggg ctcaagttgtt cccctgcctc agccccccaa 109560
gtagctgtga ctacagtcac aaactacccc ttctagotaa tttttgtat ttgttagag 109620
acggagttttt ggctttttgc ccaggctgtt ctccaaactcc tgggatttgc gggacttgc 109680
accttagctt cccaaaatgc taaaatttgc gagaatttgc cacrataat acacattaaag gagagaaaaa agatataattt 109740
cagaaaaactg aaactgtatc aagatataaag gtcttaggtt gaaagaaaaa atgaaaaaca 109800
aagaaaaatgg taaaatgttca attaccttac atggtttttaa catgacaataa gtaggttacc acaccccatat acataaaaaca 109860
ttctgcttaa gtcagcatc ttcttgc gttttttttt gggacttgc 109920
atatgttgc agatacaccc ttagatagg ccagatcaaa aaaaagagag ggaatttgc 109980
aaaaagagag ggaatttgc aatcttccct ttctgactac atctaaatgt tggtgagaaa 110160
attcctttag gcaattttt ttttaagta ggttagatagg aatcttctac ttctactttaa aagctgtatc 110220
tttttagtaa gtaagaaagg ccaattttata tttttttttt ggttccctgt 110280
ccaaatccaa ttttttttttgc gtttttttttgc gtttttttttgc gtttttttttgc 110340
tttttagtaa gtaagaaagg ttttttttttgc gtttttttttgc gtttttttttgc 110400
tttttagtaa gtaagaaagg ttttttttttgc gtttttttttgc gtttttttttgc 110460
tttttagtaa gtaagaaagg ttttttttttgc gtttttttttgc gtttttttttgc 110520
tttttagtaa gtaagaaagg ttttttttttgc gtttttttttgc gtttttttttgc 110580
tttttagtaa gtaagaaagg ttttttttttgc gtttttttttgc gtttttttttgc 110640
tttttagtaa gtaagaaagg ttttttttttgc gtttttttttgc gtttttttttgc 110700
tttttagtaa gtaagaaagg ttttttttttgc gtttttttttgc gtttttttttgc 110760
tttttagtaa gtaagaaagg ttttttttttgc gtttttttttgc gtttttttttgc 110820
tttttagtaa gtaagaaagg ttttttttttgc gtttttttttgc gtttttttttgc 110880
tttttagtaa gtaagaaagg ttttttttttgc gtttttttttgc gtttttttttgc 110940
tttttagtaa gtaagaaagg ttttttttttgc gtttttttttgc gtttttttttgc 111000
tttttagtaa gtaagaaagg ttttttttttgc gtttttttttgc gtttttttttgc 111060
tttttagtaa gtaagaaagg ttttttttttgc gtttttttttgc gtttttttttgc 111120
tttttagtaa gtaagaaagg ttttttttttgc gtttttttttgc gtttttttttgc 111180
tttttagtaa gtaagaaagg ttttttttttgc gtttttttttgc gtttttttttgc 111240
tttttagtaa gtaagaaagg ttttttttttgc gtttttttttgc gtttttttttgc 111300
tttttagtaa gtaagaaagg ttttttttttgc gtttttttttgc gtttttttttgc 111360
tttttagtaa gtaagaaagg ttttttttttgc gtttttttttgc gtttttttttgc 111420
tttttagtaa gtaagaaagg ttttttttttgc gtttttttttgc gtttttttttgc 111480
tttttagtaa gtaagaaagg ttttttttttgc gtttttttttgc gtttttttttgc 111540
tttttagtaa gtaagaaagg ttttttttttgc gtttttttttgc gtttttttttgc 111600
tttttagtaa gtaagaaagg ttttttttttgc gtttttttttgc gtttttttttgc 111660
tttttagtaa gtaagaaagg ttttttttttgc gtttttttttgc gtttttttttgc 111720
tttttagtaa gtaagaaagg ttttttttttgc gtttttttttgc gtttttttttgc 111780
tttttagtaa gtaagaaagg ttttttttttgc gtttttttttgc gtttttttttgc 111840
tttttagtaa gtaagaaagg ttttttttttgc gtttttttttgc gtttttttttgc 111900
tttttagtaa gtaagaaagg ttttttttttgc gtttttttttgc gtttttttttgc 111960
tttttagtaa gtaagaaagg ttttttttttgc gtttttttttgc gtttttttttgc 112020
tttttagtaa gtaagaaagg ttttttttttgc gtttttttttgc gtttttttttgc 112080
tttttagtaa gtaagaaagg ttttttttttgc gtttttttttgc gtttttttttgc 112140
tttttagtaa gtaagaaagg ttttttttttgc gtttttttttgc gtttttttttgc 112200
tttttagtaa gtaagaaagg ttttttttttgc gtttttttttgc gtttttttttgc 112260
tttttagtaa gtaagaaagg ttttttttttgc gtttttttttgc gtttttttttgc 112320
tttttagtaa gtaagaaagg ttttttttttgc gtttttttttgc gtttttttttgc 112380
tttttagtaa gtaagaaagg ttttttttttgc gtttttttttgc gtttttttttgc 112440
tttttagtaa gtaagaaagg ttttttttttgc gtttttttttgc gtttttttttgc 112500
tttttagtaa gtaagaaagg ttttttttttgc gtttttttttgc gtttttttttgc 112560

caaaaacagg tctgagtggc agccccctccc tgtaagacac acagaccagt gtgttatgc 112620
agtttacccat taccatggca acaccccgaaa gttacaggcc ctttccacag caatgaccca 112680
acaaccggaa gttaccatcc tccttcgtgc aatttcagca ttaactaacat cttaaatttcc 112740
atataattaa aagtgcataat aaatatgagt gcagaactgc ctctgagctg ctactgtggg 112800
cacactgcct atgggttagcc ctgttttagca aggagaggtg cctctgaggc tgctatacad 112860
tgccacttca aaaaaatttg ctgtttaaaca ccacaggcgc acccttgaat ttcttactgg 112920
acaaaaccaa gaaccttccc aggctaagac ccaatttggg ggcttgcgtg ctacatcat 112980
tatcaactca tgccatagca aaagtattta aggtaatgt tcaactgcact gagttctaat 113040
ataattttagg tatattctgt gacataactt ttaatttgcct gaatttgacta acaatcgaat 113100
gttcaagctc agtgaacca ctttcaagta gacaacaaac ggttattttg goccaagtag 113160
tcaaactctc agcatgtatg tacaacgggc ttattaaata ggtgcatac aaatttgaag 113220
gcacagaaac attttttgtat gatgtgatrt atctttaaaac taaaagaat agcacatctca 113280
tttttctcat tctagattaa tgtagtagact aagggatcat tcaactaagat ttgagttttaa 113340
acaatgaata ctttcatctt cgtttacaag tcattttat gccagttaat ttgttttaca 113400
aaacactaca ttgtgttgcgat ttaatttcat ttgctttat ttacaattt aaaatttagt 113460
tttagtcttgc tgcaatgggt catgcttata atccccagcac ttgacatgc caagtoaga 113520
ggatcaatag acccccaggag ttcaagagcca gcctggggca cgtgtgaaa ccctgtct 113580
acaaaaaaattt taaaaatttga agcaattttgg gaggccaagg cctgagcagg ccggggcg 113640
atccctgacta acactaacac ggtttaactc cgttctact gaggbcagg gatccagacc 113700
gggttgggt gtgggtgcct gtagtcccag ctactcgggc acaatatacaa aaaaatagcc 113760
gtgaacccgg gaggcggagc ctcaaaaaaaaaa aaaaaaaaaa ggctgaggca ggagaatggc 113820
gogacagago aagactccat gggatgttta ggtgggagga ttgcaccagt acgtgcagc 113880
ggctgtatac cctgtctactt gtagtccat aattttaagg taatactaaa caaaatcaag 113940
gaggctgcag tgagccatgaa atttttttttttaa gacactgcac tccagcctgg 114000
ctgttctcaas aaagtaagaa taagagtgtg aatacgttta ggatcaatagtt tgaccaaggt 114060
ggaaaatagt tataattttt acctaattttt cttttttttttaa ggttgcggc 114120
cacaagctt attacttata ttttactgt tttttttttttaa gacacttcaatggc 114180
tcaatatac ttttactgt taaaatttata tttttttttttaa ggttgcggc 114240
taattttttttaa ggttgcggc 114300
taattttttttaa ggttgcggc 114360
taattttttttaa ggttgcggc 114420
taattttttttaa ggttgcggc 114480
taattttttttaa ggttgcggc 114540
taattttttttaa ggttgcggc 114600
taattttttttaa ggttgcggc 114660
taattttttttaa ggttgcggc 114720
taattttttttaa ggttgcggc 114780
taattttttttaa ggttgcggc 114840
taattttttttaa ggttgcggc 114900
taattttttttaa ggttgcggc 114960
taattttttttaa ggttgcggc 115020
taattttttttaa ggttgcggc 115080
taattttttttaa ggttgcggc 115140
taattttttttaa ggttgcggc 115200
taattttttttaa ggttgcggc 115260
taattttttttaa ggttgcggc 115320
taattttttttaa ggttgcggc 115380
taattttttttaa ggttgcggc 115440
taattttttttaa ggttgcggc 115500
taattttttttaa ggttgcggc 115560
taattttttttaa ggttgcggc 115620
taattttttttaa ggttgcggc 115680
taattttttttaa ggttgcggc 115740
taattttttttaa ggttgcggc 115800
taattttttttaa ggttgcggc 115860
taattttttttaa ggttgcggc 115920
taattttttttaa ggttgcggc 115980
taattttttttaa ggttgcggc 116040
taattttttttaa ggttgcggc 116100
taattttttttaa ggttgcggc 116160
taattttttttaa ggttgcggc 116220
taattttttttaa ggttgcggc 116280

tctgttttag tatgaatcca aacattttac ctggggccta aatrtccaaat agtggtttct 123780
attctaatag caatattatc acttggagag tattccagaa actractaag attaatatta 123840
ttgagtgtta attatatacc aggacacagat ctaagcacat ttattcaata cttaatgcaa 123900
cacaatgaaa tggagacta ttactcttc aaaggtatag atgactgaac tgaaccacag 123960
aacatfttag caactccctt aaggtcacaa gacattgtcg gagccagta tcaaattccag 124020
tggctgtgt taaaatatg tggtaaaaaa tatagtaaaaa tattcacata tgactcttag 124080
tgtatgcctc acatttattt atittacaat tattcatata ctgtaaaagt attgaaggta 124140
cacacacaca tatatatgtt tgtggataat taaaagtaca tacaggaatg attttgctat 124200
acsaaatcttc acctaatttg caatttgtga atgtaaaatg ccactctact atccaagtag 124260
aaataatctt ctgtgattaa tttcaacaaa tatctttcg atgtattttt tttactat 124320
tttcttatac ctaccttttt tcaaagactg atggctaao 124380
ccctttttc atcaatactt tcaaaaacta caaaagtcta tcaatttgagt gttttgtt 124440
taagaaaatt agcaacat 124500
accatttaga agaccagata tataatgtt aacttataat ttatataatg ttatataatg 124550
ggatccaatt tatttcaat atttggacat taaaatattt 124620
tatgtttttc atcaatactt tataatgtt aacttataat 124680
aattttcgaa ggaagtttac aagaaagaga aattactgaa 124740
gattttaaaga scacttggat attacactgt agttaaggg 124800
gaagaatagg aaagtgtggg gactaacta gaattaaatg 124860
tggtttgcg caagggaaatt gtggagaag taaaaggagc 124920
aattccagat caaaaacttgc 124980
aatttgagaa gaaatgtaa 125040
aaaatagatg gaggaaaaaag 125100
ttcataatac aactattaca tataacagag 125160
tttgcattttt tgaacagaca ccatcaagga 125220
tttttgtaaa saattgaaga cctgagctgg cccttataa 125280
tcttatttca tgcgtatttc gactcagaga aatgacaaat 125340
ttcaggcatt tgaaggatgc 125400
atgtggata tttacagtc taagaatggc ttcaggaaat 125460
acaaaacttc agtgtctgaa actcttacca cccctgtgcc 125520
gtatgyaagg agaaaacaaga aatgtggatga ttccatttcc 125580
aattttttttt catteacaaat atattggcat 125640
gaagacattg aggtccaaact 125700
tatatcatta gaactttttt tttttttttt 125760
tgacaggatt tttccggaaa attgattttt ctcttagtaa 125820
acttgcattt acttccaaata 125880
aaagaaagac tqaatttattt ttccatattt 125940
catatgaagg aaaagtccaa 126000
actttatcatttca acaatgacta 126060
tttttatttgc cattttccata 126120
gttatttgc tttttttttt 126180
atgtttatgt tttttttttt 126240
ctccattatca agtgtatgg 126300
tctgttattt gttccatag 126360
tatttttcaact tttttttttt 126420
ttgcaatatt gtggagattt 126480
aatccattttt gagttgtattt 126540
gcatacagat accaaatttt 126600
tgtgtttttt gcacccattt 126660
gettcttatac ttgtttcg 126720
gattacaata gtttataat 126780
tttttcttattt aaaartgttt 126840
tgggtttgtc atataatgtt 126900
tggaaattttt atcatgaaaa 126950
gatgtatcattc tggttttttgt 127020
goatatgttg caacatccctt 127080
tcittcaatg tttttttttt 127140
gtqatgagag atactggccct 127200
gtatgttca tttttttttt 127260
gtaattttca tttttttttt 127320
tttgcatttgc taatataattg 127380
gtqatgagag atactggccct 127440

atccaaaataa tattgacttc atagaatgtt gtttggatc cttttccac ttcaattctt 127500
ttaaaaagtt taagaaaatcgatattgtt ctctttttttt acaggaaactt ttttttgattt caatcatttt 127550
taaaaccata cagcttttgg ctttttcttgc gatrttctattt atttaatgtt tcaggcttgg tagattgtt 127620
atttgttattt gatcttattca gatrttctattt atttaatgtt tcaggcttgg tagattgtt 127680
atgtcttaggt tgaatgttggat cccaaattattt ggttgcattt gttttttttt gtttatgtt 127740
atacattttt tcttaggtttaa aattgtttagg tttttttttt gttttttttt gtttatgtt 127800
ctttttatattt ctgtggatc aattgtttagg tttttttttt gttttttttt gtttatgtt 127860
tcatttcttctt tttttttttt agctaaatattt tttttttttt tttttttttt tttttttttt 127920
ttgattttttt ctgacttattt tttttttttt cttttttttt tttttttttt tttttttttt 127980
taggttttggaa ctttggatc tttttttttt tttttttttt tttttttttt tttttttttt 128040
ttttttatata tagacatttt gttttttttt tttttttttt tttttttttt tttttttttt 128100
tttttcgctg catccoggta gttttttttt gttttttttt tttttttttt tttttttttt 128160
tatttttattt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 128220
atattttgttaa attttttcatg tttttttttt tttttttttt tttttttttt tttttttttt 128280
ttggaaaaaga ttgttgcattt tttttttttt tttttttttt tttttttttt tttttttttt 128340
tacgatctat cttttttttt gttttttttt tttttttttt tttttttttt tttttttttt 128400
ttgggtttagaa tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 128460
ccattttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 128520
ttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 128580
ttgaagtttctt ttgttgcattt tttttttttt tttttttttt tttttttttt tttttttttt 128640
tcttcgtttt gaccgaagaa tttttttttt tttttttttt tttttttttt tttttttttt 128700
gttgcattttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 128760
catttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 128820
aactttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 128880
tcgttttacaa aatatggtaa tttttttttt tttttttttt tttttttttt tttttttttt 128940
atccatcatat gttacgtttaa tttttttttt tttttttttt tttttttttt tttttttttt 129000
gaatctgattt gtttgcattt tttttttttt tttttttttt tttttttttt tttttttttt 129060
gaaactttca tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 129120
ctttgttttat gtaaaaatcaa tttttttttt tttttttttt tttttttttt tttttttttt 129180
ggaaaaagagt taataactgc tttttttttt tttttttttt tttttttttt tttttttttt 129240
ttacaattttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 129300
tggttttttt tacacttttac tttttttttt tttttttttt tttttttttt tttttttttt 129360
ctgtctctttt ctgatttttca tttttttttt tttttttttt tttttttttt tttttttttt 129420
gtgtctctaa aggtgaattt tttttttttt tttttttttt tttttttttt tttttttttt 129480
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 129540
catttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 129600
catttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 129660
ggcttttttat ttctgcattt tttttttttt tttttttttt tttttttttt tttttttttt 129720
gggttgttatto tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 129780
tgggtttagt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 129840
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 129900
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 129960
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 130020
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 130080
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 130140
ccagactttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 130200
ccagactttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 130260
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 130320
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 130380
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 130440
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 130500
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 130560
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 130620
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 130680
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 130740
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 130800
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 130860
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 130920
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 130980
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 131040
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 131100
ttttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 131160

cacacaacac aactgcacat ttctgttctt taaaatggcat attagaaatc tgtgagcaaa 131220
gtcactttt tggcccagca ctggcaactgc atcaactttc caagctctac tgactcaatt 131280
ttaattgcta tgaatgatt aatttatatg tgcagggtgc tgtattaat gcattatcta 131340
atthaattca ctccaaaaact ttataatata ctttatcat tgcgttttc tgcttaggg 131400
atctgaattc cagagagggt tccctggctg tctggttctt caatttgagca tgcacacaat gtagtgaact tgagatttga 131460
tcccaagtgtt ttttattcca ttagagctga tattctccag tctctaatga agattcatag agtctcgctg cctttttgac 131520
tgtaatgatc atacttaagt ctaacaaatt atgtactgtc aagcttigt tcaatttttg gttttggaca gagggaaactc 131580
accagtctta cctatgtgtt ttattagttg taagtaaata acatatacatt taatgtmaat tctctaatgc agacataatt taatacgttg 131640
attttgcatt ttattatgtc taattaattt ttaatcaac caacotttttag tagattttgt gctagttcca ttgttaagt tcaaaatttca aatgtgcct 131700
ttacattact aataatattc ttgttaaaaaga yaaactttttt gtattcctca aaagtgtattt aatgtatc 131760
ttgttaaaaaga yaaactttttt gtattcctca aaagtgtattt aatgtatc 131820
staaaagcat gcattttta atcccttggg agatttctta tttagaaataas atttgaatgc tccatttagat atttttgcattt 131880
tctttaaaaaa ttactcacag ttatatacaa aatgttttaa aatgtatc 131940
aattcttagt cctgtttcag tagaacacaa tgggtatatac aatgttttattt 132000
tcacccaggc tggagttgttag tcaaaacattt ctctcgcttc actgcttaat aatgtatc 132060
agccctgtca acttttgtat tttagaaataas atttgaatgc tccatttagat atttttgcattt 132120
tctcaaaactt ctgaccccaa agccataaaggc cactgtgcoc 132180
ttaaactatt taaatltaaa coactttcac agtgagatattt ctttgcatttactt 132240
cattaaatattt gtacagttttt tggttcaaaatgtt 132300
tgttcaaaatgt cagttgaaaac accccgtact accgtatctt 132360
aaatgtttttt aactgtttttt tgggtatatac aatgtatc 132420
aaatgtttttt tgggtatatac aatgtatc 132480
tttctctgtc aggtgaattt ttgattacat atgaaaaccc 132540
atggttttag tgcagggtta attcttaggtg tcttattttgt 132600
aaatgtatc 132660
tttctctgtc aggtgaattt ttgattacat atgaaaaccc 132720
aattgtatc 132780
tttctctgtc aggtgaattt ttgattacat atgaaaaccc 132840
ttacaggcat ggcacaccac 132900
caccatgttgc accaggctag 132960
tcccaaagtgc ctgggattac 133020
ataatggcat cttaaaaatga 133080
tcttacactt gaagtaatti 133140
tcttacactt gaagtaatti 133200
taaaatgtatt tgaaaaacaa 133260
tcttacactt gaagtaatti 133320
tgggctttag ggctagttgg 133380
agattgsact acatattgac 133440
catagaactg gctgcaaaaga 133500
agaaaaagta ctctttactt 133560
ggctaaaataa cgcttaggaa 133620
tgctatgatattt ttttatgttt 133680
tcccaaactc ccaattgcac 133740
aatataaaac ttttagtta 133800
gatcacttca gacatttttgc 133860
tcacatactt cctagctatt 133920
atcttgcacac atccccctgg 133980
ttctttttttt ctctttttct 134040
tttgcgtttt gttgcccagg 134100
gcctcccccggg ttcaagttgt 134160
tgcacccacca cgcccgagta 134220
ttaggctggt ctgcgaactcc 134280
tgggattaca agcgtgagcc 134340
cagggctgct atcacaattt 134400
tggaggttag aaatattaaag 134460
gagaagaatc ttctctgtcat 134520
tttgcatcacttca tcaatatact 134580
tgcttctgtc bgtaaatctc 134640
atgttaactt gattatact 134700
tgggggttag ggttagtcagc 134760
gattgtgtgg agaaaaagtt 134820
aggcacatataaataatgcca 134880

ataagtgcag aactgagttc aaaagaata caggtaatgg aaggagaaag ccgtcaagct 134940
 agagaagaca ctc当地tgg attttgataa aatttagtaag tggtcgacag gc当地gtttt 135000
 tgaatttctg ctctgttatt ttttcttgg gttgggaaagg ttttaatcatg aagtgttattt 135060
 ctttaataga taaaatata tc当地ttaat ttttctgtt gtgttaacot tt当地taaaac 135120
 ttttattttt agtatagtttt tcaattata gaactgttgaa aaatagaata cagagaatcc 135180
 tgaatacaccc atatagaact tccccatca tt当地tatctt atattactat ggtacatttt 135240
 tc当地acaaa tgaaggcaata ttgccc当地ttaat aatttcatt aaaaatttcatg gtttacaattt 135300
 atttccat ttttaccaaa atcttctgtt tggccacga tcccatttgg gatatcaccc 135360
 atttagtcat catgtctcc tgggctcata tagactgaca gtttcttaca ct当地cttgg 135420
 tt当地tggaaa aatttgggaa gaactggta ggtatttgaa ataacatctc tcaatttggag 135480
 tt当地tggaa gtttcttca tgattaaata agggttatgg gtttcttggag gaagatcaact 135540
 cacatgaagt gtc当地tttca tt当地atccca tcaagggtac atgataccaa catacatcc 135600
 tgattatgtt aaccgtgaaatc acttggctgg agtagtgtt gtc当地gttta tacagtgttt 135660
 atttaactta tt当地cttattt tccataccgt gtttattttgg aagagcatta ct当地acac 135720
 cttatattca aggggttagga cattaagctt cacttccatttgg aaaggggaaat actacatata 135780
 tt当地tggaa tt当地tagt gtttccatctt gtttcttccat tccatattt tt当地gttcc 135840
 aatcattat gatatataat atggactcat ggatgttttag tttacat ttttggat 135900
 cccaaaactat atttattttt tt当地tggaa aatttattccca gattaggcca tt当地ggagcc 135960
 tt当地catttgg actcttggat gtttggatca tgacccatctt attttattttt tt当地gttcc 136020
 tc当地tggaa tgacactaca ggataatctt gtttccatctt gatatattccca tggctcagtc 136080
 ct当地atcg cc当地tctgc aagtaacaag cc当地tctgc tt当地tggatctt ct当地tggagg 136140
 atagttcttag aaacgaagat ctgggtctg agtgggttttgg tt当地gttcc ggtactgagg 136200
 tt当地tggatctt catagggtccat ct当地ggaaat aatagagctt gggaaatgtac ct当地gtatac 136260
 taatctatgc atgc当地atcat ttaatataat tt当地tggatctt acctatccat atattaagct 136320
 agcatgatg tcaactatgt tctctgtactt taacccatgtt ct当地agggtt tatttcttagat 136380
 tt当地tggatctt tt当地gttacat ct当地cccttccat aacatgtgaga agtggctcc taccatgtaa 136440
 catobattta tt当地tggatctt atc当地acttccat acatgttataat aatttigaga atttatttccat 136500
 cacacccacca tt当地tggatctt ct当地tggatctt tagaatatgtt ct当地acttccat gtttcttgg 136560
 ct当地tggatctt tacatgttcc aataatctt aataggatctt agataagcaa ct当地tggatctt 136620
 tt当地tggatctt tt当地gttacat acatgttataat aataggatctt tt当地tggatctt tctgaaattcc 136680
 accccagagat ccatcatctt ct当地acttccat tattttttaaa tt当地tggatctt tcaatattta 136740
 ct当地tggatctt tt当地gttacat tataatattt ttttcttccat atatttccat atatttccat 136800
 ct当地atcgatc atatgttactt gtc当地tggatctt agtggatctt aatttccat aataggatctt 136860
 gatatttttccat tt当地tggatctt attttcttccat tt当地tggatctt ttttcttccat 136920
 aatgttcttgc ct当地acttccat tt当地tggatctt ct当地tggatctt attttccat attttccat 136980
 ggtctactgg tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt taggatattt 137040
 tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt 137100
 ccactctgtt tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt 137160
 taagggtgtt tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt 137220
 tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt 137280
 aatcttccat gaaactgtggg tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt 137340
 taatcttccat tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt 137400
 catagtcactt cc当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt 137460
 tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt 137520
 tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt 137580
 aagtaatctc ct当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt 137640
 tcaaaaatttc tatttctgtt tacatgttccat atctgttccat gcatgttccat tatttcttccat 137700
 actagaaccc ttaacatattt aattttagt ttttccat ttttccat ttttccat ttttccat 137760
 gacttggatctt atataatgtt ggttacttccat tt当地tggatctt tt当地tggatctt tt当地tggatctt 137820
 gt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt 137880
 atc当地acttccat aggaactgag gtaatagat tt当地tggatctt tt当地tggatctt tt当地tggatctt 137940
 aaactgaaattt tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt 138000
 agtgttccat tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt 138060
 ctgtgttccat tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt 138120
 tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt 138180
 gt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt 138240
 tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt 138300
 tacccttccat catggctctg ggacaaatgtt tt当地tggatctt tt当地tggatctt tt当地tggatctt 138360
 tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt 138420
 cagaagaagg tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt 138480
 gcatacaaaa tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt 138540
 agtctctcat tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt tt当地tggatctt 138600

ttctctaaat tgtttctgtt ttataaaaat ttatcttattc tactaaccac taagagaggt 142380
 atgataaaat aacacagaat gttgatagat ttgtcaatat ctctttgttag atgtgtgaat 142440
 tatttcactc tcrrttctcc ctcctctttt tcttgcctc tctctccctt cccttcttct 142500
 ttctccctc tcctgtctcc taatgtctta gatagataaa attgtaaaac tggtagacat 142560
 tgagaaggga acattttacc attatgcact gatccttattt aattnataaa catittgtaa 142620
 tctagtggat tttttttagt taatttgaca attttatctt ttcactgcag agtttagccc 142680
 aatttagtgcg attgtgtattt tcaattgttt taatcatattt cctgtcatct tacaattattt 142740
 tcctctttta cactttttac ttttccctt taatgacttt ttttttatcg ttcccttattcc 142800
 attttctattt ttatatttaa ttgtttaaat cattatctta aaatgcactt aattgtataaa 142860
 aataaatcca tatttcaabg acccttccaa caataagaaa ttataataact tgcgtttta 142920
 tgactttccc aatttacatg atcttatttc ttgcgtatctt aatctgcggc ttctttaaa 142980
 caccactaac taaaaattat gattattat ttttaaggaa ataattatctt cttaaatttt 143040
 cctcaaaattt gtctctttga ctatccctctt gttgtcattt atgaaagcac aacttctaga 143100
 agcttcttcc ttcttttttctt ttttttataat gggtttttttg ctctgtcacc 143160
 caggctggca tgcagtggca tgataatggc tgacttacat cttcaattttc tgggticagg 143220
 gtgrtggAAC tgtttgcctcc ccagtgtcgc aaagaaatag cattogaaca taascttaat 143280
 totctcagca aggcaatgttt tacatcttc agaaaagggtt ctctctgcag atatacaagg 143340
 ggatctctttt gcctcagccctt cccttagtgc tggatcttca ggcatttcattc atcacacttg 143400
 gctaattttt tcttattttt tgcgtatgcg gcatcttcatc atgttactca ggctgtctt 143460
 gaatttctgg ctcgaagega ttttcatttttcc tcaatccccc aaagtgtcga gattaaaggc 143520
 atgagoogcc acacccctgtt aaaaacttctt ttaacaaaatg ctgtgtttaa taatttattag 143580
 cttttttata caaaattttt cttcaaaagag agttttctgt agtactccat tggaaagctga 143640
 tttttttttt ctcttgacaa tgcgttgcgatgatggaa ctatatttact atctcatgc ttccatctt 143700
 gtttaaaagg cttcttacag tgcgttgcgatgatggaa ttgttgcgtt tgggtgagctt tcttttttctt 143760
 ctgttcttctt taggatcttcc ttcttgcctt tagtgcctt catttttact aatgtatgcc 143820
 taggtatgcg tttctgttttta cttgtttaca acccttctgt actcattgtt ctctatctat 143880
 tttttttttt ttctgaaaaaa ttctcagaca tgatcttccaa atatgttttctt tcttttttctt 143940
 tataatattttt ttcttctggga ctcagaggta tacgataccctt tgcgtatgtt gggatcttcc 144000
 tctttcatgtt gattttgtt gttttatattt tggggctatgtt tcttcagatt tataatatttc 144060
 tttttatattt tgcgttgcgtt aattttactt tcaatgtgtt gtgtcattgtt aattttttag 144120
 gtctcattttt ttctgacttcc cacttgcgaa gacaagggtt tctgtgtttt cagtgtatgt 144180
 tgcgttgcgtt ttcacattttt cttccatgtt gggaaacatattt gaaatcatatgaa gggccatattt 144240
 tttttatattt gaaagaggaa attttcattt ggttctgcoa ggttccagaa gtcagcagtg 144300
 agccatgcacaa catttttagat agtccaaagc atccccactaa cttaaagtggaa agtaataaaaa 144360
 acacttcagaa totcagtgcc taaaatgtt gttttttttt tttttatatttgc taaaacacaca 144420
 aatgcataaaa atataataat atacaaaataa ttgcattttt tgcgttataat atacaacata 144480
 ttgtgtttgtt atgtacaataa taaaatgtt gaaatcatattt taaaacagatt ttgggtttaga 144540
 cataattttttta tagaacactt tttatattt gtttattctt ttctctactc atgtgtcttg 144600
 tttttttttttaaaggcccccatttttgg actgacacttgc tgcgttttcc tcaacccttgcgatcataatgaa 144660
 gatctcttgc tgcgtatgtt gatcttgcgatgatggaa ctgtatcttgcgatcataatgaa 144720
 tctggtaatgtt tgcgtatgtt ttctttaaaatg ttcgttatttttgcgatcataatgaa 144780
 actctcttattt aatgttgcctt agagggttcc atgggtgtat ttgcgttgc ttttttttttgcgatcataatgaa 144840
 tacagtttttca ctgttagtctt caaatactctt catttcttgcgatcataatgaa 144900
 taacattttt tctgtgttttca acccttaca ttcaatatttca ttttttttttgcgatcataatgaa 144960
 ttcaatatttctt agttttttttgcgatcataatgaa tttttttttgcgatcataatgaa 145020
 ggcttcttgc ttatttttttttgcgatcataatgaa tttttttttgcgatcataatgaa 145080
 tcaatattttttaaaggataatgtt gtttttttttgcgatcataatgaa 145140
 attttttttttgcgatcataatgaa 145200
 ttcttttttttgcgatcataatgaa 145260
 caagatgttgc tcaatatttttgcgatcataatgaa 145320
 ttttttttttgcgatcataatgaa 145380
 tataactgtttt taccatgttgc ttttttttttgcgatcataatgaa 145440
 tatataccccc ctcccttacgc ttttttttttgcgatcataatgaa 145500
 aacacagttt gaaaaatgttgc ttttttttttgcgatcataatgaa 145560
 aatacaacca tgcgttgc ttttttttttgcgatcataatgaa 145620
 aatgttgc ttttttttttgcgatcataatgaa 145680
 aaaaatgtttt ttttttttttgcgatcataatgaa 145740
 aatacaacataa gtttttttttgcgatcataatgaa 145800
 agcattgttgc ttttttttttgcgatcataatgaa 145860
 attttttttttgcgatcataatgaa 145920
 atcaacgggtt gtttttttttgcgatcataatgaa 145980
 ttttttttttgcgatcataatgaa 146040

gaatcttacca aatttgaaaa tatccacatg ttgcagtcgtc tcagttcttat tccttaggtat 146100
actcttaaaa aattttataga catgttcaacc gacagacatg atatgttattaa aaatttccaaat 146160
atctcttacg atggaattgg tgcctttcta agaagagatc caaaagagtc tictticttt 146220
caatctctct ctctccccct ttctctttct ctctctctct cactcttcc ccaccacatg 146280
aggatattac aagagagcag ccatctgtga acctaaaaga aggcaactcac caaaaacccag 146340
accattctga catttgaro ttagacttca aaccttcaga actgtgagaa ttaaatgttt 146400
gttatttaag ccacacaatt ttgtgttattc tatttttagca gcccaaattt tcaaggaaaa 146460
taarttacetc aaactacaat gcattattac cactcaccca caaagaaaaaaa aaaaagct 146520
aaatgaaaaaa aatcacatca taaggggctcc agccccaggc ccatgacta attacccccc 146580
aaaggccccg ttgtctaaag ggacacaatc atacagtccaa ctttcatatgtt catatataaa ctttcaacat gaatttgcgtg 146640
ttttcatatgtt catatataaa gataacaga tgatTTTTT tataattttc tacagtttt 146700
atthaacatt taatcatgca aaacccatct ctgtcttaaga aataatttttataacatgtt ctactttatc ttcatatgtt 146760
aaatcaataa tttccaaaang ttatattttt ttcattttt aatggaaatgt tatttttgc 146820
gttatttttgc aatggaaatgt tatttttgc 146880
ttttttttttt tgctttttt cggctccaga agcagtgagt 146940
tttcatatgtt tttcatatc tactaactgc 147000
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 147060
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 147120
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 147180
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 147240
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 147300
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 147360
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 147420
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 147480
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 147540
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 147600
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 147660
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 147720
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 147780
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 147840
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 147900
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 147960
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 148020
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 148080
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 148140
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 148200
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 148260
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 148320
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 148380
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 148440
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 148500
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 148560
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 148620
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 148680
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 148740
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 148800
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 148860
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 148920
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 148980
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 149040
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 149100
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 149160
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 149220
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 149280
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 149340
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 149400
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 149460
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 149520
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 149580
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 149640
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 149700
ttttttttttt tttcatatccc aaaaatatttgc atgcataaaac 149760

cctgggttca agccattc tc acctcagc cccctagtag ctgagattac aggcattgcga 149820
 caccacattt gctaattttt gtatttttag cagagacaag ttttccat gttggccagg 149880
 atggctctcaa actcctgacc tcaaggcata caccacttc ggcctccaa agtgctggaa 149940
 ttacaggcat gagccaccgt tccagccctgg taaaatattt tttaatttgc tatctttgaa 150000
 agtctgttat tattgtgaaa ttgatttttca tatggatca gatggactga tgctttgtgg 150060
 tgggtgtgta atcaactgcag aagaaaaattt gggactgaa cctggaaatgt tagtccatgc 150120
 caattattt gaaaatttagca tccaaaaaagg aataaaaattt gttgagaaaa attgaaagt 150180
 attacactac ctatgtttac tagaaaaaga ttctggcatt gggccaaatga tgactgataa 150240
 ttattcatag cactattgaa gagattgatg tatctttacta ggaatttttc aggtgtgagt 150300
 gatagaaatt cagcicictt aagcaaaaag aataacttattt gattctatg actgggtact 150360
 cttaggagtgg tgcttgcttt agtcatacgcc agatccagaa gattaaaaat aaatcttgc 150420
 ttgctgcaaa gtttaggtat ttccggacca ttccacaatat ggacagacat agccccctagt 150480
 tagaaatcta gcagaacaag aatttttgc tcctgataact catacatgaa atattccttg 150540
 tcaccaattgc ccatactttt tgaaccacat tagattataat gcccattgca gtatataagaa 150600
 agggtagta gaatgccacc atgatc 150626

<210> 10

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Forward promoter primer for CFH gene

<400> 10

agaatcgtagg tctctgtgtg tgg

23

<210> 11

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Reverse promoter primer for CFH gene

<400> 11

agcagctggatatacctct gg

22

<210> 12

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Forward promoter primer for CFH gene

<400> 12

tc当地atgaga gtgagccagt tgc

23

<210> 13

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Reverse promoter primer for CFH gene

<400> 13

ctgttcacaa cgtccagttc tcc

23

<210> 14
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 1 primer for CFH gene

<400> 14
gtgggagtgc agtgagaatt gg 22

<210> 15
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 1 primer for CFH gene

<400> 15
aactcaacaa tgtcaaaaagg c 21

<210> 16
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 2 primer for CFH gene

<400> 16
gatagacctg tgactgtcta ggc 33

<210> 17
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 2 primer for CFH gene

<400> 17
ggcaatagtg atataattca ggc 23

<210> 18
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 3 primer for CFH gene

<400> 18
acctcagccccc aaggatgc 20

<210> 19
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 3 primer for CFH gene

<400> 19
tgcatactgt tttcccactc tcc 23
<210> 20
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 4 primer for CFH gene

<400> 20
aaggaggagg agaaggaggga agg 23
<210> 21
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 4 primer for CFH gene

<400> 21
caggctgcat tcgtttttgg 20
<210> 23
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 5 primer for CFH gene

<400> 22
ccactcccat agaaaagaat cagg 24
<210> 23
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 5 primer for CFH gene

<400> 23
acttctttgc accagtctct tcc 23
<210> 24
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 6 primer for CFH gene

<400> 24
gataaatcat ttatthaagcg g 21
<210> 25
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 6 primer for CFH gene

<400> 25
gaacccttgaa cacagaaaaat gc 23

<210> 26
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 7 primer for CFH gene

<400> 26
ggatgacttt ggagaagaag g 21

<210> 27
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 7 primer for CFH gene

<400> 27
tatgagtttc ggcaacttcg 20

<210> 28
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 8 primer for CFH gene

<400> 28
tcatcttcat taacaaaagac c 21

<210> 29
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 8 primer for CFH gene

<400> 29
agatcttattt tggtaacttt gc 22

<210> 30
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 9 primer for CFH gene

<400> 30
cttttgttagt aacttttagtt cg 22

<210> 31

<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 9 primer for CFH gene

<400> 31
ttatacacag ttgaaaaacc 20

<210> 32
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 10 primer for CFH gene

<400> 32
ggcaactctg agcttatttt cc 22

<210> 33
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 10 primer for CFH gene

<400> 33
agagtaggaa aagcctgaat gg 22

<210> 34
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 11 primer for CFH gene

<400> 34
catagattat ttttgtacgg 20

<210> 35
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 11 primer for CFH gene

<400> 35
caaaaactcccc ttctttttccc 20

<210> 36
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 12 primer for CFH gene

<400> 36
atctgatgcc cctctgtatg acc 23
<210> 37
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 12 primer for CFH gene

<400> 37
attcagtaact caatacatgt cc 22
<210> 38
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 13 primer for CFH gene

<400> 38
cacccattttt gattgttttag g 21
<210> 39
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 13 primer for CFH gene

<400> 39
gaatctccat agtaataagg 20
<210> 40
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 14 primer for CFH gene

<400> 40
caatgttgttgc atggagatgtg g 21
<210> 41
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 14 primer for CFH gene

<400> 41
attgaatttat aagcaatatg c 21
<210> 42
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 15 primer for CFH gene

<400> 42
catttcagcg acagaataca gg 23

<210> 43
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 15 primer for CFH gene

<400> 43
gtgtgtgtgt gtgtgtgtgc 20

<210> 44
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward intron 15 primer for CFH gene

<400> 44
aaggcaggaa agtgtccctta tgc 23

<210> 45
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse intron 15 primer for CFH gene

<400> 45
gtcaaattac tgaaaaatcac c 21

<210> 46
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 16 primer for CFH gene

<400> 46
aactgttaca cagctgaaaa g 21

<210> 47
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 16 primer for CFH gene

<400> 47
gtggtgattg attaatgtgc 20

<210> 48

62/64

<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 17 primer for CFH gene

<400> 48
ggtggaggaa tataatctttg c 21

<210> 49
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 17 primer for CFH gene

<400> 49
atagaataga ttcaatcatg c 21

<210> 50
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 18 primer for CFH gene

<400> 50
cgataagacag acagacaccca gaagg 25

<210> 51
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 18 primer for CFH gene

<400> 51
cagctatast ttccccacacgc agtcc 25

<210> 53
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 19 primer for CFH gene

<400> 52
gtgttaatctc aattgctacg gctacc 26

<210> 53
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 19 primer for CFH gene

<400> 53
caagtagctg ggacttcaga tgc 23
<210> 54
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 20 primer for CFH gene

<400> 54
tagtttcatg ttctttcctc 20
<210> 55
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 20 primer for CFH gene

<400> 55
gaattttaag caccatcagt c 21
<210> 56
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 21 primer for CFH gene

<400> 56
ccagactca ttttttcac c 21
<210> 57
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 21 primer for CFH gene

<400> 57
ctttctgaca gaaatatttg g 21
<210> 58
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 22 primer for CFH gene

<400> 58
tgatgtttct acatagttgg 20
<210> 59
<211> 25
<212> DNA
<213> Artificial Sequence

64/64

<220>
<223> Reverse exon 22 primer for CFH gene

<400> 59
ggagtaaaac aatacataaaa aaatg

25